Teleflex (TFX) 10-K 28 Feb 25 2024 FY Annual report Financial data

Cover page

Cover page - USD ($)	12 Months Ended
	Dec. 31, 2024	Feb. 25, 2025	Jun. 30, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-5353
Entity Registrant Name	TELEFLEX INCORPORATED
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	23-1147939
Entity Address, Address Line One	550 East Swedesford Road, Suite 400
Entity Address, City or Town	Wayne
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19087
City Area Code	610
Local Phone Number	225-6800
Title of 12(b) Security	Common Stock, par value $1.00 per share
Trading Symbol	TFX
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 4,278,187,198
Entity Common Stock, Shares Outstanding		46,366,463
Documents Incorporated by Reference	Certain provisions of the registrant’s definitive proxy statement in connection with its 2025 Annual Meeting of Stockholders, to be filed within 120 days of the close of the registrant’s fiscal year, are incorporated by reference in Part III hereof. (1) For purposes of this computation only, the registrant has defined “affiliate” as including executive officers and directors of the registrant and owners of more than five percent of the common stock of the registrant, without conceding that all such persons are “affiliates” for purposes of the federal securities laws.
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Entity Central Index Key	0000096943

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2024
Audit Information [Abstract]
Auditor Firm ID	238
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Philadelphia, Pennsylvania

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net revenues	$ 3,047,324	$ 2,974,489	$ 2,791,041
Cost of goods sold	1,344,645	1,327,558	1,259,954
Gross profit	1,702,679	1,646,931	1,531,087
Selling, general and administrative expenses	995,271	929,867	863,748
Research and development expenses	161,672	154,351	153,819
Pension settlement charge	132,732	45,244	0
Goodwill impairment charge	240,000	0	0
Restructuring and other impairment charges	21,991	15,604	20,299
Gain on sale of assets and business	0	(4,448)	(6,504)
Income from continuing operations before interest, loss on extinguishment of debt and taxes	151,013	506,313	499,725
Interest expense	83,544	85,082	54,264
Interest income	(8,009)	(12,781)	(912)
Loss on extinguishment of debt	0	0	454
Income from continuing operations before taxes	75,478	434,012	445,919
Taxes on income from continuing operations	5,316	76,440	83,003
Income from continuing operations	70,162	357,572	362,916
Operating (loss) income from discontinued operations	(634)	(1,608)	260
(Benefit) taxes on operating loss from discontinued operations	(147)	(364)	37
(Loss) income from discontinued operations	(487)	(1,244)	223
Net income	$ 69,675	$ 356,328	$ 363,139
Basic:
Income from continuing operations (in dollars per share)	$ 1.50	$ 7.61	$ 7.74
(Loss) income from discontinued operations (in dollars per share)	(0.01)	(0.03)	0
Net income (in dollars per share)	1.49	7.58	7.74
Diluted:
Income from continuing operations (in dollars per share)	1.49	7.56	7.67
(Loss) income from discontinued operations (in dollars per share)	(0.01)	(0.03)	0.01
Net income (loss), diluted (in dollar per share)	$ 1.48	$ 7.53	$ 7.68
Weighted average shares outstanding:
Basic (in shares)	46,837	46,981	46,898
Diluted (in shares)	47,094	47,304	47,309

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 69,675	$ 356,328	$ 363,139
Foreign currency:
Foreign currency translation adjustments, net of tax of $(8,419), $7,182 and $(6,634), respectively	(92,594)	44,902	(62,904)
Foreign currency translation, net of tax	(92,594)	44,902	(62,904)
Pension and other postretirement benefits plans:
Prior service cost recognized in net periodic cost, net of tax of $449, $233 and $232, respectively	(1,518)	(775)	(785)
Unamortized gain (loss) arising during the period, net of tax of $(3,073), $(2,284) and $850, respectively	10,232	7,922	(3,649)
Plan settlement charge, net of tax of $(58,065), $(10,352) and $0, respectively	80,074	34,892	0
Net loss recognized in net periodic cost, net of tax of $(286), $(1,844) and $(1,778), respectively	866	6,145	5,882
Foreign currency translation, net of tax of $(87), $145 and $(366), respectively	233	(434)	1,043
Pension and other postretirement benefits plans adjustment, net of tax	89,887	47,750	2,491
Derivatives qualifying as hedges:
Unrealized gain on derivatives arising during the period, net of tax $(454), $123 and $(551), respectively	1,977	8,314	7,179
Reclassification adjustment on derivatives included in net income, net of tax of $92, $385 and $203, respectively	(1,534)	(11,849)	(3,329)
Derivatives qualifying as hedges, net of tax	443	(3,535)	3,850
Other comprehensive (loss) income, net of tax	(2,264)	89,117	(56,563)
Comprehensive income	$ 67,411	$ 445,445	$ 306,576

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Foreign currency translation, continuing operations, adjustments, tax	$ (8,419)	$ 7,182	$ (6,634)
Prior service cost recognized in net periodic cost, tax	449	233	232
Unamortized (loss) gain arising during the period, tax	(3,073)	(2,284)	850
Plan amendments, curtailments, and settlements, tax	(58,065)	(10,352)	0
Net loss recognized in net periodic cost, tax	(286)	(1,844)	(1,778)
Foreign currency translation, tax	(87)	145	(366)
Unrealized gain (loss) on derivatives arising during the period, tax	(454)	123	(551)
Reclassification adjustment on derivatives included in net income, tax	$ 92	$ 385	$ 203

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 290,188	$ 222,848
Accounts receivable, net	459,495	443,467
Inventories	600,133	626,216
Prepaid expenses and other current assets	117,851	107,471
Prepaid taxes	3,457	7,404
Total current assets	1,471,124	1,407,406
Property, plant and equipment, net	502,852	479,913
Operating lease assets	108,912	123,521
Goodwill	2,632,314	2,914,055
Intangibles assets, net	2,268,714	2,501,960
Deferred tax assets	11,374	6,748
Other assets	102,624	98,943
Total assets	7,097,914	7,532,546
Current liabilities
Current borrowings	100,000	87,500
Accounts payable	141,031	132,247
Accrued expenses	143,167	146,880
Payroll and benefit-related liabilities	151,263	146,535
Accrued interest	5,338	5,583
Income taxes payable	41,318	41,453
Other current liabilities	67,243	46,547
Total current liabilities	649,360	606,745
Long-term borrowings	1,555,871	1,727,572
Deferred tax liabilities	391,066	456,080
Pension and postretirement benefit liabilities	20,185	23,989
Noncurrent liability for uncertain tax positions	1,831	3,370
Noncurrent operating lease liabilities	99,154	111,300
Other liabilities	102,307	162,502
Total liabilities	2,819,774	3,091,558
Commitments and contingencies
Shareholders’ equity
Common shares, $1 par value Issued: 2024 — 48,096 shares; 2023 — 48,046 shares	48,096	48,046
Additional paid-in capital	781,184	749,712
Retained earnings	4,115,870	4,109,736
Accumulated other comprehensive loss	(316,669)	(314,405)
Shareholders equity before treasury stock, total	4,628,481	4,593,089
Less: Treasury stock, at cost	350,341	152,101
Total shareholders' equity	4,278,140	4,440,988
Total liabilities and shareholders' equity	$ 7,097,914	$ 7,532,546

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common shares, par value (in dollars per share)	$ 1	$ 1
Common shares, shares issued (in shares)	48,096	48,046

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities of continuing operations:
Net income	$ 69,675	$ 356,328	$ 363,139
Adjustments to reconcile net income to net cash provided by operating activities:
Loss (income) from discontinued operations	487	1,244	(223)
Depreciation expense	76,932	68,144	66,502
Intangible asset amortization expense	197,669	173,974	164,088
Deferred financing costs and debt discount amortization expense	3,415	3,400	4,053
Loss on extinguishment of debt	0	0	454
Pension settlement charge	132,732	45,244	0
Fair value step up of acquired inventory sold	1,722	1,536	0
Changes in contingent consideration	10,027	(27,243)	2,350
Asset impairments	7,834	0	1,497
Stock-based compensation	31,348	31,465	27,224
Gain on sale of assets and business	0	(4,448)	(6,504)
Goodwill impairment charge	240,000	0	0
Deferred income taxes, net	(130,237)	(13,046)	(13,008)
Payments for contingent consideration	0	(289)	(3,016)
Interest benefit on swaps designated as net investment hedges	(17,410)	(18,814)	(20,880)
Other	15,888	5,960	(2,906)
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	(27,952)	(15,763)	(38,459)
Inventories	1,925	(41,068)	(110,686)
Prepaid expenses and other assets	43,026	(11,420)	13,420
Accounts payable, accrued expenses and other liabilities	9,665	(31,258)	(24,786)
Income taxes	(28,486)	(12,263)	(79,453)
Net cash provided by operating activities from continuing operations	638,260	511,683	342,806
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(126,434)	(91,442)	(79,190)
Payments for businesses and intangibles acquired, net of cash acquired	(120)	(603,920)	(198,429)
Proceeds from sales of business and assets	0	15,000	12,434
Net interest proceeds on swaps designated as net investment hedges	27,196	63,134	20,775
Proceeds from sales of investments	7,300	7,300	7,300
Purchase of investments	(7,300)	(11,300)	(22,300)
Net cash (used in) provided by investing activities from continuing operations	(99,358)	(621,228)	(259,410)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	130,000	646,000	744,250
Reduction in borrowings	(291,500)	(544,750)	(884,500)
Debt extinguishment, issuance and amendment fees	0		(5,200)
Repurchase of common stock	(200,000)		0
Net proceeds from share based compensation plans and the related tax impacts	3,352	5,190	(4,308)
Payments for contingent consideration	(236)	(4,004)	(3,959)
Dividends paid	(63,541)	(63,896)	(63,789)
Net cash (used in) provided by financing activities from continuing operations	(421,925)	38,540	(217,506)
Cash flows from discontinued operations:
Net cash used in operating activities	(2,521)	(1,045)	(665)
Net cash provided by investing activities	0	0	1,469
Net cash (used in) provided by discontinued operations	(2,521)	(1,045)	804
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents	(9,654)	2,864	(19,744)
Net increase (decrease) in cash, cash equivalents and restricted cash equivalents	104,802	(69,186)	(153,050)
Cash, cash equivalents and restricted cash equivalents at the beginning of the year	222,848	292,034	445,084
Cash, cash equivalents and restricted cash equivalents at the end of the year	$ 327,650	$ 222,848	$ 292,034

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid in Capital	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Treasury Stock, Common
Common stock, shares issued, beginning balance (in shares) at Dec. 31, 2021		47,929
Treasury shares, beginning balance (in shares) at Dec. 31, 2021						1,069
Beginning Balance at Dec. 31, 2021	$ 3,754,748	$ 47,929	$ 693,090	$ 3,517,954	$ (346,959)	$ (157,266)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	363,139			363,139
Cash dividends	(63,789)			(63,789)
Other comprehensive (loss) income	(56,563)				(56,563)
Shares issued under compensation plans (in shares)		28				(32)
Shares issued under compensation plans	23,502	$ 28	21,930			$ 1,544
Deferred compensation (in shares)						(5)
Deferred compensation	931		98			$ 833
Common stock, shares issued, ending balance (in shares) at Dec. 31, 2022		47,957
Treasury shares, ending balance (in shares) at Dec. 31, 2022						1,032
Ending Balance at Dec. 31, 2022	4,021,968	$ 47,957	715,118	3,817,304	(403,522)	$ (154,889)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	356,328			356,328
Cash dividends	(63,896)			(63,896)
Other comprehensive (loss) income	89,117				89,117
Shares issued under compensation plans (in shares)		89				(21)
Shares issued under compensation plans	37,146	$ 89	34,270			$ 2,787
Deferred compensation (in shares)						(5)
Deferred compensation	$ 325		324			$ 1
Common stock, shares issued, ending balance (in shares) at Dec. 31, 2023	48,046	48,046
Treasury shares, ending balance (in shares) at Dec. 31, 2023						1,006
Ending Balance at Dec. 31, 2023	$ 4,440,988	$ 48,046	749,712	4,109,736	(314,405)	$ (152,101)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	69,675			69,675
Cash dividends	(63,541)			(63,541)
Other comprehensive (loss) income	(2,264)				(2,264)
Shares issued under compensation plans (in shares)		50				(29)
Shares issued under compensation plans	34,029	$ 50	30,583			$ 3,396
Repurchase of common stock	(201,895)		540			$ (202,435)
Repurchase of common stock (in shares)						850
Deferred compensation (in shares)						(5)
Deferred compensation	$ 1,148		349			$ 799
Common stock, shares issued, ending balance (in shares) at Dec. 31, 2024	48,096	48,096
Treasury shares, ending balance (in shares) at Dec. 31, 2024						1,822
Ending Balance at Dec. 31, 2024	$ 4,278,140	$ 48,096	$ 781,184	$ 4,115,870	$ (316,669)	$ (350,341)

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]
Dividends, per common share (in dollars per share)	$ 1.36	$ 1.36	$ 1.36

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Consolidation: The consolidated financial statements include the accounts of Teleflex Incorporated and its subsidiaries (referred to herein as “we,” “us,” “our” and “Teleflex"). Intercompany transactions are eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and reflect management’s estimates and assumptions that affect the recorded amounts. Use of estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Cash and cash equivalents: All highly liquid debt instruments with an original maturity of three months or less are classified as cash equivalents. The carrying value of cash equivalents approximates the current market value. Accounts receivable: Accounts receivable represent amounts due from customers related to the sale of products and provision of services. Our allowance for credit losses is maintained for trade accounts receivable based on the expected collectability of accounts receivable and losses expected to be incurred over the life of our receivables. Considerations to determine credit losses include our historical collection experience, the length of time an account is outstanding, the financial position of the customer, information provided by credit rating services, as well as the consideration of events or circumstances indicating historic collection rates may not be indicative of future collectability. The allowance for credit losses as of December 31, 2024 and December 31, 2023 was $10.0 million and $9.5 million, respectively. The current portion of the allowance for credit losses, which was $6.1 million and $5.5 million as of December 31, 2024 and December 31, 2023, respectively, was recognized as a reduction of accounts receivable, net. Inventories: Inventories are valued at the lower of cost or net realizable value. The cost of our inventories is determined using the first in, first out cost method. Elements of cost in inventory include raw materials, direct labor, and manufacturing overhead. In estimating net realizable value, we evaluate inventory for excess and obsolete quantities based on estimated usage and sales, among other factors. Property, plant and equipment: Property, plant and equipment are stated at cost, net of accumulated depreciation. Costs incurred to develop internal-use computer software during the application development stage generally are capitalized. Costs of enhancements to internal-use computer software are capitalized, provided that these enhancements result in additional functionality. Other additions and improvements that increase the capacity or lengthen the useful lives of the assets are also capitalized. Composite useful lives for categories of property, plant and equipment, which are depreciated on a straight-line basis, are as follows: buildings - 30 years; machinery and equipment - 3 to 15 years; computer equipment and software - 3 to 10 years. Leasehold improvements are depreciated over the lesser of the useful lives of the leasehold improvements or the remaining lease term. Repairs and maintenance costs are expensed as incurred. Goodwill and other intangible assets: Goodwill and other indefinite-lived intangible assets are not amortized but are tested for impairment annually during the fourth quarter or more frequently if events or changes in circumstances indicate that an impairment may exist. Impairment losses, if any, are included in income from operations. The goodwill impairment test is applied to each of our reporting units. For purposes of this assessment, a reporting unit is an operating segment, or a business one level below an operating segment (also known as a component) if discrete financial information is prepared for that business and regularly reviewed by segment management. However, separate components are aggregated as a single reporting unit if they have similar economic characteristics. In performing the goodwill impairment test, we may assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Qualitative factors may include, but are not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for our products and services, regulatory and political developments, and entity specific factors such as strategies and financial performance. If, after completing the qualitative assessment, we determine it is more likely than not that the fair value of a reporting unit is less than its carrying value, we proceed to a quantitative impairment test, described below. Alternatively, we may elect to bypass the qualitative assessment and perform the quantitative impairment test. Under a quantitative impairment test, we compare the fair value of a reporting unit to its carrying value. If the reporting unit fair value exceeds the carrying value, there is no impairment. If the reporting unit carrying value exceeds the fair value, we recognize an impairment loss based on the amount the carrying value of the reporting unit exceeds its fair value. For the year ended December 31, 2024, we recognized a goodwill impairment charge of $240 million related to our Interventional Urology North America reporting unit. For further information refer to Note 8. Our intangible assets consist of customer relationships, intellectual property, distribution rights, in-process research and development ("IPR&D"), trade names and non-competition agreements. We define IPR&D as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business acquisition is recognized at fair value and is required to be capitalized as an indefinite-lived intangible asset until completion of the IPR&D project or upon abandonment. Upon completion of the development project (generally when regulatory approval to market the product that utilizes the technology is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. If the IPR&D projects are abandoned, the related IPR&D assets would be written off. We test our indefinite-lived intangible assets for impairment annually, or more frequently if events or changes in circumstances indicate that an impairment may have occurred. Similar to the goodwill impairment test process, we may elect to perform a qualitative assessment. If, after completing the qualitative assessment, we determine it is more likely than not that the fair value of the indefinite-lived intangible asset is greater than its carrying amount, the asset is not impaired. If we conclude it is more likely than not that the fair value of the indefinite-lived intangible asset is less than the carrying value, we then proceed to a quantitative impairment test, which consists of a comparison of the fair value of the intangible asset to its carrying amount. Intangible assets that do not have indefinite lives, consisting of intellectual property, customer relationships, distribution rights, certain trade names and non-competition agreements, are amortized over their estimated useful lives, which are as follows: intellectual property, 8 to 20 years; customer relationships, 8 to 27 years; distribution rights, 10 years; trade names, 15 to 30 years. The weighted average remaining amortization period with respect to our intangible assets is approximately 12 years. We periodically evaluate the reasonableness of the useful lives of these assets. Long-lived assets: We assess the remaining useful life and recoverability of long-lived assets whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The assessment is based on various analyses, including undiscounted cash flow and profitability projections that incorporate, as applicable, the impact of the asset on the existing business. Therefore, the evaluation involves significant management judgment. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset. Foreign currency translation: Assets and liabilities of subsidiaries with non-United States dollar denominated functional currencies are translated into United States dollars at the rates of exchange at the balance sheet date; income and expenses are translated at the average rates of exchange prevailing during the year. The translation adjustments are reported as a component of accumulated other comprehensive loss. Derivative financial instruments: We use derivative financial instruments primarily for purposes of hedging exposures to fluctuations in foreign currency exchange rates. All instruments are entered into for other than trading purposes. All derivatives are recognized on the balance sheet at fair value. Changes in the fair value of derivatives are recorded in the consolidated statement of comprehensive income as other comprehensive income (loss), if the instrument is designated as part of a hedge transaction. Gains or losses on derivative instruments reported in other comprehensive income (loss) are reclassified to the Consolidated Statement of Income in the period in which earnings are affected by the underlying hedged item. Gains or losses on derivative instruments representing hedge ineffectiveness or hedge components excluded from the assessment of effectiveness, if any, are recognized in the Consolidated Statement of Income for the period in which such gains and losses occur. If the hedging relationship ceases to be highly effective or it becomes probable that an expected transaction will no longer occur, gains or losses on the derivative instrument are recorded in the Consolidated Statement of Income for the period in which either such event occurs. For non-designated derivatives, gains and losses are reported as selling, general and administrative expenses in the Consolidated Statement of Income. Cash flows from derivatives are recognized in the consolidated statements of cash flows in a manner consistent with the recognition of the underlying transactions. Share-based compensation: We estimate the fair value of share-based awards on the date of grant using an option pricing model. The value of the portion of the award that is ultimately expected to vest, which is derived, in part, following consideration of estimated forfeitures, is recognized as expense over the requisite service periods. Share-based compensation expense related to stock options is measured using a Black-Scholes option pricing model that takes into account subjective and complex assumptions with respect to the expected life of the options, volatility, risk-free interest rate and expected dividend yield. The expected life of options granted is derived from the vesting period of the award, as well as historical exercise behavior, and represents the period of time that options granted are expected to be outstanding. Expected volatility is based on a blend of historical volatility and implied volatility derived from publicly traded options to purchase our common stock, which we believe is more reflective of market conditions and a better indicator of expected volatility than would be the case if we only used historical volatility. The risk-free interest rate is the implied yield currently available on United States (or "U.S.") Treasury zero-coupon issues with a remaining term equal to the expected life of the option. Forfeitures are estimated at the time of grant based on management’s expectations regarding the extent to which awards ultimately will vest and are adjusted for actual forfeitures when they occur. Income taxes: The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred tax assets and liabilities are recognized to reflect the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases, and to reflect operating loss and tax credit carryforwards. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Provision has been made for income taxes on unremitted earnings of subsidiaries and affiliates, except to the extent that such earnings are deemed to be permanently reinvested. Significant judgment is required in determining income tax provisions and in evaluating tax positions. We establish additional provisions for income taxes when, despite the belief that tax positions are supportable, there remain certain positions that do not meet the minimum probability threshold, which is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority. In the normal course of business, we are examined by various federal, state and non-U.S. tax authorities. We regularly assess the potential outcomes of these examinations and any future examinations for the current or prior years in determining the adequacy of our provision for income taxes. Interest accrued with respect to unrecognized tax benefits and income tax related penalties are both included in taxes on income from continuing operations. We periodically assess the likelihood and amount of potential adjustments and adjust the income tax provision, the current tax liability and deferred taxes in the period in which the facts that give rise to an adjustment become known. Pensions and other postretirement benefits: We provide a range of benefits to eligible employees and retired employees, including benefits available pursuant to pension and postretirement healthcare benefits plans. We record annual amounts relating to these plans based on calculations which include various actuarial assumptions such as discount rates, expected rates of return on plan assets, compensation increases, turnover rates and healthcare cost trend rates. We review our actuarial assumptions on an annual basis and make modifications to the assumptions based on current rates and trends when appropriate. The effect of the modifications is generally amortized over future periods. Restructuring costs: We primarily recognize employee termination benefits when payment becomes probable and reasonably estimable because they are provided under an ongoing benefit arrangement and are based on existing plans, historical experience and negotiated settlements of prior plans. Termination benefits provided under one-time termination benefits arrangements, if any, are recognized upon communication to the employee. We recognize charges ratably over the future service period if the employee is required to render service until termination. Other restructuring costs may include facility closure, employee relocation, equipment relocation and outplacement costs and are recognized in the period they are incurred. Contingent consideration related to business acquisitions: In connection with business acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified objectives such as receipt of regulatory approval, commercialization of a product or achievement of sales targets. In a business combination, we record a contingent liability, as of the acquisition date, representing the estimated fair value of the contingent consideration that we expect to pay. We remeasure the fair value of our contingent consideration arrangements each reporting period and, based on new developments, record changes in fair value until either the contingent consideration obligation is satisfied through payment upon the achievement of, or the obligation no longer exists due to the failure to achieve, the specified objectives. The change in the fair value is recorded in selling, general and administrative expenses in the Consolidated Statement of Income. A contingent consideration payment is classified as a financing activity in the consolidated statement of cash flows to the extent it was recorded as a liability as of the acquisition date. Any additional amount paid in excess of the amount initially accrued is classified as an operating activity in the consolidated statement of cash flows. If the transaction is determined to be an asset acquisition rather than a business combination, a contingent consideration liability is recognized when the specified objective is deemed probable and is estimable. Revenue recognition: We primarily generate revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when our products are shipped from the manufacturing or distribution facility. For the OEM (Original Equipment Manufacturer and Development Services) product category, included within our Americas segment, most revenue is recognized over time because OEM generates revenue from the sale of custom products that have no alternative use and we have an enforceable right to payment to the extent that performance has been completed. We market and sell products through our direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers, which represented 87%, 11% and 2% of our consolidated net revenues, respectively, for the year ended December 31, 2024. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods. With respect to the custom products sold in the OEM, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice. We have made the following revenue accounting policy elections and elected to use certain practical expedients: (1) we account for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) we do not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, we expect the period between the time when we transfer a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) we expense costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) we account for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service; (5) we classify shipping and handling costs within cost of goods sold; and (6) with respect to OEM, we have applied the practical expedient to exclude disclosure of remaining performance obligations as the contracts typically have a term of one year or less. The amount of consideration we receive and revenue we recognize varies as a result of changes in customer sales incentives, including discounts and rebates, and returns offered to customers. The estimate of revenue is adjusted upon the earlier of the following events: (i) the most likely amount of consideration expected to be received changes or (ii) the consideration becomes fixed. Our policy is to accept returns only in cases in which the product is defective and covered under our standard warranty provisions. When we give customers the right to return products, we estimate the expected returns based on an analysis of historical experience. The liability for returns and allowances, which includes liabilities established related to the Italian payback matter discussed in Note 17, was $41.7 million and $22.2 million as of December 31, 2024 and 2023, respectively. In estimating customer rebates, we consider the lag time between the point of sale and the payment of the customer’s rebate claim, customer-specific trend analyses, contractual commitments, including stated rebate rates, historical experience with respect to specific customers (as we have a history of providing similar rebates on similar products to similar customers) and other relevant information. The reserve for customer incentive programs, including customer rebates, was $24.9 million and $26.7 million at December 31, 2024 and 2023, respectively. We expect the amounts subject to the reserve as of December 31, 2024 to be paid within 90 days subsequent to period-end. Leases: We determine whether a contract is, or includes, a lease at inception. Right-of-use assets and lease liabilities are recognized at lease commencement based on the estimated present value of unpaid lease payments over the lease term. To determine the present value we use an incremental borrowing rate derived from information available at lease commencement.

Recently issued accounting stan

Recently issued accounting standards	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Recently issued accounting standards	Recently issued accounting standards In November 2023, the Financial Accounting Standard Board ("FASB") issued new guidance designed to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses per segment. We adopted the new standard for the fiscal year ended December 31, 2024 using a retrospective transition approach. Additional information and disclosures required by the new guidance are provided in Note 18. In December 2023, the FASB issued new guidance designed to improve income tax disclosure requirements, primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our consolidated financial statements. In November 2024, the FASB issued new guidance designed to enhance disclosures regarding the nature of expenses included in the income statement. The guidance requires tabular disclosures that disaggregate information about prescribed expense categories within relevant income statement expense captions. The guidance is effective for all fiscal years beginning after December 15, 2026 and for interim periods beginning after December 15, 2027. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our consolidated financial statements. In March 2024, the SEC adopted final rules that require registrants to include certain climate-related disclosures in registration statements and annual reports. The required disclosures include information about a registrant's climate-related risks that are reasonably likely to have a material impact on its business, results of operations or financial condition. The required information about climate-related risks will also include disclosure of a registrant's greenhouse gas emissions and will require registrants to present certain climate-related financial disclosures in their audited financial statements. The rules were to be effective for all fiscal years beginning in 2025. However, following the adoption of the rules, challenges to the rules were brought in six federal appellate courts. These challenges were consolidated for review in the U.S. Court of Appeals for the Eighth Circuit. Additional cases have been filed since the consolidation order. On April 4, 2024, the SEC announced that it had stayed the rules pending the completion of judicial review of the consolidated Eighth Circuit petitions. The SEC has further stated that it plans to designate a new effective date and phase-in period for the implementation of the rules at the conclusion of the stay, though this would occur only if the SEC prevails in the ongoing legal proceedings. We plan to monitor the status of these rules, and, as appropriate, to evaluate the rules to determine their impact on our consolidated financial statements. From time to time, new accounting guidance issued by the FASB or other standard setting bodies is adopted as of the specified effective date or, when permitted by the guidance and as determined by us, as of an earlier date. We have assessed recently issued guidance that is not yet effective, except as noted above, and believe the new guidance that we have assessed will not have a material impact on our results of operations, cash flows or financial position.

Net revenues

Net revenues	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Net revenues	Net revenues The following table disaggregates revenue by global product category for the years ended December 31, 2024, 2023 and 2022. Year Ended December 31, 2024 2023 2022 Vascular access $ 732,675 $ 708,044 $ 683,612 Interventional 586,057 511,434 445,018 Anesthesia 395,285 389,957 388,890 Surgical 450,482 427,359 392,917 Interventional urology 331,092 319,785 322,832 OEM 344,511 326,008 272,624 Other (1) 207,222 291,902 285,148 Net revenues (2) $ 3,047,324 $ 2,974,489 $ 2,791,041 (1) Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products). (2) The product categories listed above are presented on a global basis, as each of our reportable segments is defined based on the geographic location of its operations.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Acquisitions	Acquisitions 2023 acquisition In the fourth quarter of 2023, we completed the acquisition of Palette Life Sciences AB (“Palette”), a privately held medical device company that sells a portfolio of hyaluronic acid gel-based products primarily utilized in the treatment of urology diseases including a rectal spacing product used in connection with radiation therapy treatment of prostate cancer. Under the terms of the agreement, we acquired Palette for an initial cash payment of $594.9 million, with the potential to make two milestone payments up to $50 million in the aggregate if certain commercial milestones are met. The milestone payments are based on net sales growth over the two-year period beginning January 1, 2024. The fair value of the assets acquired and the liabilities assumed resulted in the recognition of $355.1 million of goodwill, $264.0 million of intellectual property, $40.5 million of trade name assets and $29.0 million of customer relationship assets. The fair value of the asset acquired reflects a modification in the third quarter of 2024 to our allocation of the intangible assets acquired between our domestic and foreign entities as we identified new facts and circumstances that existed as of the acquisition date. As a result, we recorded a measurement period adjustment recognizing a $2.0 million decrease in the deferred tax liabilities and goodwill. The allocation change also impacted the currency translation of certain assets and liabilities and as a result, we reversed previously recorded foreign currency translation of $19.7 million, which decreased comprehensive income in the period. The adjustment did not have a significant impact on our results from operations. We have not reached an agreement on the closing statement adjustments with the seller. However, the measurement period related to this acquisition expired during the fourth quarter of 2024, and as a result, any subsequent adjustments to the consideration transferred will be recognized in the reporting period in which they are settled. The following unaudited pro forma combined financial presentation of Net income and Earnings per share for the years ended December 31, 2023 and 2022, respectively, gives effect to the Palette acquisition as if it was completed at the beginning of the earliest period presented. Revenues are not significant to the periods presented and have not been included. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have occurred under our ownership and management. Year Ended December 31, 2023 2022 (Unaudited) Net income $ 310,356 $ 282,425 Basic earnings per share: Net income $ 6.61 $ 6.02 Diluted earnings per share: Net income $ 6.56 $ 5.97 The unaudited pro forma combined financial information presented above includes the accounting effects of the Palette acquisition, including, to the extent applicable, amortization charges from acquired intangible assets; interest expense associated with borrowings to finance the acquisition; the revaluation of inventory; and the related tax effects. The unaudited pro forma financial information also includes non-recurring charges specifically related to the Palette acquisition. Supplemental cash flow information Year Ended December 31, 2024 2023 2022 Non cash investing and financing activities of continuing operations: Acquisition of businesses $ — $ 27,000 $ 43,168 Acquisition of BIOTRONIK Vascular Intervention business On February 24, 2025, we executed a definitive agreement to acquire substantially all of the Vascular Intervention business ("the VI Business") of privately-held BIOTRONIK SE & Co. KG (“BIOTRONIK”). See Note 20 for additional information related to this acquisition.

Restructuring and other impairm

Restructuring and other impairment charges	12 Months Ended
	Dec. 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring and other impairment charges	Restructuring and other impairment charges 2024 Restructuring plan During the fourth quarter of 2024, we initiated the "2024 restructuring plan," a strategic restructuring plan aimed at optimizing operations, reducing costs and enhancing efficiencies across our business lines, and includes the relocation of select office administrative operations. We estimate that we will incur aggregate pre-tax restructuring charges of $6 million to $7 million consisting primarily of termination benefits. In addition, we expect to incur $3 million to $4 million in restructuring related charges, most of which are expected to be recognized in selling, general and administrative expenses. We expect this plan will be substantially completed by the end of 2025. For the year ended December 31, 2024, we incurred $0.2 million in restructuring related charges in connection with the 2024 restructuring plan, substantially all of which was recognized in selling, general and administrative expenses. 2024 Footprint realignment plan During the second quarter of 2024, we initiated the "2024 Footprint realignment plan," encompassing several strategic restructuring initiatives. These initiatives primarily include the relocation of select manufacturing operations to existing lower-cost locations, the optimization of specific product portfolios through targeted rationalization efforts, the relocation of certain integral product development and manufacturing support functions, the optimization of certain supply chain activities and related workforce reductions. The actions under the 2024 Footprint realignment plan are expected to be substantially completed by the end of 2025. The following table provides a summary of the cost estimates by major type of expense associated with the 2024 Footprint realignment plan: Total estimated amount expected to be incurred Plan expense estimates: (Dollars in millions) Restructuring charges (1) $16 million to $20 million Restructuring related charges (2) $21 million to $26 million Total restructuring and restructuring related charges $37 million to $46 million (1) Substantially all of the charges consist of employee termination benefit cost. (2) Consists of pre-tax charges related to accelerated depreciation and other costs directly related to the plan, primarily project management costs and costs to relocate manufacturing operations and support functions to the new locations. Substantially all of the charges are expected to be recognized within costs of goods sold. For the year ended December 31, 2024, we incurred $6.6 million in restructuring related charges in connection with the 2024 Footprint realignment plan, substantially all of which was recognized in cost of goods sold. 2023 Footprint Realignment plan During the third quarter of 2023, we initiated the "2023 Footprint realignment plan," a restructuring plan primarily involving the relocation of certain manufacturing operations to existing lower-cost locations, the outsourcing of certain manufacturing processes and related workforce reductions. These actions are expected to be substantially completed by the end of 2027. The following table provides a summary of the cost estimates by major type of expense associated with the 2023 Footprint realignment plan: Total estimated amount expected to be incurred Plan expense estimates: (Dollars in millions) Restructuring charges (1) $4 million to $6 million Restructuring related charges (2) $7 million to $9 million Total restructuring and restructuring related charges $11 million to $15 million (1) Substantially all of the charges consist of employee termination benefit cost. (2) Restructuring related charges represent costs that are directly related to the 2023 Footprint realignment plan and principally constitute costs to transfer manufacturing operations to existing lower-cost locations and project management costs. Substantially all of these charges are expected to be recognized within cost of goods sold. For the year ended December 31, 2024, we incurred $2.6 million in restructuring related charges in connection with the 2023 Footprint realignment plan, all of which was recognized in cost of goods sold. As of December 31, 2024, we have incurred aggregate restructuring charges in connection with the 2023 Footprint realignment plan of $2.8 million. In addition, as of December 31, 2024, we have incurred aggregate restructuring related charges of $2.7 million with respect to the 2023 Footprint realignment plan, consisting of certain costs that principally resulted from the transfer of manufacturing operations to new locations. 2023 Restructuring plan During the fourth quarter of 2023, we initiated the "2023 restructuring plan," which primarily involves the integration of Palette into Teleflex and workforce reductions designed to improve operating performance across the organization by creating efficiencies that align with evolving market demands and our strategy to enhance long-term value creation. The plan is substantially complete and as a result, we expect future restructuring expenses associated with the plan to be immaterial. The following table summarizes the restructuring reserve activity related to our 2024 Restructuring plan, 2024 Footprint realignment plan and 2023 Footprint realignment plan: 2024 Restructuring plan 2024 Footprint realignment plan 2023 Footprint realignment plan Balance at December 31, 2022 $ — $ — $ — Subsequent accruals — — 1,451 Cash payments — — (108) Balance at December 31, 2023 (1) — — 1,343 Accruals 6,100 11,203 1,377 Cash payments (777) (1,442) (32) Foreign currency translation and other 427 961 — Balance at December 31, 2024 (1) $ 5,750 $ 10,722 $ 2,688 (1) The restructuring reserves as of December 31, 2024 and 2023 consisted mainly of accruals related to termination benefits. Other costs (facility closure, employee relocation, equipment relocation and outplacement costs) were expensed and paid in the same period. The restructuring and impairment charges recognized for the years ended December 31, 2024, 2023, and 2022 consisted of the following: 2024 Termination benefits Other Costs (1) Total 2024 Restructuring plan $ 6,086 $ 14 $ 6,100 2024 Footprint realignment plan 11,164 39 11,203 2023 Restructuring plan (1,524) 82 (1,442) 2023 Footprint realignment plan 1,344 33 1,377 2022 Restructuring plan (1,454) 22 (1,432) Other restructuring programs (2) (1,665) 16 (1,649) Total restructuring charges 13,951 206 14,157 Asset impairment charges — 7,834 7,834 Total restructuring and other impairment charges $ 13,951 $ 8,040 $ 21,991 2023 Termination benefits Other Costs (1) Total 2023 Restructuring plan $ 12,535 $ — $ 12,535 2023 Footprint realignment plan 1,451 — 1,451 2022 Restructuring plan 2,759 369 3,128 Respiratory divestiture plan (946) 17 (929) Other restructuring programs (3) (1,015) 434 (581) Total restructuring and other impairment charges $ 14,784 $ 820 $ 15,604 2022 Termination benefits Other Costs (1) Total 2022 Restructuring plan $ 15,465 $ 58 $ 15,523 Respiratory divestiture plan 504 74 578 2019 Footprint realignment plan (1,120) 133 (987) 2018 Footprint realignment plan 1,230 846 2,076 Other restructuring programs (3) 1,306 306 1,612 Total restructuring charges 17,385 1,417 18,802 Asset impairment charges — 1,497 1,497 Total restructuring and other impairment charges $ 17,385 $ 2,914 $ 20,299 (1) Includes facility closure, contract termination and other exit costs. (2) Includes activity primarily related to our 2018 and 2019 Footprint realignment plans, which have concluded. (3) Includes activity primarily related to a restructuring plan initiated in the first quarter of 2022 that is designed to relocate manufacturing operations at certain of our facilities (the "2022 Manufacturing relocation plan") and our 2014, 2018, and 2019 Footprint realignment plans, which have concluded. Other Impairment charges For the year ended December 31, 2024, we recorded non-cash impairment charges totaling $7.8 million related to a decrease in the carrying value of an equity investment and an impairment of a portion of our operating lease assets stemming from our cessation of occupancy of a specific facility. For the year ended December 31, 2022, we recorded impairment charges of $1.5 million related to our decision to abandon certain assets.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories at December 31, 2024 and 2023 consist of the following: 2024 2023 Raw materials $ 155,201 $ 179,517 Work-in-process 115,814 111,132 Finished goods 329,118 335,567 Inventories $ 600,133 $ 626,216

Property, plant and equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Property, plant and equipment	Property, plant and equipment The major classes of property, plant and equipment, at cost, at December 31, 2024 and 2023 were as follows: 2024 2023 Land, buildings and leasehold improvements $ 291,696 $ 284,604 Machinery and equipment 474,879 459,268 Computer equipment and software 234,251 214,573 Construction in progress 112,708 94,633 1,113,534 1,053,078 Less: Accumulated depreciation (610,682) (573,165) Property, plant and equipment, net $ 502,852 $ 479,913

Goodwill and other intangible a

Goodwill and other intangible assets	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets	Goodwill and other intangible assets Changes in the carrying amount of goodwill, by reportable operating segment, for the years ended December 31, 2024 and 2023 were as follows: Americas EMEA Asia Total Balance as of December 31, 2022 Goodwill $ 1,843,103 $ 468,524 $ 225,103 $ 2,536,730 Goodwill related to acquisitions 333,462 4,284 19,279 357,025 Translation and other adjustments 3,517 14,936 1,847 20,300 Balance as of December 31, 2023 2,180,082 487,744 246,229 2,914,055 Goodwill impairment charge (240,000) — — (240,000) Goodwill related to acquisitions (1,953) — — (1,953) Translation and other adjustments (5,360) (22,255) (12,173) (39,788) Balance as of December 31, 2024 $ 1,932,769 $ 465,489 $ 234,056 $ 2,632,314 Our goodwill impairment testing is performed annually during the fourth quarter of each fiscal year in addition to periods where changes in circumstances indicate that the carrying value of our goodwill assets may not be recoverable. During the second quarter of 2024, we identified indicators of a potential impairment related to our Interventional Urology North America reporting unit (the “IU reporting unit”), included within our Americas operating segment. The indicators of a potential impairment primarily arose from lower than anticipated sales results from our UroLift product line (“UroLift"), primarily driven by the adverse impact of persistent end-market challenges within the U.S. office site of service. We performed a quantitative impairment test of the reporting unit using both the income and the market approaches and no impairment to goodwill was recognized in the second quarter of 2024 as the fair value of the reporting unit exceeded the carrying value. During the third quarter of 2024, the IU reporting unit performed largely in line with the forecast used in the second quarter 2024 quantitative fair value test. In connection with preparing the financial statements for the year ended December 31, 2024, we performed our annual impairment test for goodwill and determined that the carrying value of the IU reporting unit exceeded its fair value. Consequently, we recognized an impairment charge of $240 million in the goodwill impairment line in the Consolidated Statements of Income. The charge was primarily driven by updates to our UroLift forecast, done as part of our annual operating plan process, which reflects management's expectations of a prolonged period of subdued revenue growth due to persistent end-market challenges and changes in competitive pressures in the short to mid-term. Moreover, we anticipate that challenges related to a combination of price, mainly within the office site of service, and volume, will likely continue to impact growth rates. As of December 31, 2024, goodwill of the IU reporting unit was $403.9 million after the impairment charge. We estimated the fair value of the reporting unit using both the income and the market approaches. The more significant judgments and assumptions in determining the fair value of the IU reporting unit for our 2024 impairment assessments included the revenue growth rates, the projected operating margins and the discount rate. The quantitative assessment utilized a discount rate of 10.75%. Intangible assets at December 31, 2024 and 2023 consisted of the following: Gross Carrying Amount Accumulated Amortization 2024 2023 2024 2023 Customer relationships $ 1,354,087 $ 1,363,839 $ (620,619) $ (561,753) In-process research and development 23,666 27,476 — — Intellectual property 1,870,407 1,890,957 (863,066) (745,094) Distribution rights 23,004 23,301 (22,524) (22,048) Trade names 603,202 610,146 (99,443) (84,864) Non-compete agreements 21,894 21,934 (21,894) (21,934) $ 3,896,260 $ 3,937,653 $ (1,627,546) $ (1,435,693) As of December 31, 2024, trade names having a carrying value of $227.7 million are considered indefinite-lived. Acquired IPR&D is indefinite-lived until the completion of the related development project, at which point amortization of the carrying value of the technology will commence. Amortization expense related to intangible assets was $197.7 million, $174.0 million, and $164.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. The estimated annual amortization expense for each of the five succeeding years is as follows: 2025 $ 189,100 2026 186,300 2027 183,100 2028 179,100 2029 169,900

Leases

Leases	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Leases	Leases We have operating leases for various types of properties, consisting of manufacturing plants, engineering and research centers, distribution warehouses, offices and other facilities, and equipment used in operations. Some leases provide us with an option, exercisable at our sole discretion, to terminate the lease or extend the lease term for one Maturities of lease liabilities December 31, 2024 2025 $ 21,965 2026 23,254 2027 21,860 2028 20,327 2029 16,745 2030 and thereafter 32,764 Total lease payments 136,915 Less: interest (20,403) Present value of lease liabilities $ 116,512 Supplemental information December 31, 2024 December 31, 2023 Total lease liabilities (1) $ 116,512 $ 130,801 Cash paid for amounts included in the measurement of lease liabilities within operating cash flows $ 24,483 $ 26,938 Right of use assets obtained in exchange for operating lease obligations $ 4,349 $ 12,145 Weighted average remaining lease term 6.5 years 7.0 years Weighted average discount rate 4.6 % 4.4 % (1) The current portion of the operating lease liability is included in other current liabilities .

Borrowings

Borrowings	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Borrowings	Borrowings Our borrowings at December 31, 2024 and 2023 were as follows: 2024 2023 Senior Credit Facility: Revolving credit facility, at a rate of 5.71% at December 31, 2024, and 6.71% at December 31, 2023, due 2027 $ 113,000 $ 262,000 Term loan facility, at a rate of 5.71% at December 31, 2024 and 6.71% at December 31 2023, due 2027 475,000 487,500 4.625% Senior Notes due 2027 500,000 500,000 4.25% Senior Notes due 2028 500,000 500,000 Securitization program, at a rate of 5.18% at December 31, 2024 and 6.34% at December 31, 2023 75,000 75,000 1,663,000 1,824,500 Less: Unamortized debt issuance costs (7,129) (9,428) 1,655,871 1,815,072 Current portion of borrowings (100,000) (87,500) Long-term borrowings $ 1,555,871 $ 1,727,572 Senior credit facility In 2022, we amended and restated our existing credit agreement by entering into a Third Amended and Restated Credit Agreement (the “Credit Agreement”) which provides for a five-year revolving credit facility of $1.0 billion and a term loan facility of $500.0 million. The obligations under the Credit Agreement are guaranteed (subject to certain exceptions and limitations) by substantially all of our material domestic subsidiaries. The obligations under the Credit Agreement are secured, subject to certain exceptions and limitations, by a lien on substantially all of the assets owned by us and each guarantor. The maturity date of the revolving credit facility and the term loan facility under the Credit Agreement is November 4, 2027. At our option, loans under the Credit Agreement will bear interest at a rate equal to adjusted Term SOFR plus an applicable margin ranging from 1.125% to 2.00% or at an alternate base rate, which is defined as the highest of (i) the “Prime Rate” in the U.S. last quoted by The Wall Street Journal, (ii) 0.50% above the greater of the federal funds rate and the rate comprised of both overnight federal funds and overnight eurodollar transactions denominated in Dollars and (iii) 1.00% above the Term SOFR Rate for a one month interest period, plus an applicable margin ranging from 0.125% to 1.00%, in each case subject to adjustments based on our total net leverage ratio. Overdue loans will bear interest at the rate otherwise applicable to such loans plus 2.00%. The obligations to extend credit under the Credit Agreement are subject to customary conditions for transactions of this type. The Credit Agreement contains customary representations and warranties and covenants that, in each case, subject to certain exceptions, qualifications and thresholds, (a) place limitations on us and our subsidiaries regarding the incurrence of additional indebtedness, additional liens, fundamental changes, dispositions of property, investments and acquisitions, dividends and other restricted payments, transactions with affiliates, restrictive agreements, changes in lines of business and swap agreements, and (b) require us and our subsidiaries to comply with sanction laws and other laws and agreements, to deliver financial information and certain other information and give notice of certain events, to maintain their existence and good standing, to pay their other obligations, to permit the administrative agent and the lenders to inspect their books and property, to use the proceeds of the Credit Agreement only for certain permitted purposes and to provide collateral in the future. Subject to certain exceptions, we are required to maintain a maximum total net leverage ratio of 4.50 to 1.00. We are further required to maintain a minimum interest coverage ratio of 3.50 to 1.00. 4.625% Senior notes due 2027 In 2017, we issued $500.0 million of 4.625% Senior Notes due 2027 (the "2027 Notes"). We pay interest on the 2027 Notes semi-annually on May 15 and November 15, commencing on May 15, 2018, at a rate of 4.625% per year. The 2027 Notes mature on November 15, 2027 unless earlier redeemed by us at our option, as described below, or purchased by us at the holder’s option under specified circumstances following a Change of Control or Asset Sale (each as defined in the indenture related to the 2027 Notes), coupled with a downgrade in the ratings of the 2027 Notes, or upon our election to exercise our optional redemption rights, as described below. We incurred transaction fees of $7.9 million, including underwriters’ discounts and commissions, in connection with the offering of the 2027 Notes, which were recorded on the consolidated balance sheet as a reduction to long-term borrowings and are being amortized over the term of the 2027 Notes. We used the net proceeds from the offering to repay borrowings under our revolving credit facility. Our obligations under the 2027 Notes are fully and unconditionally guaranteed, jointly and severally, by each of our existing and future 100% owned domestic subsidiaries that is a guarantor or other obligor under the Credit Agreement and by certain of our other 100% owned domestic subsidiaries. We may, on one or more occasions, redeem some or all of the 2027 Notes at a redemption price of 102.313% of the principal amount of the 2027 Notes subject to redemption, declining, in annual increments of 0.771%, to 100% of the principal amount on November 15, 2025, plus accrued and unpaid interest. The indenture relating to the 2027 Notes contains covenants that, among other things and subject to certain exceptions, limit or restrict our ability to create liens; merge, consolidate, sell or otherwise dispose of all or substantially all of our assets; or enter into sale leaseback transactions. 4.25% Senior Notes due 2028 In 2020, we issued $500.0 million of 4.25% Senior Notes due 2028 (the "2028 Notes"). We pay interest on the 2028 Notes semi-annually on June 1 and December 1, commencing on December 1, 2020, at a rate of 4.25% per year. The 2028 Notes mature on June 1, 2028 unless earlier redeemed at our option, as described below, or purchased at the holder’s option under specified circumstances following a Change of Control or Event of Default (each as defined in the indenture related to the 2028 Notes), coupled with a downgrade in the ratings of the 2028 Notes, or upon our election to exercise its optional redemption rights, as described below. We incurred transaction fees of $8.5 million, including underwriters’ discounts and commissions, in connection with the offering of the 2028 Notes, which were recorded on the consolidated balance sheet as a reduction to long-term borrowings and are being amortized over the term of the 2028 Notes. We used the net proceeds from the offering to repay borrowings under our revolving credit facility. Our obligations under the 2028 Notes are fully and unconditionally guaranteed, jointly and severally, by each of our existing and future 100% owned domestic subsidiaries that is a guarantor or other obligor under the Credit Agreement and by certain of our other 100% owned domestic subsidiaries. We may, on one or more occasions, redeem some or all of the 2028 Notes at a redemption price of 102.125% of the principal amount of the 2028 Notes subject to redemption, declining, in annual increments of 1.0625%, to 100% of the principal amount on June 1, 2025, plus accrued and unpaid interest. The indenture relating to the 2028 Notes contains covenants that, among other things, limit or restrict our ability, and the ability of our subsidiaries, to create liens; merge, consolidate, sell or otherwise dispose of all or substantially all of our assets; and enter into sale leaseback transactions. Securitization program We have an accounts receivable securitization facility under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of Teleflex. Accordingly, the assets of the SPE are not available to satisfy the obligations of Teleflex or any of its subsidiaries. The SPE sells undivided interests in those receivables to an asset backed commercial paper conduit for consideration of up to the maximum available capacity. This facility is utilized from time to time to provide increased flexibility in funding short term working capital requirements. The agreement governing the accounts receivable securitization facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this facility may give rise to the right of its counterparty to terminate this facility. As of December 31, 2024, we were in compliance with the covenants, and none of the termination events had occurred. As of December 31, 2024 and 2023, we had $75.0 million (the maximum amount available) of outstanding borrowings under our accounts receivable securitization facility. VI Business acquisition financing On February 24, 2025, we amended and restated our existing Credit Agreement to facilitate our upcoming acquisition of the VI Business. See Note 20 for additional information. Fair value of long-term debt To determine the fair value of our debt for which quoted prices are not available, we use a discounted cash flow technique that incorporates a market interest yield curve with adjustments for duration, optionality and risk profile. Our implied credit rating is a factor in determining the market interest yield curve. The following table provides the fair value of our debt as of December 31, 2024 and 2023, which is valued based on Level 2 inputs within the hierarchy used to measure fair value (see Note 12 for further information): December 31, 2024 December 31, 2023 Fair value of debt $ 1,632,020 $ 1,838,993 Debt Maturities As of December 31, 2024, the aggregate amounts of long-term debt, demand loans and debt under our securitization program that will mature during each of the next four years and thereafter were as follows: 2025 $ 100,000 2026 25,000 2027 1,038,000 2028 500,000 2029 and thereafter — Supplemental cash flow information Year Ended December 31, 2024 2023 2022 Cash interest paid $ 98,376 $ 100,218 $ 70,918

Financial instruments

Financial instruments	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial instruments Foreign currency forward contracts We use derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage foreign currency transaction exposure. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. We enter into the non-designated foreign currency forward contracts for periods consistent with the currency exposures, which generally approximate one month. For the years ended December 31, 2024 and 2023, we recognized a gain of $4.1 million and a loss of $3.2 million, respectively, related to non-designated foreign currency forward contracts. The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of December 31, 2024 and 2023 was $270.9 million and $234.1 million, respectively. The total notional amount for all open non-designated foreign currency forward contracts as of December 31, 2024 and 2023 was $168.6 million and $195.0 million, respectively. All open foreign currency forward contracts as of December 31, 2024 have durations of 12 months or less. VI Business acquisition foreign exchange derivative contracts In conjunction with our upcoming acquisition of the VI Business, we entered into foreign exchange derivative contracts with an aggregate notional value of €700 million to economically hedge against the foreign currency exposure associated with the cash consideration needed to complete the acquisition. See Note 20 for additional information. Cross-currency interest rate swaps During 2019, we entered into cross-currency swap agreements with five different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate (the "2019 Cross-currency swaps"). Under the terms of the cross-currency swap agreements, we notionally exchanged $250 million at an annual interest rate of 4.88% for €219.2 million at an annual interest rate of 2.46%. The swap agreements are designed as net investment hedges. On February 26, 2024, the agreements related to our 2019 Cross-currency swap with an original maturity date of March 4, 2024 were terminated resulting in $12.1 million in cash settlement proceeds. On February 26, 2024, we executed two separate term cross-currency swap agreements set to expire on February 26, 2027 and February 28, 2029, respectively, to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Each of the swap agreements had a notional principal amount of $250 million and was designated as a net investment hedge. On April 25, 2024, the cross-currency agreements executed in February 2024 were terminated in response to changes in market conditions, resulting in $0.4 million in a cash settlement payment, and we simultaneously executed two new separate term cross-currency swap agreements with the same expiration dates and notional values (together, the "2024 Cross-currency swap agreements"). The cross-currency swap agreements expiring in 2027 include five different financial institution counterparties and notionally exchanged $250 million at an annual interest rate of 4.25% for €233.4 million at an annual interest rate of 2.44%. The cross-currency swap agreements expiring in 2029 include four different financial institution counterparties and notionally exchanged $250 million at an annual interest rate of 4.25% for €233.4 million at an annual interest rate of 2.45%. Both of the 2024 Cross-currency swap agreements are designated as net investment hedges. During 2023, we executed new cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate, ("the 2023 Cross-currency swaps"). Under the terms of the cross-currency swap agreements, we have notionally exchanged $500 million at an annual interest rate of 4.63% for €474.7 million at an annual interest rate of 3.05%. The swap agreements are designated as net investment hedges and expire on October 4, 2025. Shortly after the execution of the 2023 Cross-currency swaps, we entered into a zero cost foreign exchange collar contract that aligns with the notional amount and expiration date of the 2023 Cross-currency swaps. We sold a put option with a lower strike price and bought a call option with a higher strike price to manage the foreign exchange risk related to the final settlement of the $500 million notional cross currency swaps. Upon the execution of the zero cost foreign exchange collar contract, we have de-designated the existing $500 million notional cross-currency swaps and re-designated the combined $500 million notional cross currency swaps and zero cost collar into a new hedging instrument. At re-designation, the existing $500 million notional cross-currency swaps were off- market due to changes in foreign exchange rates and interest rates. The off-market value due to interest rates will be amortized ratably into earnings through October 2025 and the off-market value due to foreign exchange rates will remain in accumulated other comprehensive income until the underlying net investment is sold. The combined cross-currency swaps and zero cost collar has been designated as a net investment hedge for accounting purposes. The swap agreements described above require an exchange of the notional amounts upon expiration or earlier termination of the agreements. We and the counterparties have agreed to effect the exchange through a net settlement. The cross-currency swaps are marked to market at each reporting date and any changes in fair value are recognized as a component of accumulated other comprehensive income (loss) ("AOCI") while the accrued interest is recognized in interest expense in the statement of operations. The following table summarizes the foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense related to cross currency swaps for the years ended December 31, 2024 and December 31, 2023: December 31, 2024 December 31, 2023 Foreign exchange gains (losses) $ 28,387 $ (24,210) Interest benefit 17,410 18,814 Balance sheet presentation The following table presents the locations in the consolidated balance sheets and fair value of derivative instruments as of December 31, 2024 and 2023: December 31, 2024 December 31, 2023 Asset derivatives: Designated foreign currency forward contracts $ 5,780 $ 1,629 Non-designated foreign currency forward contracts 254 937 Cross-currency interest rate swap 15,972 16,883 Prepaid expenses and other current assets 22,006 19,449 Cross-currency interest rate swap 5,409 — Other assets 5,409 — Total asset derivatives $ 27,415 $ 19,449 Liability derivatives: Designated foreign currency forward contracts $ 3,078 $ 1,866 Non-designated foreign currency forward contracts 931 1,340 Cross-currency interest rate swap 9,575 — Other current liabilities 13,584 3,206 Cross-currency interest rate swap — 32,097 Other liabilities — 32,097 Total liability derivatives $ 13,584 $ 35,303 See Note 13 for information on the location and amount of gains and losses attributable to derivatives that were reclassified from AOCI to expense (income), net of tax. For the years ended December 31, 2024, 2023 and 2022, there was no ineffectiveness related to our hedging derivatives.

Fair value measurement

Fair value measurement	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement Fair value is the price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. Under GAAP, there is a three-level hierarchy of the inputs (i.e., assumptions that market participants would use in pricing an asset or liability) used to measure fair value. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the entire fair value measurement. The levels of inputs within the hierarchy used to measure fair value are as follows: Level 1 — inputs to the fair value measurement that are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 — inputs to the fair value measurement that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 — inputs to the fair value measurement that are unobservable inputs for the asset or liability. The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024 and 2023: Basis of fair value measurement December 31, 2024 (Level 1) (Level 2) (Level 3) Investments in marketable securities $ 39,559 $ 39,559 $ — $ — Derivative assets 27,415 — 27,415 — Derivative liabilities 13,584 — 13,584 — Contingent consideration liabilities 49,277 — — 49,277 Basis of fair value measurement December 31, 2023 (Level 1) (Level 2) (Level 3) Investments in marketable securities $ 5,306 $ 5,306 $ — $ — Derivative assets 19,449 — 19,449 — Derivative liabilities 35,303 — 35,303 — Contingent consideration liabilities 39,486 — — 39,486 There were no transfers of financial assets or liabilities into or out of Level 3 within the fair value hierarchy during the years ended December 31, 2024 or 2023. Valuation Techniques Our financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities, including money market funds. The investment assets are valued using quoted market prices. Our financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts and cross-currency interest rate swap agreements. We use foreign currency forward contracts and cross-currency interest rate swap agreements to manage foreign currency transaction exposure as well as exposure to foreign currency denominated monetary assets and liabilities. We measure the fair value of the foreign currency forward and cross-currency swap agreements by calculating the amount required to enter into offsetting contracts with similar remaining maturities, based on quoted market prices, and taking into account the creditworthiness of the counterparties. Our financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to our acquisitions. Our primary non-recurring fair value estimates, which utilize Level 3 inputs, typically include the following: business acquisitions (Note 4); goodwill impairment testing (Note 8) and asset impairments (Note 5). Contingent consideration Contingent consideration liabilities, which primarily consist of payment obligations that are contingent upon the achievement of revenue-based goals, but also can be based on other milestones such as regulatory approvals, are remeasured to fair value each reporting period using assumptions including revenue growth rates (based on internal operational budgets and long-range strategic plans), revenue volatility, discount rates, probability of payment and projected payment dates. We determine the fair value of certain contingent consideration liabilities using a Monte Carlo simulation (which involves a simulation of future revenues during the earn-out period using management's best estimates) or discounted cash flow analysis. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect. As of December 31, 2024, the maximum amount we could be required to pay under the contingent consideration arrangements related to the Palette and 2022 acquisition of Standard Bariatrics Inc. was $177.0 million. The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of our significant contingent consideration liabilities. Contingent Consideration Liability Valuation Technique Unobservable Input Revenue-based Monte Carlo simulation Revenue volatility 17.5% Risk free rate Cost of debt structure Projected year of payment 2025 - 2026 The following table provides information regarding changes in our contingent consideration liabilities for the years ended December 31, 2024 and 2023: Contingent consideration 2024 2023 Beginning balance – January 1 $ 39,486 $ 44,022 Initial estimate upon acquisition — 27,000 Payments (236) (4,293) Revaluations and other adjustments 10,027 (27,243) Ending balance – December 31 $ 49,277 $ 39,486

Shareholders' equity

Shareholders' equity	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Shareholders' equity	Shareholders' equity Our authorized capital is comprised of 200 million common shares, $1 par value, and 500,000 preference shares. No preference shares have been outstanding during the last three years. Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average shares outstanding: 2024 2023 2022 Basic 46,837 46,981 46,898 Dilutive effect of share based awards 257 323 411 Diluted 47,094 47,304 47,309 Weighted average shares that were antidilutive and therefore excluded from the calculation of diluted earnings per share were 0.9 million, 0.7 million, and 0.5 million for the years ended December 31, 2024, 2023, and 2022, respectively. On July 30, 2024, the Board of Directors authorized a share repurchase program for up to $500 million of our common stock. The timing, price and actual number of shares of common stock that may be repurchased under the share repurchase authorization will depend on a variety of factors including price, market conditions and corporate and regulatory requirements. The repurchases may occur in open market transactions, transactions structured through investment banking institutions, in privately negotiated transactions, by direct purchases of common stock or a combination of the foregoing, and the timing and amount of stock repurchased will depend on market and business conditions, applicable legal and credit requirements and other corporate considerations. The authorization of the repurchase program does not constitute a binding obligation to acquire any specific amount of common stock, and the repurchase program may be suspended or discontinued at any time. On August 2, 2024, we entered into an accelerated share repurchase agreement for $200 million of our common stock. Under this agreement, 678,110 shares of common stock, representing 80% of the $200 million aggregate, were delivered and included in treasury stock. The initial shares received were calculated based on a price per share of $235.95, which was the closing share price of our common stock on August 1, 2024. Final settlement under the ASR Transaction occurred on October 30, 2024, at which time we received 172,351 additional shares of common stock. The total shares received were calculated based on a price per share of $235.17, which was based on volume-weighted average prices of our common stock during the accelerated share repurchase period less a discount. In February 2025, we entered into a new $300 million accelerated share repurchase agreement. See Note 20 for additional information related to this agreement. The following table provides information relating to the changes in accumulated other comprehensive income (loss), net of tax, for each of the years ended December 31, 2024 and 2023: Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive Income (Loss) Balance at December 31, 2022 $ 4,931 $ (135,799) $ (272,654) $ (403,522) Other comprehensive income before reclassifications 8,314 42,380 44,902 95,596 Amounts reclassified from accumulated other comprehensive income (11,849) 5,370 — (6,479) Net current-year other comprehensive income (loss) (3,535) 47,750 44,902 89,117 Balance at December 31, 2023 1,396 (88,049) (227,752) (314,405) Other comprehensive income (loss) before reclassifications 1,977 10,465 (92,594) (80,152) Amounts reclassified from accumulated other comprehensive income (1,534) 79,422 — 77,888 Net current-year other comprehensive (loss) income 443 89,887 (92,594) (2,264) Balance at December 31, 2024 $ 1,839 $ 1,838 $ (320,346) $ (316,669) The following table provides information relating to the (gains) losses recognized in the statements of income including the reclassifications of losses (gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the years ended December 31, 2024, 2023 and 2022: Year Ended December 31, 2024 2023 2022 (Gains) losses on designated foreign exchange forward contracts: Cost of goods sold $ (1,626) $ (12,234) $ (3,532) Total before tax (1,626) (12,234) (3,532) Taxes expense 92 385 203 Net of tax (1,534) (11,849) (3,329) Amortization of pension and other postretirement benefits items: Actuarial losses (1) 1,152 7,989 7,660 Prior-service credits (1) (1,967) (1,008) (1,017) Settlements 138,139 — — Total before tax 137,324 6,981 6,643 Tax benefit (57,902) (1,611) (1,546) Net of tax 79,422 5,370 5,097 Impact on income from continuing operations, net of tax $ 77,888 $ (6,479) $ 1,768 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 16 for additional information).

Stock compensation plans

Stock compensation plans	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement, Noncash Expense [Abstract]
Stock compensation plans	Stock compensation plans In May 2023, our stockholders approved the Teleflex Incorporated 2023 Stock Incentive Plan (the "Plan”), The Plan provides for several different kinds of awards, including stock options, stock appreciation rights, stock awards, stock unit awards and other stock-based awards to directors, officers and key employees. Under the Plan, the Company is authorized to issue up to 4.3 million shares of common stock, subject to adjustment in accordance with special share counting rules in the Plan. Options granted under the Plan have an exercise price equal to the closing price of the Company's common stock on the date of the grant. In 2024, we granted incentive and non-qualified options to purchase 193,826 shares of common stock and granted restricted stock units representing 108,777 shares of common stock under the Plan. Under our equity incentive program, we issue performance share units ("PSUs") designed to further incentivize our senior management with respect to the achievement of our long term financial objectives. The PSU component of the equity incentive program is designed to provide shares of our common stock to the holder based upon our achievement of certain financial performance criteria during a designated performance period of three years. The number of shares to be awarded under the PSUs granted are subject to modification based upon our total stockholder return relative to a designated group of public companies. Assuming target performance is achieved, a total of 45,052 shares of common stock would be issuable in respect of the PSUs granted and a maximum of 111,696 shares would be issuable in respect of such PSUs upon achievement of maximum performance levels. The following table summarizes the share-based compensation activity: 2024 2023 2022 Share-based compensation expense $ 31,348 $ 31,465 $ 27,224 Total income tax benefit recognized for share-based compensation arrangements 5,325 7,820 6,824 Net excess tax (deficiency) benefit (1,542) 1,351 1,292 The unrecognized compensation expense for all awards granted in 2024 as of the grant date was $41.5 million, which will be recognized over the vesting period of the awards. As of December 31, 2024, 3,583,530 shares were available for future grants under the Plan. Option Awards The fair value of options granted in 2024, 2023 and 2022 was estimated at the date of grant using a Black-Scholes option pricing model. The following weighted-average assumptions were used: 2024 2023 2022 Risk-free interest rate 4.28 % 4.13 % 1.56 % Expected life of option 5.11 years 5.07 years 5.03 years Expected dividend yield 0.60 % 0.57 % 0.41 % Expected volatility 30.00 % 31.42 % 30.09 % The following table summarizes the option activity during 2024: Shares Subject to Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life In Years Aggregate Intrinsic Value Outstanding, beginning of the year 1,293,775 $ 239.55 Granted 193,826 223.94 Exercised (50,465) 135.91 Forfeited or expired (43,382) 294.22 Outstanding, end of the year 1,393,754 239.43 4.5 $ 13,718 Exercisable, end of the year 1,052,394 $ 238.65 3.2 $ 13,718 The weighted average grant date fair value for options granted during 2024, 2023 and 2022 was $70.28, $76.46 and $88.92, respectively. The total intrinsic value of options exercised during 2024, 2023 and 2022 was $4.7 million, $13.5 million and $5.0 million, respectively. We recorded $12.8 million of expense related to options during 2024, which is included in cost of goods sold or selling, general and administrative expenses. As of December 31, 2024, the unamortized share-based compensation cost related to non-vested stock options, net of expected forfeitures, was $13.7 million, which is expected to be recognized over a weighted-average period of 1.5 years. Authorized but unissued shares of our common stock are issued upon exercises of options. Stock Awards The fair value of PSUs granted were determined using a Monte Carlo simulation valuation model. The grant date fair value for the 2024 PSU awards was $220.45. The fair value for restricted stock units approximates the closing market price of Teleflex’s common stock on the grant date, adjusted for units that are ineligible for the accrual of dividend equivalents. The following table summarizes the non-vested restricted stock unit activity during 2024: Number of Non-Vested Shares Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding, beginning of the year 190,500 $ 294.63 Granted 108,777 220.18 Vested (42,896) 370.96 Forfeited (28,057) 262.41 Outstanding, end of the year 228,324 $ 248.79 1.3 $ 40,637 We issued 108,777, 98,201 and 85,780 of non-vested restricted stock units in 2024, 2023 and 2022, respectively, the majority of which provide for vesting as to all underlying shares on the third anniversary of the grant date. The weighted average grant-date fair value for non-vested restricted stock units granted during 2024, 2023 and 2022 was $220.18, $235.14 and $323.35, respectively.

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The following table summarizes the components of the provision for income taxes from continuing operations: 2024 2023 2022 Current: Federal $ 74,748 $ 51,717 $ 32,798 State 16,476 8,266 8,747 Non-U.S. 43,830 30,408 56,442 Deferred: Federal (103,387) (24,396) (27,528) State (10,265) 5,439 10,116 Non-U.S. (16,086) 5,006 2,428 $ 5,316 $ 76,440 $ 83,003 At December 31, 2024, the cumulative unremitted earnings of subsidiaries outside the U.S. that are considered non-permanently reinvested and for which taxes have been provided approximated $2.6 billion. At December 31, 2024, no cumulative unremitted earnings of subsidiaries outside the U.S. are considered permanently reinvested. The following table summarizes the U.S. and non-U.S. components of income from continuing operations before taxes: 2024 2023 2022 U.S. $ (171,380) $ 45,363 $ 164,151 Non-U.S. 246,858 388,649 281,768 $ 75,478 $ 434,012 $ 445,919 Reconciliations between the statutory federal income tax rate and the effective income tax rate are as follows: 2024 2023 2022 Federal statutory rate 21.0 % 21.0 % 21.0 % Tax effect of international items (57.6) (6.1) (4.6) Pension settlement charge (38.5) (0.2) — Legal entity rationalization - deferred taxes — 5.7 — Excess tax benefits related to share-based compensation 2.0 (0.3) (0.3) State taxes, net of federal benefit 10.4 0.6 3.4 Uncertain tax contingencies (1.2) (0.6) (0.4) Contingent consideration 3.8 (1.3) 0.1 Goodwill impairment charge 66.8 — — Research and development tax credit (5.9) (1.3) (1.0) Other, net 6.2 0.1 0.5 7.0 % 17.6 % 18.6 % The effective income tax rate for 2024 was 7.0% compared to 17.6% for 2023. The effective income tax rate for 2024 reflects a non-deductible goodwill impairment charge recognized in connection with our annual impairment test for goodwill. Tax benefits were recognized in both 2024 and 2023 related to the pension settlement charge recognized in connection with the termination of the TRIP, as described in Note 16. The effective income tax rate for 2023 reflects the impact of deferred charges resulting from a legal entity rationalization, the impact of a non-taxable contingent consideration adjustment recognized in connection with a decrease in the estimated fair value of our contingent consideration liabilities and a tax expense resulting from a deferred charge relating to the 2022 Restructuring Plan. We are routinely subject to examinations by various taxing authorities. In conjunction with these examinations and as a regular practice, we establish and adjust reserves with respect to its uncertain tax positions to address developments related to those positions. We realized a net benefit of $0.9 million, $2.3 million and $2.0 million in 2024, 2023 and 2022 respectively, as a result of reducing our reserves with respect to uncertain tax positions, principally due to the expiration of a number of applicable statutes of limitations. The following table summarizes significant components of our deferred tax assets and liabilities at December 31, 2024 and 2023: 2024 2023 Deferred tax assets: Tax loss and credit carryforwards $ 114,244 $ 114,147 Lease Liabilities 26,897 30,397 Reserves and accruals 77,493 72,040 Other 11,079 33,472 Less: valuation allowances (88,412) (95,747) Total deferred tax assets 141,301 154,309 Deferred tax liabilities: Property, plant and equipment 16,598 34,852 Intangibles — stock acquisitions 419,172 462,559 Unremitted non-U.S. earnings 51,638 61,734 Lease Assets 26,897 30,397 Other 6,688 14,099 Total deferred tax liabilities 520,993 603,641 Net deferred tax liability $ (379,692) $ (449,332) Under the tax laws of various jurisdictions in which we operate, deductions or credits that cannot be fully utilized for tax purposes during the current year may be carried forward, subject to statutory limitations, to reduce taxable income or taxes payable in a future tax year. At December 31, 2024, the tax effect of such carryforwards approximated $114.2 million. Of this amount, $21.0 million has no expiration date, $12.5 million expires after 2024 but before the end of 2029 and $80.7 million expires after 2029. A portion of these carryforwards consists of tax losses and credits obtained by us as a result of acquisitions; the utilization of these carryforwards is subject to an annual limitation imposed by Section 382 of the Internal Revenue Code of 1986, as amended (the "Code"), which limits a company’s ability to deduct prior net operating losses following a more than 50 percent change in ownership. It is not expected that the Section 382 limitation will prevent us ultimately from utilizing the applicable loss carryforwards. The determination of state net operating loss carryforwards is dependent upon the U.S. subsidiaries’ taxable income or loss, the state’s proportion of each subsidiary's taxable net income and the application of state laws, which can change from year to year and impact the amount of such carryforward. The valuation allowance for deferred tax assets of $88.4 million and $95.7 million at December 31, 2024 and 2023, respectively, relates principally to the uncertainty of our ability to utilize certain deferred tax assets, primarily tax loss and credit carryforwards in various jurisdictions. The valuation allowance was calculated in accordance with applicable accounting standards, which require that a valuation allowance be established and maintained when it is “more likely than not” that all or a portion of deferred tax assets will not be realized. Uncertain Tax Positions : The following table is a reconciliation of the beginning and ending balances for liabilities associated with unrecognized tax benefits for the years ended December 31, 2024, 2023 and 2022: 2024 2023 2022 Balance at January 1 $ 2,020 $ 4,260 $ 6,105 Increase in unrecognized tax benefits related to prior years — — 215 Decrease in unrecognized tax benefits related to prior years — — (761) Reductions in unrecognized tax benefits due to lapse of applicable statute of limitations (902) (2,287) (1,117) (Decrease) increase in unrecognized tax benefits due to foreign currency translation (97) 47 (182) Balance at December 31 $ 1,021 $ 2,020 $ 4,260 The total liabilities associated with the unrecognized tax benefits that, if recognized, would impact the effective tax rate for continuing operations, were $0.7 million at December 31, 2024. We accrue interest and penalties associated with unrecognized tax benefits in income tax expense in the consolidated statements of income, and the corresponding liability is included in the consolidated balance sheets. The net interest expense (benefit) and penalties reflected in income from continuing operations for the year ended December 31, 2024 was $0.1 million and $(0.3) million, respectively; for the year ended December 31, 2023, $0.1 million and $(0.6) million, respectively; and for the year ended December 31, 2022, $0.2 million and $(0.2) million, respectively. The liabilities in the consolidated balance sheets for interest and penalties at December 31, 2024 were $0.3 million and $0.5 million, respectively, and at December 31, 2023, $0.4 million and $1.0 million, respectively. The taxable years for which the applicable statute of limitations remains open by major tax jurisdictions are as follows: Beginning Ending U.S. 2017 2024 Canada 2020 2024 China 2019 2024 Czech Republic 2021 2024 France 2022 2024 Germany 2011 2024 India 2017 2024 Ireland 2020 2024 Italy 2019 2024 Malaysia 2018 2024 Singapore 2020 2024 We are routinely subject to income tax examinations by various taxing authorities. As of December 31, 2024, the most significant tax examinations in process were in Germany and the United States. The date at which these examinations may be concluded and the ultimate outcome of the examinations are uncertain. As a result of the uncertain outcome of these ongoing examinations, future examinations or the expiration of statutes of limitation, it is reasonably possible that the related unrecognized tax benefits for tax positions taken could materially change from those recorded as liabilities at December 31, 2024. Due to the potential for resolution of certain examinations, and the expiration of various statutes of limitations, it is reasonably possible that our unrecognized tax benefits may change within the next year by a range of zero to $0.7 million. Supplemental cash flow information Year Ended December 31, 2024 2023 2022 Income taxes paid, net of refunds $ 164,902 $ 114,211 $ 162,046

Pension and other postretiremen

Pension and other postretirement benefits	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Pension and other postretirement benefits	Pension and other postretirement benefits We have a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. The defined benefit pension plans are noncontributory. The benefits under these plans are based primarily on years of service and employees’ pay near retirement. Our funding policy for U.S. plans is to contribute annually, at a minimum, amounts required by applicable laws and regulations. Obligations under non-U.S. plans are systematically provided for by depositing funds with trustees or by book reserves. As of December 31, 2024, no further benefits are being accrued under the U.S. defined benefit pension plans and the other postretirement benefit plans, other than certain postretirement benefit plans covering employees subject to a collective bargaining agreement. In 2023, we began the execution of a plan to terminate the TRIP, a U.S. defined benefit pension plan. The TRIP is subject to Title IV of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), and, therefore, must be terminated in accordance with the requirements of ERISA and the process governed by the Pension Benefit Guaranty Corporation (the “PBGC”). The termination date of the TRIP was August 1, 2023, which is the date upon which the timing of the requirements for the formal termination process is based. On September 8, 2023, we filed the required notice regarding the TRIP termination with the PBGC. The termination process requires that all TRIP benefits be distributed to participants, beneficiaries and alternate payees or transferred to a group annuity contract or the PBGC. In December 2023, we made payments to eligible participants, beneficiaries and alternate payees who elected the one-time lump sum distribution option offered in connection with the TRIP termination, resulting in the recognition of a pre-tax settlement charge of $45.2 million. In 2024, we purchased a group annuity contract, using TRIP assets, which resulted in the recognition of net pre-tax settlement charges of $132.7 million for the year-ended December 31, 2024. The participants, beneficiaries, and alternate payees whose benefits were transferred to the group annuity contract will each receive from such group annuity contract the full value of their benefit that accrued under the TRIP. The assets in the TRIP Trust exceed the estimated liability for amounts to be transferred to the PBGC for missing participants and beneficiaries (“surplus plan assets”) and as a result, we transferred $43.0 million of the surplus plan assets to a suspense account within the Teleflex 401(k) Savings Plan, a qualified defined contribution plan. These assets are restricted for future use in accordance with our election to use them to fund future employer contributions to participants in the Teleflex 401(k) Savings Plan. The surplus assets contributed to the suspense account remaining as of December 31, 2024 are included within prepaid and other current assets and other assets on the Consolidated Balance Sheet. For additional information regarding the surplus plan assets classified as restricted cash equivalents included within prepaid and other current assets and other assets for the year ended December 31, 2024, refer to Note 19 within the consolidated financial statements included in this report. Teleflex and certain of our subsidiaries provide medical, dental and life insurance benefits to pensioners or their survivors. The associated plans are unfunded and approved claims are paid from our funds. The following table provides information regarding the components of the net benefit (income) expense of the pension and postretirement benefit plans for the years ended December 31, 2024, 2023 and 2022: Pension Other Benefits 2024 2023 2022 2024 2023 2022 Service cost $ 823 $ 1,435 $ 1,346 $ — $ — $ — Interest cost 2,940 17,297 10,776 384 824 477 Expected return on plan assets (2,591) (25,277) (25,776) — — — Net amortization and deferral 1,849 8,536 7,900 (2,664) (1,564) (1,258) Settlements, net 132,732 45,244 — — — — Net benefit expense (income) $ 135,753 $ 47,235 $ (5,754) $ (2,280) $ (740) $ (781) Net benefit expense (income) is primarily included in selling, general and administrative expenses within the consolidated statements of income. The following table provides the weighted average assumptions for U.S. and foreign plans used in determining net benefit cost: Pension Other Benefits 2024 2023 2022 2024 2023 2022 Discount rate 4.7 % 5.1 % 2.8 % 5.0 % 5.1 % 2.7 % Rate of return 4.8 % 7.3 % 5.6 % Initial healthcare trend rate 6.9 % 6.1 % 6.4 % Ultimate healthcare trend rate 4.5 % 4.5 % 4.5 % The following table provides summarized information with respect to the pension and postretirement benefit plans, measured as of December 31, 2024 and 2023: Pension Other Benefits 2024 2023 2024 2023 Benefit obligation, beginning of year $ 275,397 $ 356,757 $ 9,535 $ 18,620 Service cost 823 1,435 — — Interest cost 2,940 17,297 384 824 Actuarial loss (gain) (7,798) 11,557 (2,150) (508) Currency translation (1,028) 1,067 — — Benefits paid (227,491) (21,208) (545) (1,910) Liability gain due to settlement (16,969) (15,272) — — Medicare Part D reimbursement — — 51 (3) Plan amendments — — — (7,488) Settlements — (73,932) — — Administrative costs (767) (2,304) — — Projected benefit obligation, end of year 25,107 275,397 7,275 9,535 Fair value of plan assets, beginning of year 285,513 357,270 Actual return on plan assets (5,241) 23,740 Contributions 1,663 1,276 Benefits paid (227,491) (95,139) Administrative costs (767) (2,304) Assets Transferred to Qualified Replacement Plan (42,966) — Currency translation (179) 670 Fair value of plan assets, end of year 10,532 285,513 Funded status, end of year $ (14,575) $ 10,116 $ (7,275) $ (9,535) The actuarial gain for pension for the year ended December 31, 2024 was primarily due to an increase in the discount rate for the TRIP plan prior to its termination in Q1 2024 and an increase in the discount rate and financial assumption changes for non-US pension plans. The actuarial loss for pension for the year ended December 31, 2023 was primarily due to a decrease in the discount rate used to measure the obligation, offset by demographic gains. The accumulated benefit obligations (ABO) and the projected benefit obligations (PBO) for plans with ABO and PBO in excess of plan assets were $14.6 million and $15.1 million, respectively, at December 31, 2024 and $262.6 million and $263.2 million respectively, at December 31, 2023. The fair value of plan assets for plans with PBO and ABO in excess of plan assets were $0.0 million and $272.3 million at December 31, 2024 and December 31, 2023, respectively. The following table sets forth the amounts recognized in the consolidated balance sheet with respect to the pension and postretirement plans: Pension Other Benefits 2024 2023 2024 2023 Other assets $ 477 $ 27,370 $ — $ — Payroll and benefit-related liabilities (1,117) (1,439) (1,025) (1,361) Pension and postretirement benefit liabilities (13,935) (15,815) (6,250) (8,174) Accumulated other comprehensive loss (gain) 12,677 164,139 (13,730) (14,244) $ (1,898) $ 174,255 $ (21,005) $ (23,779) The following tables set forth the amounts recognized in accumulated other comprehensive income with respect to the plans: Pension Prior Service Cost Net Loss or (Gain) Deferred Taxes Accumulated Other Comprehensive Balance at December 31, 2022 $ 200 $ 219,355 $ (77,347) $ 142,208 Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral (9) (8,527) 1,961 (6,575) Amounts arising during the period: Actuarial changes in benefit obligation — (47,453) 10,805 (36,648) Impact of currency translation — 573 (139) 434 Balance at December 31, 2023 191 163,948 (64,720) 99,419 Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral — (1,849) 446 (1,403) Amounts arising during the period: Actuarial changes in benefit obligation (1) — (149,294) 60,645 (88,649) Impact of currency translation — (319) 86 (233) Balance at December 31, 2024 $ 191 $ 12,486 $ (3,543) $ 9,134 (1) The tax benefit primarily relates to an adjustment to deferred taxes associated with the settlement charge and stranded tax costs within accumulated other comprehensive income. Other Benefits Prior Service Cost Net (Gain) or Loss Deferred Taxes Accumulated Other Comprehensive Balance at December 31, 2022 $ (2,635) $ (5,177) $ 1,403 $ (6,409) Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral 1,017 547 (359) 1,205 Amounts arising during the period: Actuarial changes in benefit obligation — (7,996) 1,830 (6,166) Balance at December 31, 2023 (1,618) (12,626) 2,874 (11,370) Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral 1,967 697 (609) 2,055 Amounts arising during the period: Actuarial changes in benefit obligation — (2,150) 493 (1,657) Balance at December 31, 2024 $ 349 $ (14,079) $ 2,758 $ (10,972) The following table provides the weighted average assumptions for U.S. and foreign plans used in determining benefit obligations: Pension Other Benefits 2024 2023 2024 2023 Discount rate 4.4 % 4.7 % 5.6 % 5.0 % Rate of compensation increase 2.9 % 3.0 % Initial healthcare trend rate 6.8 % 6.6 % Ultimate healthcare trend rate 4.5 % 4.5 % The discount rate represents the interest rate used to determine the present value of future cash flows currently expected to be required to settle the pension and other benefit obligations. The weighted average discount rates for U.S. pension plans and other benefit plans of 5.48% and 5.61%, respectively, were established by comparing the projection of expected benefit payments to the AA Above Median yield curve as of December 31, 2024. The expected benefit payments are discounted by each corresponding discount rate on the yield curve. For payments beyond 30 years, we extend the curve assuming that the discount rate derived in year 30 is extended to the end of the plan’s payment expectations. Once the present value of the string of benefit payments is established, we determine the single rate on the yield curve that, when applied to all obligations of the plan, will exactly match the previously determined present value. As part of the evaluation of pension and other postretirement assumptions, we applied assumptions for mortality and healthcare cost trends that incorporate generational white and blue collar mortality trends. In determining its benefit obligations, we used generational tables that take into consideration increases in plan participant longevity. Our assumption for the expected return on plan assets is primarily based on the determination of an expected return for its current portfolio. This determination is made using assumptions for return and volatility of the portfolio. Asset class assumptions are set using a combination of empirical and forward-looking analysis. To the extent historical results have been affected by unsustainable trends or events, the effects of those trends are quantified and removed. We apply a variety of models for filtering historical data and isolating the fundamental characteristics of asset classes. These models provide empirical return estimates for each asset class, which are then reviewed and combined with a qualitative assessment of long term relationships between asset classes before a return estimate is finalized. The qualitative analysis is intended to provide an additional means for addressing the effect of unrealistic or unsustainable short-term valuations or trends, resulting in return levels and behavior we believe are more likely to prevail over long periods. The accumulated benefit obligation for all U.S. and foreign defined benefit pension plans was $24.7 million and $274.9 million for 2024 and 2023, respectively. All of the pension plans had accumulated benefit obligations in excess of their respective plan assets as of December 31, 2024 and 2023, with the exception of one foreign plan that had plan assets of $0.5 million and $1.0 million in excess of the accumulated benefit obligation as of December 31, 2024 and 2023, respectively. Our investment objective is to achieve an enhanced long-term rate of return on plan assets, subject to a prudent level of portfolio risk, for the purpose of enhancing the availability of benefits for participants. These investments are comprised of fixed income mutual funds. Fixed-income funds are held for diversification relative to equities and as a partial hedge of interest rate risk with respect to plan liabilities. The plans may also hold cash to meet liquidity requirements. Actual performance may not be consistent with the respective investment strategies. Investment risks and returns are measured and monitored on an ongoing basis through annual liability measurements and investment portfolio reviews to determine whether the asset allocation targets continue to represent an appropriate balance of expected risk and reward. The following table provides the fair values of the pension plan assets at December 31, 2024 by asset category: Fair Value Measurements Asset Category (a) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash $ 110 $ 110 $ — $ — Money market funds 19 19 — — Other types of investments: Contract with insurance company (b) 10,403 — — 10,403 Total investments at fair value $ 10,532 $ 129 $ — $ 10,403 Total $ 10,532 The following table provides the fair values of the pension plan assets at December 31, 2023 by asset category: Fair Value Measurements Asset Category (a) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash $ 909 $ 909 $ — $ — Money market funds 4,424 4,424 — — Fixed income securities: Intermediate duration fund (c) 193,674 193,674 — — Long duration bond fund (d) 1,357 1,357 — — Corporate, government and foreign bonds 72,037 — 72,037 — Absolute return credit fund (e) 317 — 317 — Other types of investments: Contract with insurance company (b) 12,795 — — 12,795 Total investments at fair value $ 285,513 $ 200,364 $ 72,354 $ 12,795 Total $ 285,513 (a) Information on asset categories described in notes (b)-(e) is derived from prospectuses and other material provided by the respective funds comprising the respective asset categories. (b) This category comprises the asset established out of an agreement to purchase a bulk-annuity policy from an insurer to fully cover the liabilities for members of the pension plan. The asset value is based on the fair value of the contract as determined by the insurance company using inputs that are not observable. (c) This category comprises a mutual fund that invests in instruments or derivatives having economic characteristics similar to fixed income securities. The fund invests in investment grade fixed income instruments, including U.S. and foreign corporate obligations, fixed income securities issued by sovereigns or agencies in both developed and emerging foreign markets, debt obligations issued by governments or other municipalities, and securities issued or guaranteed by the U.S. Government and its agencies. The fund will seek to maintain an effective average duration between three (d) This category comprises a mutual fund that invests in instruments or derivatives having economic characteristics similar to fixed income securities. The fund invests in investment grade fixed income instruments, including securities issued or guaranteed by the U.S. Government and its agencies and instrumentalities, corporate bonds, asset-backed securities, exchange traded funds, mortgage-backed securities and collateralized mortgage-backed securities. The fund invests primarily in long duration government and corporate fixed income securities, and uses derivative instruments, including interest rate swap agreements and Treasury futures contracts, for the purpose of managing the overall duration and yield curve exposure of the Fund’s portfolio of fixed income securities. (e) This category comprises a mutual fund that invests primarily in investment grade bonds and similar fixed income and floating rate securities. Our contributions to U.S. and foreign pension plans during 2025 are expected to be approximately $1.1 million. Contributions to postretirement healthcare plans during 2025 are expected to be approximately $1.0 million. The following table provides information about the expected benefit payments under its U.S. and foreign plans for each of the five succeeding years and the aggregate of the five years thereafter: Pension Other Benefits 2025 $ 2,080 $ 1,022 2026 2,114 756 2027 2,014 602 2028 2,086 574 2029 2,174 563 Years 2030 — 2034 10,693 2,488 We maintain a number of defined contribution savings plans covering eligible U.S. and non-U.S. employees. We partially match employee contributions. Costs related to these plans were $33.2 million, $26.1 million and $24.3 million for 2024, 2023 and 2022, respectively.

Commitments and contingent liab

Commitments and contingent liabilities	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingent liabilities	Commitments and contingent liabilities Environmental: We are subject to contingencies as a result of environmental laws and regulations that in the future may require us to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by us or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require us to undertake certain investigative and remedial activities at sites where we conduct or once conducted operations or at sites where Company-generated waste was disposed. Remediation activities vary substantially in duration and cost from site to site. The nature of these activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At December 31, 2024 and 2023, we have recorded $0.5 million and $2.5 million in accrued liabilities other liabilities Legal matters: We are a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability and product warranty, intellectual property, commercial disputes, acquisition and divestiture related matters, contracts, employment, environmental and other matters. As of December 31, 2024 and 2023, we have recorded accrued liabilities of $0.8 million in connection with such contingencies, representing our best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. Amounts accrued for legal contingencies are often determined based on a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions, including as to the timing of related payments. The ability to make such estimates and judgments can be affected by various factors including whether, among other things, damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has commenced or is complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute, or procedural or jurisdictional issues; there is uncertainty or unpredictability regarding the number of potential claims; there is the potential to achieve comprehensive multi-party settlements; there is complexity regarding related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against us, we do not record an accrual until a loss is determined to be probable and can be reasonably estimated. While the results of such litigation or claims cannot be predicted with certainty, based on information currently available, advice of counsel, established reserves and other resources, we do not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred. Other: In 2015, the Italian parliament enacted legislation that, among other things, imposed a “payback” measure on medical device companies that supply goods and services to the Italian National Healthcare System. Under the measure, companies are required to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. The payment amounts are calculated based on the amount by which the regional ceilings for the given year were exceeded. Considerable uncertainty exists related to the enforceability of and implementation process for the payback law. In response to decrees issued by the Italian Ministry of Health, the various Italian regions issued invoices to medical device companies, including Teleflex, under the payback measure in the fourth quarter of 2022 seeking payment with respect to excess expenditures for the years 2015 through 2018. Following the issuance of the invoices, we and numerous other medical device companies filed appeals with the Italian administrative courts challenging the enforceability of the payback measure, primarily on the basis that the law was unconstitutional. The Italian administrative courts referred the question regarding the constitutionality of the law to the Italian Constitutional Court, which in July 2024, issued a ruling upholding the law as constitutional. During the year ended December 31, 2024 we recognized increases to our reserve and corresponding reductions to revenue of $22.1 million. The increase in reserve for the year ended December 31, 2024 included $13.8 million pertaining to prior years stemming from the July 2024 ruling. As of December 31, 2024, our reserve related to this matter is $35.7 million. Following the ruling of the Italian Constitutional Court, the appeal before the Italian administrative court will proceed with respect to the remaining legal arguments asserted by the appellants to the enforceability of the payback law. On April 4, 2023, one of our Mexican subsidiaries received a notification from the Mexican Federal Tax Administration Service (“SAT”) setting forth its preliminary findings with respect to a foreign trade operations audit carried out by SAT for the period from July 1, 2017 to June 6, 2019. The preliminary findings stated that our Mexican subsidiary did not evidence the export of goods temporarily imported under Mexico’s Manufacturing, Maquila and Export Services Industries Program (“IMMEX Program”), therefore triggering the potential obligation for payment of import duties, value added tax, customs processing fees and other fines and penalties, which may cause an adverse impact on our gross profit in the future. In response to the notification, our Mexican subsidiary has requested that the matter be referred to the Procuraduría de la Defensa del Contribuyente, or “PRODECON,” (local tax ombudsperson) to help facilitate the process. In June 2023, SAT was provided with the appropriate documentation evidencing the export of the goods in accordance with the requirements of the IMMEX Program. In 2024, SAT concluded its examination of the export documentation resulting in no material assessment and the matter has been closed.

Business segments and other inf

Business segments and other information	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Business segments and other information	Business segments and other information An operating segment is a component (a) that engages in business activities from which it may earn revenues and incur expenses, (b) whose operating results are regularly reviewed by the chief operating decision maker, our President and Chief Executive Officer, to make decisions about resources to be allocated to the segment and to assess its performance, and (c) for which discrete financial information is available. The chief operating decision maker utilizes segment operating profit to evaluate operating expenses through a comparison of budget to actual results as well as an analysis of operating expenses as a percentage of revenue. We do not evaluate our operating segments using discrete asset information. During the fourth quarter 2024, our chief operating decision maker changed the manner in which he reviews financial information for purposes of assessing business performance and allocating resources solely focusing on the geographic location. As a result, we changed our segment presentation by incorporating the OEM operating segment into the Americas segment. We now have three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). In addition to the changing of our segments, our chief operating decision maker now evaluates segment operating profit without an allocation of corporate expenses compared to the prior measure, which included these expenses in the evaluation. Our prior period segment disclosures have been revised to reflect the new segment presentation of our three reportable segments and segment operating profit. Our reportable segments primarily design, manufacture and distribute medical devices primarily used in critical care and surgical applications and generally serve two end-markets: hospitals and healthcare providers, and home health. The products of these segments are most widely used in the acute care setting for a range of diagnostic and therapeutic procedures and in general and specialty surgical applications. The Americas also includes our OEM product portfolio that designs, manufactures and supplies devices and instruments for other medical device manufacturers. The following tables present our segment results for the years ended December 31, 2024, 2023 and 2022: 2024 Americas EMEA Asia Segment Total Net revenues $ 2,066,292 $ 617,984 $ 363,048 $ 3,047,324 Cost of goods sold 834,987 289,645 132,030 1,256,662 Research and development expenses 94,912 38,939 18,584 152,435 Selling, general and administrative expenses 465,917 156,375 97,764 720,056 Segment operating profit (1) $ 670,476 $ 133,025 $ 114,670 $ 918,171 2023 Americas EMEA Asia Segment Total Net revenues $ 2,041,339 $ 586,245 $ 346,905 $ 2,974,489 Cost of goods sold 824,514 273,772 118,729 1,217,015 Research and development expenses 82,685 54,787 14,105 151,577 Selling, general and administrative expenses 420,158 146,551 93,119 659,828 Segment operating profit (1) $ 713,982 $ 111,135 $ 120,952 $ 946,069 2022 Americas EMEA Asia Segment Total Net revenues $ 1,926,348 $ 558,373 $ 306,320 $ 2,791,041 Cost of goods sold 780,538 255,210 101,037 1,136,785 Research and development expenses 67,795 69,822 13,379 150,996 Selling, general and administrative expenses 408,068 136,464 87,211 631,743 Segment operating profit (1) $ 669,947 $ 96,877 $ 104,693 $ 871,517 (1) Segment operating profit represents income from continuing operations before interest, loss on extinguishment of debt and taxes adjusted to exclude unallocated corporate expenses manufacturing variances other than fixed manufacturing cost absorption variances, restructuring and impairment charges. See reconciliation of segment operating profit measures for further details. Year Ended December 31, 2024 2023 2022 Reconciliation of segment operating profit measure Segment operating profit $ 918,171 $ 946,069 $ 871,517 Other unallocated expenses (1) 372,435 383,356 357,997 Goodwill impairment charge 240,000 — — Restructuring and impairment charges 21,991 15,604 20,299 Gain on sale of assets and business — (4,448) (6,504) Pension settlement charge 132,732 45,244 — Income from continuing operations before interest, loss on extinguishments of debt and taxes $ 151,013 $ 506,313 $ 499,725 (1) Other unallocated expenses include expenses within costs of goods sold, research and development and selling, general and administrative costs and primarily consist of manufacturing variances other than fixed manufacturing cost absorption variances and unallocated corporate function expenses. Year Ended December 31, Depreciation and amortization 2024 2023 2022 Americas $ 193,949 $ 168,787 $ 161,842 EMEA 49,596 42,057 38,266 Asia 12,344 10,548 9,311 Corporate (1) 18,712 20,726 21,171 Consolidated depreciation and amortization $ 274,601 $ 242,118 $ 230,590 (1) Reflects depreciation and amortization included within other allocated expenses per reconciliation of segment operating profit measure. Geographic data The following tables provide total net revenues and total net property, plant and equipment by geographic region for the years ended December 31, 2024, 2023 and 2022 and as of December 31, 2024 and 2023, respectively. Year Ended December 31, 2024 2023 2022 Net revenues (based on selling location): U.S. $ 1,889,312 $ 1,879,898 $ 1,786,467 Europe 705,094 665,185 622,343 Asia Pacific 326,371 307,513 270,749 All other 126,547 121,893 111,482 $ 3,047,324 $ 2,974,489 $ 2,791,041 As of December 31, Net property, plant and equipment: 2024 2023 U.S. $ 215,806 $ 200,969 Malaysia 73,430 71,947 Mexico 121,287 112,339 All other 92,329 94,658 $ 502,852 $ 479,913

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	12 Months Ended
	Dec. 31, 2024
Condensed Consolidated Guarantor Financial Information [Abstract]
Supplemental Balance Sheet Disclosures	Supplemental Balance Sheet Information Cash, cash equivalents, and restricted cash equivalents consisted of the following at December 31, 2024 and December 31, 2023: December 31, 2024 December 31, 2023 Cash and cash equivalents $ 290,188 $ 222,848 Restricted cash equivalents in other current assets (1) 14,700 — Restricted cash equivalents in other assets (1) 22,762 — Total cash, cash equivalents and restricted cash equivalents $ 327,650 $ 222,848 (1) Restricted cash equivalents represent surplus plan assets resulting from the termination of the Teleflex Incorporated Retirement Income Plan that were transferred to a suspense account within the Teleflex 401(k) Savings Plan as of December 31, 2024 as described in Note 16. Amounts expected to be transferred from the suspense account to employees within one year are classified as other current assets.

Subsequent events

Subsequent events	12 Months Ended
	Dec. 31, 2024
Subsequent Events [Abstract]
Subsequent events	Subsequent events Acquisition of BIOTRONIK Vascular Intervention business On February 24, 2025, we executed a definitive agreement to acquire substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition will include a broad suite of coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters, which will complement our interventional product portfolio. Under the terms of the agreement, we will acquire the VI Business for an initial cash payment of €760 million reduced by certain adjustments as provided in the purchase agreement including certain working capital not transferring and other customary adjustments. The acquisition is subject to customary closing conditions, including receipt of certain regulatory approvals, and is expected to be completed in the third quarter of 2025. Concurrent with the execution of the agreement to acquire the VI Business, we entered into an amendment to our Third Amended and Restated Credit Agreement (the “Credit Agreement”), which, among other things, (a) provides for a delayed draw term loan facility in an aggregate principal amount of $500 million, which will be available to be drawn on the date on which we consummate the VI Business acquisition and (b) permits us to borrow up to $550 million under the revolving facility provided for under the Credit Agreement on a limited condition basis on the date on which the VI Business acquisition is consummated. Borrowings under the delayed draw term loan will bear interest at a rate per annum equal to the applicable margin plus, at our option, either (1) the highest of (i) the “Prime Rate” in the U.S. last quoted by The Wall Street Journal, (ii) 0.50% above the greater of the federal funds rate and the rate comprised of both overnight federal funds and overnight eurodollar transactions denominated in dollars and (iii) 1.00% above the Term SOFR Rate for a one month interest period, plus an applicable margin ranging from 0.125% to 1.00%, in each case subject to adjustments based on our total net leverage ratio or (2) a Term Secured Overnight Financing Rate (“SOFR”) rate (which includes a credit spread adjustment of 10 basis points). The applicable margin for borrowings under the delayed draw term loan range from 1.125% to 2.00% for SOFR borrowings and from 0.125% to 1.00% for base-rate borrowings, in each case, depending on, at our election, either (x) our public corporate family rating or (y) our consolidated total net leverage ratio, in each case, based on the most recently ended fiscal quarter. The obligations under the delayed draw term loan will be guaranteed and secured on the same basis as the facilities provided for under the Credit Agreement. The delayed draw term loan will not amortize and will mature on the earlier of (x) the date that is two years after the date on which such loans are funded and (y) the maturity date for the revolving facility provided for under the Credit Agreement. In addition to amending our Credit Agreement, we also entered into foreign exchange derivative contracts with an aggregate notional value of €700 million to economically hedge against the foreign currency exposure associated with the cash consideration needed to complete the VI Business acquisition. We anticipate using the new delayed draw term loan along with revolving credit borrowings under the Credit Agreement and cash on hand to finance the VI Business acquisition. For the year ended December 31, 2024, we incurred transaction costs of $11.5 million in connection with the acquisition, which was recognized in selling, general and administrative expenses in the Consolidated Statement of Income. The majority of the transaction costs were recognized in the fourth quarter of 2024. Recently Announced Strategic Actions On February 27, 2025, we announced our intention to create a new, independently traded public company comprising Urology (consisting of our Interventional Urology and Urology product categories), Acute Care (consisting of our Respiratory product category, the majority of our Anesthesia product category and certain products within our Interventional Access and Surgical product categories) and our OEM businesses. Our Vascular Access product category, most of our products within our Interventional Access and Surgical product categories and the expected acquisition of the VI business will remain with Teleflex. The completion of any separation transaction and the achievement of tax-free status will be contingent upon various conditions and approvals, including approval of our Board of Directors, receipt of requisite regulatory clearances and compliance with applicable SEC requirements. There can be no guarantees that the proposed separation will be completed on the terms and within the timeframe we announced, or at all. Accelerated share repurchase agreement On February 28, 2025, we entered into an accelerated share repurchase agreement for $300 million of our common stock, representing the remainder of the share repurchase program approved by the Board of Directors in 2024.

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2024
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS (Dollars in thousands) DEFERRED TAX ASSET VALUATION ALLOWANCE Balance at Beginning of Year Additions Charged to Expense Reductions Credited to Expense Translation and Other Balance at End of Year December 31, 2024 $ 95,747 $ 5,413 $ (2,813) $ (9,935) $ 88,412 December 31, 2023 $ 91,531 $ 4,799 $ (4,937) $ 4,354 $ 95,747 December 31, 2022 $ 143,177 $ 8,489 $ (59,520) $ (615) $ 91,531

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss) Attributable to Parent	$ 69,675	$ 356,328	$ 363,139

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Cyberattacks continue to evolve in sophistication and frequency. Among other things, an attack could impair our ability to interact with customers and suppliers, fulfill orders, generate invoices, collect and make payments, ship products, provide support to customers, fulfill contractual obligations and otherwise perform business functions. Management has implemented a program (“Program”), which is part of our overall Enterprise Risk Management system, focused on the assessment, identification, and management of material risks associated with cybersecurity threats. The Program was developed and is managed by our Vice President of Information Security and Privacy (CISSP, CISM and CISA) with oversight from the Chief Information Officer. Both leaders collectively have over 60 years of technology risk and cybersecurity work experience supporting multiple life science organizations. The Program is also closely aligned with the Legal and Global Compliance organizations to oversee adherence with legal, regulatory and contractual requirements from an information security and data privacy perspective. Industry standard frameworks including International Organization of Standardization (ISO)/27001 and National Institute of Standards and Technology (NIST) are the foundation of the Program, which includes but is not limited to the fundamental security principles of least privilege access, event monitoring, vulnerability management, education, third-party risk management and incident response. The Program leverages external subject-matter experts that assist with identifying and remediating security risks present in our environment through threat hunting and vulnerability/control testing with a focus on the latest attack vectors. These external experts bring to bear risk mitigation tactics based on current threats observed across multiple organizations with similar risk profiles. Key Program activities include: • Annual risk assessment to evaluate our profile against cyber risk threats; • Global policies based on the guiding principles of security by design and least-privilege access; • Maintenance of a critical incident response plan and simulation programs, which include procedures to comply with material security incident reporting requirements in collaboration with key members of Executive Management; • A communication framework designed to ensure that the individuals managing the Program are informed about, and in position to monitor the prevention, detection, mitigation, and remediation of, cybersecurity incidents; • Internal and external security assessments and testing to determine our susceptibility to compromise, lateral movement, privilege escalation and overall cybersecurity internal control posture; • Routine phishing simulations to identify areas for control enhancement and additional training; • Periodic end-user security training and cyber-threat awareness; • Suite of tools and processes to minimize the risk of security compromise in addition to detect controls alerting of potential malicious activity; and • Review and approval process focused on evaluating cybersecurity posture and internal controls relating to third party service providers.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	Management has implemented a program (“Program”), which is part of our overall Enterprise Risk Management system, focused on the assessment, identification, and management of material risks associated with cybersecurity threats. The Program was developed and is managed by our Vice President of Information Security and Privacy (CISSP, CISM and CISA) with oversight from the Chief Information Officer. Both leaders collectively have over 60 years of technology risk and cybersecurity work experience supporting multiple life science organizations. The Program is also closely aligned with the Legal and Global Compliance organizations to oversee adherence with legal, regulatory and contractual requirements from an information security and data privacy perspective
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	The Audit Committee of the Board of Directors receives an update from the members of management referenced above on our security posture on at least an annual basis, and more often as needed. The Audit Committee provides oversight as to the status of our cybersecurity apparatus and overall Program management (including with respect to the identification and implementation of planned security enhancements), while also advising on risk mitigation activities to address the latest threats.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit Committee provides oversight as to the status of our cybersecurity apparatus and overall Program management (including with respect to the identification and implementation of planned security enhancements), while also advising on risk mitigation activities to address the latest threats.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit Committee provides oversight as to the status of our cybersecurity apparatus and overall Program management (including with respect to the identification and implementation of planned security enhancements), while also advising on risk mitigation activities to address the latest threats
Cybersecurity Risk Role of Management [Text Block]	The Audit Committee of the Board of Directors receives an update from the members of management referenced above on our security posture on at least an annual basis, and more often as needed. The Audit Committee provides oversight as to the status of our cybersecurity apparatus and overall Program management (including with respect to the identification and implementation of planned security enhancements), while also advising on risk mitigation activities to address the latest threats. To date, we have not experienced any known cybersecurity incidents that have materially affected or are reasonably likely to materially affect us in the future, including our business strategy, results of operations, or financial condition.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	The Audit Committee of the Board of Directors receives an update from the members of management referenced above on our security posture on at least an annual basis, and more often as needed. The Audit Committee provides oversight as to the status of our cybersecurity apparatus and overall Program management (including with respect to the identification and implementation of planned security enhancements), while also advising on risk mitigation activities to address the latest threats.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	The Program is also closely aligned with the Legal and Global Compliance organizations to oversee adherence with legal, regulatory and contractual requirements from an information security and data privacy perspective.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	The Program leverages external subject-matter experts that assist with identifying and remediating security risks present in our environment through threat hunting and vulnerability/control testing with a focus on the latest attack vectors. These external experts bring to bear risk mitigation tactics based on current threats observed across multiple organizations with similar risk profiles. Key Program activities include: • Annual risk assessment to evaluate our profile against cyber risk threats; • Global policies based on the guiding principles of security by design and least-privilege access; • Maintenance of a critical incident response plan and simulation programs, which include procedures to comply with material security incident reporting requirements in collaboration with key members of Executive Management; • A communication framework designed to ensure that the individuals managing the Program are informed about, and in position to monitor the prevention, detection, mitigation, and remediation of, cybersecurity incidents; • Internal and external security assessments and testing to determine our susceptibility to compromise, lateral movement, privilege escalation and overall cybersecurity internal control posture; • Routine phishing simulations to identify areas for control enhancement and additional training; • Periodic end-user security training and cyber-threat awareness; • Suite of tools and processes to minimize the risk of security compromise in addition to detect controls alerting of potential malicious activity; and • Review and approval process focused on evaluating cybersecurity posture and internal controls relating to third party service providers.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Consolidation	Consolidation: The consolidated financial statements include the accounts of Teleflex Incorporated and its subsidiaries (referred to herein as “we,” “us,” “our” and “Teleflex"). Intercompany transactions are eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and reflect management’s estimates and assumptions that affect the recorded amounts.
Use of estimates	Use of estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.
Cash and cash equivalents	Cash and cash equivalents: All highly liquid debt instruments with an original maturity of three months or less are classified as cash equivalents. The carrying value of cash equivalents approximates the current market value.
Accounts receivable	Accounts receivable:
Inventories	Inventories: Inventories are valued at the lower of cost or net realizable value. The cost of our inventories is determined using the first in, first out cost method. Elements of cost in inventory include raw materials, direct labor, and manufacturing overhead. In estimating net realizable value, we evaluate inventory for excess and obsolete quantities based on estimated usage and sales, among other factors.
Property, plant and equipment	Property, plant and equipment: Property, plant and equipment are stated at cost, net of accumulated depreciation. Costs incurred to develop internal-use computer software during the application development stage generally are capitalized. Costs of enhancements to internal-use computer software are capitalized, provided that these enhancements result in additional functionality. Other additions and improvements that increase the capacity or lengthen the useful lives of the assets are also capitalized. Composite useful lives for categories of property, plant and equipment, which are depreciated on a straight-line basis, are as follows: buildings - 30 years; machinery and equipment - 3 to 15 years; computer equipment and software - 3 to 10 years. Leasehold improvements are depreciated over the lesser of the useful lives of the leasehold improvements or the remaining lease term. Repairs and maintenance costs are expensed as incurred.
Goodwill and other intangible assets	Goodwill and other intangible assets: Goodwill and other indefinite-lived intangible assets are not amortized but are tested for impairment annually during the fourth quarter or more frequently if events or changes in circumstances indicate that an impairment may exist. Impairment losses, if any, are included in income from operations. The goodwill impairment test is applied to each of our reporting units. For purposes of this assessment, a reporting unit is an operating segment, or a business one level below an operating segment (also known as a component) if discrete financial information is prepared for that business and regularly reviewed by segment management. However, separate components are aggregated as a single reporting unit if they have similar economic characteristics. In performing the goodwill impairment test, we may assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Qualitative factors may include, but are not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for our products and services, regulatory and political developments, and entity specific factors such as strategies and financial performance. If, after completing the qualitative assessment, we determine it is more likely than not that the fair value of a reporting unit is less than its carrying value, we proceed to a quantitative impairment test, described below. Alternatively, we may elect to bypass the qualitative assessment and perform the quantitative impairment test. Under a quantitative impairment test, we compare the fair value of a reporting unit to its carrying value. If the reporting unit fair value exceeds the carrying value, there is no impairment. If the reporting unit carrying value exceeds the fair value, we recognize an impairment loss based on the amount the carrying value of the reporting unit exceeds its fair value. For the year ended December 31, 2024, we recognized a goodwill impairment charge of $240 million related to our Interventional Urology North America reporting unit. For further information refer to Note 8. Our intangible assets consist of customer relationships, intellectual property, distribution rights, in-process research and development ("IPR&D"), trade names and non-competition agreements. We define IPR&D as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business acquisition is recognized at fair value and is required to be capitalized as an indefinite-lived intangible asset until completion of the IPR&D project or upon abandonment. Upon completion of the development project (generally when regulatory approval to market the product that utilizes the technology is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. If the IPR&D projects are abandoned, the related IPR&D assets would be written off. We test our indefinite-lived intangible assets for impairment annually, or more frequently if events or changes in circumstances indicate that an impairment may have occurred. Similar to the goodwill impairment test process, we may elect to perform a qualitative assessment. If, after completing the qualitative assessment, we determine it is more likely than not that the fair value of the indefinite-lived intangible asset is greater than its carrying amount, the asset is not impaired. If we conclude it is more likely than not that the fair value of the indefinite-lived intangible asset is less than the carrying value, we then proceed to a quantitative impairment test, which consists of a comparison of the fair value of the intangible asset to its carrying amount. Intangible assets that do not have indefinite lives, consisting of intellectual property, customer relationships, distribution rights, certain trade names and non-competition agreements, are amortized over their estimated useful lives, which are as follows: intellectual property, 8 to 20 years; customer relationships, 8 to 27 years; distribution rights, 10 years; trade names, 15 to 30 years. The weighted average remaining amortization period with respect to our intangible assets is approximately 12 years. We periodically evaluate the reasonableness of the useful lives of these assets.
Long-lived assets	Long-lived assets:
Foreign currency translation	Foreign currency translation: Assets and liabilities of subsidiaries with non-United States dollar denominated functional currencies are translated into United States dollars at the rates of exchange at the balance sheet date; income and expenses are translated at the average rates of exchange prevailing during the year. The translation adjustments are reported as a component of accumulated other comprehensive loss.
Derivative financial instruments	Derivative financial instruments: We use derivative financial instruments primarily for purposes of hedging exposures to fluctuations in foreign currency exchange rates. All instruments are entered into for other than trading purposes. All derivatives are recognized on the balance sheet at fair value. Changes in the fair value of derivatives are recorded in the consolidated statement of comprehensive income as other comprehensive income (loss), if the instrument is designated as part of a hedge transaction. Gains or losses on derivative instruments reported in other comprehensive income (loss) are reclassified to the Consolidated Statement of Income in the period in which earnings are affected by the underlying hedged item. Gains or losses on derivative instruments representing hedge ineffectiveness or hedge components excluded from the assessment of effectiveness, if any, are recognized in the Consolidated Statement of Income for the period in which such gains and losses occur. If the hedging relationship ceases to be highly effective or it becomes probable that an expected transaction will no longer occur, gains or losses on the derivative instrument are recorded in the Consolidated Statement of Income for the period in which either such event occurs. For non-designated derivatives, gains and losses are reported as selling, general and administrative expenses in the Consolidated Statement of Income. Cash flows from derivatives are recognized in the consolidated statements of cash flows in a manner consistent with the recognition of the underlying transactions.
Share-based compensation	Share-based compensation: We estimate the fair value of share-based awards on the date of grant using an option pricing model. The value of the portion of the award that is ultimately expected to vest, which is derived, in part, following consideration of estimated forfeitures, is recognized as expense over the requisite service periods. Share-based compensation expense related to stock options is measured using a Black-Scholes option pricing model that takes into account subjective and complex assumptions with respect to the expected life of the options, volatility, risk-free interest rate and expected dividend yield. The expected life of options granted is derived from the vesting period of the award, as well as historical exercise behavior, and represents the period of time that options granted are expected to be outstanding. Expected volatility is based on a blend of historical volatility and implied volatility derived from publicly traded options to purchase our common stock, which we believe is more reflective of market conditions and a better indicator of expected volatility than would be the case if we only used historical volatility. The risk-free interest rate is the implied yield currently available on United States (or "U.S.") Treasury zero-coupon issues with a remaining term equal to the expected life of the option. Forfeitures are estimated at the time of grant based on management’s expectations regarding the extent to which awards ultimately will vest and are adjusted for actual forfeitures when they occur.
Income taxes	Income taxes: The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred tax assets and liabilities are recognized to reflect the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases, and to reflect operating loss and tax credit carryforwards. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Provision has been made for income taxes on unremitted earnings of subsidiaries and affiliates, except to the extent that such earnings are deemed to be permanently reinvested. Significant judgment is required in determining income tax provisions and in evaluating tax positions. We establish additional provisions for income taxes when, despite the belief that tax positions are supportable, there remain certain positions that do not meet the minimum probability threshold, which is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority. In the normal course of business, we are examined by various federal, state and non-U.S. tax authorities. We regularly assess the potential outcomes of these examinations and any future examinations for the current or prior years in determining the adequacy of our provision for income taxes. Interest accrued with respect to unrecognized tax benefits and income tax related penalties are both included in taxes on income from continuing operations. We periodically assess the likelihood and amount of potential adjustments and adjust the income tax provision, the current tax liability and deferred taxes in the period in which the facts that give rise to an adjustment become known.
Pensions and other postretirement benefits	Pensions and other postretirement benefits: We provide a range of benefits to eligible employees and retired employees, including benefits available pursuant to pension and postretirement healthcare benefits plans. We record annual amounts relating to these plans based on calculations which include various actuarial assumptions such as discount rates, expected rates of return on plan assets, compensation increases, turnover rates and healthcare cost trend rates. We review our actuarial assumptions on an annual basis and make modifications to the assumptions based on current rates and trends when appropriate. The effect of the modifications is generally amortized over future periods.
Restructuring costs	Restructuring costs: We primarily recognize employee termination benefits when payment becomes probable and reasonably estimable because they are provided under an ongoing benefit arrangement and are based on existing plans, historical experience and negotiated settlements of prior plans. Termination benefits provided under one-time termination benefits arrangements, if any, are recognized upon communication to the employee. We recognize charges ratably over the future service period if the employee is required to render service until termination. Other restructuring costs may include facility closure, employee relocation, equipment relocation and outplacement costs and are recognized in the period they are incurred.
Contingent consideration related to business acquisitions	Contingent consideration related to business acquisitions: In connection with business acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified objectives such as receipt of regulatory approval, commercialization of a product or achievement of sales targets. In a business combination, we record a contingent liability, as of the acquisition date, representing the estimated fair value of the contingent consideration that we expect to pay. We remeasure the fair value of our contingent consideration arrangements each reporting period and, based on new developments, record changes in fair value until either the contingent consideration obligation is satisfied through payment upon the achievement of, or the obligation no longer exists due to the failure to achieve, the specified objectives. The change in the fair value is recorded in selling, general and administrative expenses in the Consolidated Statement of Income. A contingent consideration payment is classified as a financing activity in the consolidated statement of cash flows to the extent it was recorded as a liability as of the acquisition date. Any additional amount paid in excess of the amount initially accrued is classified as an operating activity in the consolidated statement of cash flows. If the transaction is determined to be an asset acquisition rather than a business combination, a contingent consideration liability is recognized when the specified objective is deemed probable and is estimable.
Revenue recognition	Revenue recognition: We primarily generate revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when our products are shipped from the manufacturing or distribution facility. For the OEM (Original Equipment Manufacturer and Development Services) product category, included within our Americas segment, most revenue is recognized over time because OEM generates revenue from the sale of custom products that have no alternative use and we have an enforceable right to payment to the extent that performance has been completed. We market and sell products through our direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers, which represented 87%, 11% and 2% of our consolidated net revenues, respectively, for the year ended December 31, 2024. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods. With respect to the custom products sold in the OEM, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice. We have made the following revenue accounting policy elections and elected to use certain practical expedients: (1) we account for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) we do not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, we expect the period between the time when we transfer a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) we expense costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) we account for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service; (5) we classify shipping and handling costs within cost of goods sold; and (6) with respect to OEM, we have applied the practical expedient to exclude disclosure of remaining performance obligations as the contracts typically have a term of one year or less. The amount of consideration we receive and revenue we recognize varies as a result of changes in customer sales incentives, including discounts and rebates, and returns offered to customers. The estimate of revenue is adjusted upon the earlier of the following events: (i) the most likely amount of consideration expected to be received changes or (ii) the consideration becomes fixed. Our policy is to accept returns only in cases in which the product is defective and covered under our standard warranty provisions. When we give customers the right to return products, we estimate the expected returns based on an analysis of historical experience. The liability for returns and allowances, which includes liabilities established related to the Italian payback matter discussed in Note 17, was $41.7 million and $22.2 million as of December 31, 2024 and 2023, respectively. In estimating customer rebates, we consider the lag time between the point of sale and the payment of the customer’s rebate claim, customer-specific trend analyses, contractual commitments, including stated rebate rates, historical experience with respect to specific customers (as we have a history of providing similar rebates on similar products to similar customers) and other relevant information. The reserve for customer incentive programs, including customer rebates, was $24.9 million and $26.7 million at December 31, 2024 and 2023, respectively. We expect the amounts subject to the reserve as of December 31, 2024 to be paid within 90 days subsequent to period-end.
Leases	Leases: We determine whether a contract is, or includes, a lease at inception. Right-of-use assets and lease liabilities are recognized at lease commencement based on the estimated present value of unpaid lease payments over the lease term. To determine the present value we use an incremental borrowing rate derived from information available at lease commencement.
Recently issued accounting standards	Recently issued accounting standards In November 2023, the Financial Accounting Standard Board ("FASB") issued new guidance designed to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses per segment. We adopted the new standard for the fiscal year ended December 31, 2024 using a retrospective transition approach. Additional information and disclosures required by the new guidance are provided in Note 18. In December 2023, the FASB issued new guidance designed to improve income tax disclosure requirements, primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our consolidated financial statements. In November 2024, the FASB issued new guidance designed to enhance disclosures regarding the nature of expenses included in the income statement. The guidance requires tabular disclosures that disaggregate information about prescribed expense categories within relevant income statement expense captions. The guidance is effective for all fiscal years beginning after December 15, 2026 and for interim periods beginning after December 15, 2027. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our consolidated financial statements. In March 2024, the SEC adopted final rules that require registrants to include certain climate-related disclosures in registration statements and annual reports. The required disclosures include information about a registrant's climate-related risks that are reasonably likely to have a material impact on its business, results of operations or financial condition. The required information about climate-related risks will also include disclosure of a registrant's greenhouse gas emissions and will require registrants to present certain climate-related financial disclosures in their audited financial statements. The rules were to be effective for all fiscal years beginning in 2025. However, following the adoption of the rules, challenges to the rules were brought in six federal appellate courts. These challenges were consolidated for review in the U.S. Court of Appeals for the Eighth Circuit. Additional cases have been filed since the consolidation order. On April 4, 2024, the SEC announced that it had stayed the rules pending the completion of judicial review of the consolidated Eighth Circuit petitions. The SEC has further stated that it plans to designate a new effective date and phase-in period for the implementation of the rules at the conclusion of the stay, though this would occur only if the SEC prevails in the ongoing legal proceedings. We plan to monitor the status of these rules, and, as appropriate, to evaluate the rules to determine their impact on our consolidated financial statements. From time to time, new accounting guidance issued by the FASB or other standard setting bodies is adopted as of the specified effective date or, when permitted by the guidance and as determined by us, as of an earlier date. We have assessed recently issued guidance that is not yet effective, except as noted above, and believe the new guidance that we have assessed will not have a material impact on our results of operations, cash flows or financial position.

Net revenues (Tables)

Net revenues (Tables)	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table disaggregates revenue by global product category for the years ended December 31, 2024, 2023 and 2022. Year Ended December 31, 2024 2023 2022 Vascular access $ 732,675 $ 708,044 $ 683,612 Interventional 586,057 511,434 445,018 Anesthesia 395,285 389,957 388,890 Surgical 450,482 427,359 392,917 Interventional urology 331,092 319,785 322,832 OEM 344,511 326,008 272,624 Other (1) 207,222 291,902 285,148 Net revenues (2) $ 3,047,324 $ 2,974,489 $ 2,791,041 (1) Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products). (2) The product categories listed above are presented on a global basis, as each of our reportable segments is defined based on the geographic location of its operations.

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of Business acquisition, Pro Forma Information	The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have occurred under our ownership and management. Year Ended December 31, 2023 2022 (Unaudited) Net income $ 310,356 $ 282,425 Basic earnings per share: Net income $ 6.61 $ 6.02 Diluted earnings per share: Net income $ 6.56 $ 5.97
Schedule of Business Acquisitions, by Acquisition	Year Ended December 31, 2024 2023 2022 Non cash investing and financing activities of continuing operations: Acquisition of businesses $ — $ 27,000 $ 43,168

Restructuring and other impai_2

Restructuring and other impairment charges (Tables)	12 Months Ended
	Dec. 31, 2024
Restructuring and Related Activities [Abstract]
Summary of Current Cost Estimates by Major Type of Cost	The following table provides a summary of the cost estimates by major type of expense associated with the 2024 Footprint realignment plan: Total estimated amount expected to be incurred Plan expense estimates: (Dollars in millions) Restructuring charges (1) $16 million to $20 million Restructuring related charges (2) $21 million to $26 million Total restructuring and restructuring related charges $37 million to $46 million (1) Substantially all of the charges consist of employee termination benefit cost. (2) Consists of pre-tax charges related to accelerated depreciation and other costs directly related to the plan, primarily project management costs and costs to relocate manufacturing operations and support functions to the new locations. Substantially all of the charges are expected to be recognized within costs of goods sold. Total estimated amount expected to be incurred Plan expense estimates: (Dollars in millions) Restructuring charges (1) $4 million to $6 million Restructuring related charges (2) $7 million to $9 million Total restructuring and restructuring related charges $11 million to $15 million (1) Substantially all of the charges consist of employee termination benefit cost. (2) Restructuring related charges represent costs that are directly related to the 2023 Footprint realignment plan and principally constitute costs to transfer manufacturing operations to existing lower-cost locations and project management costs. Substantially all of these charges are expected to be recognized within cost of goods sold.
Schedule of Restructuring Reserve	The following table summarizes the restructuring reserve activity related to our 2024 Restructuring plan, 2024 Footprint realignment plan and 2023 Footprint realignment plan: 2024 Restructuring plan 2024 Footprint realignment plan 2023 Footprint realignment plan Balance at December 31, 2022 $ — $ — $ — Subsequent accruals — — 1,451 Cash payments — — (108) Balance at December 31, 2023 (1) — — 1,343 Accruals 6,100 11,203 1,377 Cash payments (777) (1,442) (32) Foreign currency translation and other 427 961 — Balance at December 31, 2024 (1) $ 5,750 $ 10,722 $ 2,688 (1) The restructuring reserves as of December 31, 2024 and 2023 consisted mainly of accruals related to termination benefits. Other costs (facility closure, employee relocation, equipment relocation and outplacement costs) were expensed and paid in the same period.
Restructuring and Other Impairment Charges	The restructuring and impairment charges recognized for the years ended December 31, 2024, 2023, and 2022 consisted of the following: 2024 Termination benefits Other Costs (1) Total 2024 Restructuring plan $ 6,086 $ 14 $ 6,100 2024 Footprint realignment plan 11,164 39 11,203 2023 Restructuring plan (1,524) 82 (1,442) 2023 Footprint realignment plan 1,344 33 1,377 2022 Restructuring plan (1,454) 22 (1,432) Other restructuring programs (2) (1,665) 16 (1,649) Total restructuring charges 13,951 206 14,157 Asset impairment charges — 7,834 7,834 Total restructuring and other impairment charges $ 13,951 $ 8,040 $ 21,991 2023 Termination benefits Other Costs (1) Total 2023 Restructuring plan $ 12,535 $ — $ 12,535 2023 Footprint realignment plan 1,451 — 1,451 2022 Restructuring plan 2,759 369 3,128 Respiratory divestiture plan (946) 17 (929) Other restructuring programs (3) (1,015) 434 (581) Total restructuring and other impairment charges $ 14,784 $ 820 $ 15,604 2022 Termination benefits Other Costs (1) Total 2022 Restructuring plan $ 15,465 $ 58 $ 15,523 Respiratory divestiture plan 504 74 578 2019 Footprint realignment plan (1,120) 133 (987) 2018 Footprint realignment plan 1,230 846 2,076 Other restructuring programs (3) 1,306 306 1,612 Total restructuring charges 17,385 1,417 18,802 Asset impairment charges — 1,497 1,497 Total restructuring and other impairment charges $ 17,385 $ 2,914 $ 20,299 (1) Includes facility closure, contract termination and other exit costs. (2) Includes activity primarily related to our 2018 and 2019 Footprint realignment plans, which have concluded. (3) Includes activity primarily related to a restructuring plan initiated in the first quarter of 2022 that is designed to relocate manufacturing operations at certain of our facilities (the "2022 Manufacturing relocation plan") and our 2014, 2018, and 2019 Footprint realignment plans, which have concluded.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Inventories	Inventories at December 31, 2024 and 2023 consist of the following: 2024 2023 Raw materials $ 155,201 $ 179,517 Work-in-process 115,814 111,132 Finished goods 329,118 335,567 Inventories $ 600,133 $ 626,216

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Major Classes of Property, Plant and Equipment at Cost	The major classes of property, plant and equipment, at cost, at December 31, 2024 and 2023 were as follows: 2024 2023 Land, buildings and leasehold improvements $ 291,696 $ 284,604 Machinery and equipment 474,879 459,268 Computer equipment and software 234,251 214,573 Construction in progress 112,708 94,633 1,113,534 1,053,078 Less: Accumulated depreciation (610,682) (573,165) Property, plant and equipment, net $ 502,852 $ 479,913

Goodwill and other intangible_2

Goodwill and other intangible assets (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill, by Reporting Segment	Changes in the carrying amount of goodwill, by reportable operating segment, for the years ended December 31, 2024 and 2023 were as follows: Americas EMEA Asia Total Balance as of December 31, 2022 Goodwill $ 1,843,103 $ 468,524 $ 225,103 $ 2,536,730 Goodwill related to acquisitions 333,462 4,284 19,279 357,025 Translation and other adjustments 3,517 14,936 1,847 20,300 Balance as of December 31, 2023 2,180,082 487,744 246,229 2,914,055 Goodwill impairment charge (240,000) — — (240,000) Goodwill related to acquisitions (1,953) — — (1,953) Translation and other adjustments (5,360) (22,255) (12,173) (39,788) Balance as of December 31, 2024 $ 1,932,769 $ 465,489 $ 234,056 $ 2,632,314
Components of Intangible Assets	Intangible assets at December 31, 2024 and 2023 consisted of the following: Gross Carrying Amount Accumulated Amortization 2024 2023 2024 2023 Customer relationships $ 1,354,087 $ 1,363,839 $ (620,619) $ (561,753) In-process research and development 23,666 27,476 — — Intellectual property 1,870,407 1,890,957 (863,066) (745,094) Distribution rights 23,004 23,301 (22,524) (22,048) Trade names 603,202 610,146 (99,443) (84,864) Non-compete agreements 21,894 21,934 (21,894) (21,934) $ 3,896,260 $ 3,937,653 $ (1,627,546) $ (1,435,693)
Estimated Annual Amortization Expense	The estimated annual amortization expense for each of the five succeeding years is as follows: 2025 $ 189,100 2026 186,300 2027 183,100 2028 179,100 2029 169,900

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of Lessee, Operating Lease, Liability, Maturity	Maturities of lease liabilities December 31, 2024 2025 $ 21,965 2026 23,254 2027 21,860 2028 20,327 2029 16,745 2030 and thereafter 32,764 Total lease payments 136,915 Less: interest (20,403) Present value of lease liabilities $ 116,512
Supplemental Information, Lessee, Operating Lease	Supplemental information December 31, 2024 December 31, 2023 Total lease liabilities (1) $ 116,512 $ 130,801 Cash paid for amounts included in the measurement of lease liabilities within operating cash flows $ 24,483 $ 26,938 Right of use assets obtained in exchange for operating lease obligations $ 4,349 $ 12,145 Weighted average remaining lease term 6.5 years 7.0 years Weighted average discount rate 4.6 % 4.4 % (1) The current portion of the operating lease liability is included in other current liabilities .

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Components of Long-Term Debt	Our borrowings at December 31, 2024 and 2023 were as follows: 2024 2023 Senior Credit Facility: Revolving credit facility, at a rate of 5.71% at December 31, 2024, and 6.71% at December 31, 2023, due 2027 $ 113,000 $ 262,000 Term loan facility, at a rate of 5.71% at December 31, 2024 and 6.71% at December 31 2023, due 2027 475,000 487,500 4.625% Senior Notes due 2027 500,000 500,000 4.25% Senior Notes due 2028 500,000 500,000 Securitization program, at a rate of 5.18% at December 31, 2024 and 6.34% at December 31, 2023 75,000 75,000 1,663,000 1,824,500 Less: Unamortized debt issuance costs (7,129) (9,428) 1,655,871 1,815,072 Current portion of borrowings (100,000) (87,500) Long-term borrowings $ 1,555,871 $ 1,727,572
Fair Value of Debt	The following table provides the fair value of our debt as of December 31, 2024 and 2023, which is valued based on Level 2 inputs within the hierarchy used to measure fair value (see Note 12 for further information): December 31, 2024 December 31, 2023 Fair value of debt $ 1,632,020 $ 1,838,993
Aggregate Amounts of Long-Term Debt	Debt Maturities As of December 31, 2024, the aggregate amounts of long-term debt, demand loans and debt under our securitization program that will mature during each of the next four years and thereafter were as follows: 2025 $ 100,000 2026 25,000 2027 1,038,000 2028 500,000 2029 and thereafter —
Schedule of Cash Flow, Supplemental Disclosures, Debt	Supplemental cash flow information Year Ended December 31, 2024 2023 2022 Cash interest paid $ 98,376 $ 100,218 $ 70,918

Financial instruments (Tables)

Financial instruments (Tables)	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The following table presents the locations in the consolidated balance sheets and fair value of derivative instruments as of December 31, 2024 and 2023: December 31, 2024 December 31, 2023 Asset derivatives: Designated foreign currency forward contracts $ 5,780 $ 1,629 Non-designated foreign currency forward contracts 254 937 Cross-currency interest rate swap 15,972 16,883 Prepaid expenses and other current assets 22,006 19,449 Cross-currency interest rate swap 5,409 — Other assets 5,409 — Total asset derivatives $ 27,415 $ 19,449 Liability derivatives: Designated foreign currency forward contracts $ 3,078 $ 1,866 Non-designated foreign currency forward contracts 931 1,340 Cross-currency interest rate swap 9,575 — Other current liabilities 13,584 3,206 Cross-currency interest rate swap — 32,097 Other liabilities — 32,097 Total liability derivatives $ 13,584 $ 35,303
Schedule of foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense	The following table summarizes the foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense related to cross currency swaps for the years ended December 31, 2024 and December 31, 2023: December 31, 2024 December 31, 2023 Foreign exchange gains (losses) $ 28,387 $ (24,210) Interest benefit 17,410 18,814

Fair value measurement (Tables)

Fair value measurement (Tables)	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024 and 2023: Basis of fair value measurement December 31, 2024 (Level 1) (Level 2) (Level 3) Investments in marketable securities $ 39,559 $ 39,559 $ — $ — Derivative assets 27,415 — 27,415 — Derivative liabilities 13,584 — 13,584 — Contingent consideration liabilities 49,277 — — 49,277 Basis of fair value measurement December 31, 2023 (Level 1) (Level 2) (Level 3) Investments in marketable securities $ 5,306 $ 5,306 $ — $ — Derivative assets 19,449 — 19,449 — Derivative liabilities 35,303 — 35,303 — Contingent consideration liabilities 39,486 — — 39,486 There were no transfers of financial assets or liabilities into or out of Level 3 within the fair value hierarchy during the years ended December 31, 2024 or 2023.
Schedule of Valuation Techniques	The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of our significant contingent consideration liabilities. Contingent Consideration Liability Valuation Technique Unobservable Input Revenue-based Monte Carlo simulation Revenue volatility 17.5% Risk free rate Cost of debt structure Projected year of payment 2025 - 2026
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	The following table provides information regarding changes in our contingent consideration liabilities for the years ended December 31, 2024 and 2023: Contingent consideration 2024 2023 Beginning balance – January 1 $ 39,486 $ 44,022 Initial estimate upon acquisition — 27,000 Payments (236) (4,293) Revaluations and other adjustments 10,027 (27,243) Ending balance – December 31 $ 49,277 $ 39,486

Shareholders' equity (Tables)

Shareholders' equity (Tables)	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Schedule of Weighted Average Number of Shares	The following table provides a reconciliation of basic to diluted weighted average shares outstanding: 2024 2023 2022 Basic 46,837 46,981 46,898 Dilutive effect of share based awards 257 323 411 Diluted 47,094 47,304 47,309
Schedule of Accumulated Other Comprehensive Income (Loss)	The following table provides information relating to the changes in accumulated other comprehensive income (loss), net of tax, for each of the years ended December 31, 2024 and 2023: Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive Income (Loss) Balance at December 31, 2022 $ 4,931 $ (135,799) $ (272,654) $ (403,522) Other comprehensive income before reclassifications 8,314 42,380 44,902 95,596 Amounts reclassified from accumulated other comprehensive income (11,849) 5,370 — (6,479) Net current-year other comprehensive income (loss) (3,535) 47,750 44,902 89,117 Balance at December 31, 2023 1,396 (88,049) (227,752) (314,405) Other comprehensive income (loss) before reclassifications 1,977 10,465 (92,594) (80,152) Amounts reclassified from accumulated other comprehensive income (1,534) 79,422 — 77,888 Net current-year other comprehensive (loss) income 443 89,887 (92,594) (2,264) Balance at December 31, 2024 $ 1,839 $ 1,838 $ (320,346) $ (316,669)
Reclassification out of Accumulated Other Comprehensive Income	The following table provides information relating to the (gains) losses recognized in the statements of income including the reclassifications of losses (gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the years ended December 31, 2024, 2023 and 2022: Year Ended December 31, 2024 2023 2022 (Gains) losses on designated foreign exchange forward contracts: Cost of goods sold $ (1,626) $ (12,234) $ (3,532) Total before tax (1,626) (12,234) (3,532) Taxes expense 92 385 203 Net of tax (1,534) (11,849) (3,329) Amortization of pension and other postretirement benefits items: Actuarial losses (1) 1,152 7,989 7,660 Prior-service credits (1) (1,967) (1,008) (1,017) Settlements 138,139 — — Total before tax 137,324 6,981 6,643 Tax benefit (57,902) (1,611) (1,546) Net of tax 79,422 5,370 5,097 Impact on income from continuing operations, net of tax $ 77,888 $ (6,479) $ 1,768 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 16 for additional information).

Stock compensation plans (Table

Stock compensation plans (Tables)	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement, Noncash Expense [Abstract]
Summary of Share-based Compensation Activity	The following table summarizes the share-based compensation activity: 2024 2023 2022 Share-based compensation expense $ 31,348 $ 31,465 $ 27,224 Total income tax benefit recognized for share-based compensation arrangements 5,325 7,820 6,824 Net excess tax (deficiency) benefit (1,542) 1,351 1,292
Weighted-Average Assumptions used to Estimate Fair Value of Options Granted	The fair value of options granted in 2024, 2023 and 2022 was estimated at the date of grant using a Black-Scholes option pricing model. The following weighted-average assumptions were used: 2024 2023 2022 Risk-free interest rate 4.28 % 4.13 % 1.56 % Expected life of option 5.11 years 5.07 years 5.03 years Expected dividend yield 0.60 % 0.57 % 0.41 % Expected volatility 30.00 % 31.42 % 30.09 %
Summary of Stock Option Activity	The following table summarizes the option activity during 2024: Shares Subject to Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life In Years Aggregate Intrinsic Value Outstanding, beginning of the year 1,293,775 $ 239.55 Granted 193,826 223.94 Exercised (50,465) 135.91 Forfeited or expired (43,382) 294.22 Outstanding, end of the year 1,393,754 239.43 4.5 $ 13,718 Exercisable, end of the year 1,052,394 $ 238.65 3.2 $ 13,718
Summary of Non-Vested Restricted Stock Unit Activity	The following table summarizes the non-vested restricted stock unit activity during 2024: Number of Non-Vested Shares Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding, beginning of the year 190,500 $ 294.63 Granted 108,777 220.18 Vested (42,896) 370.96 Forfeited (28,057) 262.41 Outstanding, end of the year 228,324 $ 248.79 1.3 $ 40,637

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Components of Provision for Income Taxes from Continuing Operations	The following table summarizes the components of the provision for income taxes from continuing operations: 2024 2023 2022 Current: Federal $ 74,748 $ 51,717 $ 32,798 State 16,476 8,266 8,747 Non-U.S. 43,830 30,408 56,442 Deferred: Federal (103,387) (24,396) (27,528) State (10,265) 5,439 10,116 Non-U.S. (16,086) 5,006 2,428 $ 5,316 $ 76,440 $ 83,003
Summaries of U.S. and Non-U.S. Components of Income from Continuing Operations Before Taxes	The following table summarizes the U.S. and non-U.S. components of income from continuing operations before taxes: 2024 2023 2022 U.S. $ (171,380) $ 45,363 $ 164,151 Non-U.S. 246,858 388,649 281,768 $ 75,478 $ 434,012 $ 445,919
Reconciliations Between Statutory Federal Income Tax Rate and Effective Income Tax Rate	Reconciliations between the statutory federal income tax rate and the effective income tax rate are as follows: 2024 2023 2022 Federal statutory rate 21.0 % 21.0 % 21.0 % Tax effect of international items (57.6) (6.1) (4.6) Pension settlement charge (38.5) (0.2) — Legal entity rationalization - deferred taxes — 5.7 — Excess tax benefits related to share-based compensation 2.0 (0.3) (0.3) State taxes, net of federal benefit 10.4 0.6 3.4 Uncertain tax contingencies (1.2) (0.6) (0.4) Contingent consideration 3.8 (1.3) 0.1 Goodwill impairment charge 66.8 — — Research and development tax credit (5.9) (1.3) (1.0) Other, net 6.2 0.1 0.5 7.0 % 17.6 % 18.6 %
Deferred Tax Assets and Liabilities	The following table summarizes significant components of our deferred tax assets and liabilities at December 31, 2024 and 2023: 2024 2023 Deferred tax assets: Tax loss and credit carryforwards $ 114,244 $ 114,147 Lease Liabilities 26,897 30,397 Reserves and accruals 77,493 72,040 Other 11,079 33,472 Less: valuation allowances (88,412) (95,747) Total deferred tax assets 141,301 154,309 Deferred tax liabilities: Property, plant and equipment 16,598 34,852 Intangibles — stock acquisitions 419,172 462,559 Unremitted non-U.S. earnings 51,638 61,734 Lease Assets 26,897 30,397 Other 6,688 14,099 Total deferred tax liabilities 520,993 603,641 Net deferred tax liability $ (379,692) $ (449,332)
Schedule of Unrecognized Tax Benefits Roll Forward	Uncertain Tax Positions : The following table is a reconciliation of the beginning and ending balances for liabilities associated with unrecognized tax benefits for the years ended December 31, 2024, 2023 and 2022: 2024 2023 2022 Balance at January 1 $ 2,020 $ 4,260 $ 6,105 Increase in unrecognized tax benefits related to prior years — — 215 Decrease in unrecognized tax benefits related to prior years — — (761) Reductions in unrecognized tax benefits due to lapse of applicable statute of limitations (902) (2,287) (1,117) (Decrease) increase in unrecognized tax benefits due to foreign currency translation (97) 47 (182) Balance at December 31 $ 1,021 $ 2,020 $ 4,260
Examinations by Major Tax Jurisdictions	The taxable years for which the applicable statute of limitations remains open by major tax jurisdictions are as follows: Beginning Ending U.S. 2017 2024 Canada 2020 2024 China 2019 2024 Czech Republic 2021 2024 France 2022 2024 Germany 2011 2024 India 2017 2024 Ireland 2020 2024 Italy 2019 2024 Malaysia 2018 2024 Singapore 2020 2024
Schedule of Cash Flow, Supplemental Disclosures, Income Tax	Supplemental cash flow information Year Ended December 31, 2024 2023 2022 Income taxes paid, net of refunds $ 164,902 $ 114,211 $ 162,046

Pension and other postretirem_2

Pension and other postretirement benefits (Tables)	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Net Benefit Cost of Pension and Postretirement Benefit Plans	The following table provides information regarding the components of the net benefit (income) expense of the pension and postretirement benefit plans for the years ended December 31, 2024, 2023 and 2022: Pension Other Benefits 2024 2023 2022 2024 2023 2022 Service cost $ 823 $ 1,435 $ 1,346 $ — $ — $ — Interest cost 2,940 17,297 10,776 384 824 477 Expected return on plan assets (2,591) (25,277) (25,776) — — — Net amortization and deferral 1,849 8,536 7,900 (2,664) (1,564) (1,258) Settlements, net 132,732 45,244 — — — — Net benefit expense (income) $ 135,753 $ 47,235 $ (5,754) $ (2,280) $ (740) $ (781)
Weighted Average Assumptions used in Determining Net Periodic Benefit Cost	The following table provides the weighted average assumptions for U.S. and foreign plans used in determining net benefit cost: Pension Other Benefits 2024 2023 2022 2024 2023 2022 Discount rate 4.7 % 5.1 % 2.8 % 5.0 % 5.1 % 2.7 % Rate of return 4.8 % 7.3 % 5.6 % Initial healthcare trend rate 6.9 % 6.1 % 6.4 % Ultimate healthcare trend rate 4.5 % 4.5 % 4.5 % The following table provides the weighted average assumptions for U.S. and foreign plans used in determining benefit obligations: Pension Other Benefits 2024 2023 2024 2023 Discount rate 4.4 % 4.7 % 5.6 % 5.0 % Rate of compensation increase 2.9 % 3.0 % Initial healthcare trend rate 6.8 % 6.6 % Ultimate healthcare trend rate 4.5 % 4.5 %
Pension and Postretirement Benefit Plans	The following table provides summarized information with respect to the pension and postretirement benefit plans, measured as of December 31, 2024 and 2023: Pension Other Benefits 2024 2023 2024 2023 Benefit obligation, beginning of year $ 275,397 $ 356,757 $ 9,535 $ 18,620 Service cost 823 1,435 — — Interest cost 2,940 17,297 384 824 Actuarial loss (gain) (7,798) 11,557 (2,150) (508) Currency translation (1,028) 1,067 — — Benefits paid (227,491) (21,208) (545) (1,910) Liability gain due to settlement (16,969) (15,272) — — Medicare Part D reimbursement — — 51 (3) Plan amendments — — — (7,488) Settlements — (73,932) — — Administrative costs (767) (2,304) — — Projected benefit obligation, end of year 25,107 275,397 7,275 9,535 Fair value of plan assets, beginning of year 285,513 357,270 Actual return on plan assets (5,241) 23,740 Contributions 1,663 1,276 Benefits paid (227,491) (95,139) Administrative costs (767) (2,304) Assets Transferred to Qualified Replacement Plan (42,966) — Currency translation (179) 670 Fair value of plan assets, end of year 10,532 285,513 Funded status, end of year $ (14,575) $ 10,116 $ (7,275) $ (9,535)
Amounts Recognized in the Consolidated Balance Sheet	The following table sets forth the amounts recognized in the consolidated balance sheet with respect to the pension and postretirement plans: Pension Other Benefits 2024 2023 2024 2023 Other assets $ 477 $ 27,370 $ — $ — Payroll and benefit-related liabilities (1,117) (1,439) (1,025) (1,361) Pension and postretirement benefit liabilities (13,935) (15,815) (6,250) (8,174) Accumulated other comprehensive loss (gain) 12,677 164,139 (13,730) (14,244) $ (1,898) $ 174,255 $ (21,005) $ (23,779)
Amounts Recognized in Accumulated Other Comprehensive (Income) Loss	The following tables set forth the amounts recognized in accumulated other comprehensive income with respect to the plans: Pension Prior Service Cost Net Loss or (Gain) Deferred Taxes Accumulated Other Comprehensive Balance at December 31, 2022 $ 200 $ 219,355 $ (77,347) $ 142,208 Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral (9) (8,527) 1,961 (6,575) Amounts arising during the period: Actuarial changes in benefit obligation — (47,453) 10,805 (36,648) Impact of currency translation — 573 (139) 434 Balance at December 31, 2023 191 163,948 (64,720) 99,419 Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral — (1,849) 446 (1,403) Amounts arising during the period: Actuarial changes in benefit obligation (1) — (149,294) 60,645 (88,649) Impact of currency translation — (319) 86 (233) Balance at December 31, 2024 $ 191 $ 12,486 $ (3,543) $ 9,134 (1) The tax benefit primarily relates to an adjustment to deferred taxes associated with the settlement charge and stranded tax costs within accumulated other comprehensive income. Other Benefits Prior Service Cost Net (Gain) or Loss Deferred Taxes Accumulated Other Comprehensive Balance at December 31, 2022 $ (2,635) $ (5,177) $ 1,403 $ (6,409) Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral 1,017 547 (359) 1,205 Amounts arising during the period: Actuarial changes in benefit obligation — (7,996) 1,830 (6,166) Balance at December 31, 2023 (1,618) (12,626) 2,874 (11,370) Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral 1,967 697 (609) 2,055 Amounts arising during the period: Actuarial changes in benefit obligation — (2,150) 493 (1,657) Balance at December 31, 2024 $ 349 $ (14,079) $ 2,758 $ (10,972)
Fair Values of Pension Plan Assets	The following table provides the fair values of the pension plan assets at December 31, 2024 by asset category: Fair Value Measurements Asset Category (a) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash $ 110 $ 110 $ — $ — Money market funds 19 19 — — Other types of investments: Contract with insurance company (b) 10,403 — — 10,403 Total investments at fair value $ 10,532 $ 129 $ — $ 10,403 Total $ 10,532 The following table provides the fair values of the pension plan assets at December 31, 2023 by asset category: Fair Value Measurements Asset Category (a) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash $ 909 $ 909 $ — $ — Money market funds 4,424 4,424 — — Fixed income securities: Intermediate duration fund (c) 193,674 193,674 — — Long duration bond fund (d) 1,357 1,357 — — Corporate, government and foreign bonds 72,037 — 72,037 — Absolute return credit fund (e) 317 — 317 — Other types of investments: Contract with insurance company (b) 12,795 — — 12,795 Total investments at fair value $ 285,513 $ 200,364 $ 72,354 $ 12,795 Total $ 285,513 (a) Information on asset categories described in notes (b)-(e) is derived from prospectuses and other material provided by the respective funds comprising the respective asset categories. (b) This category comprises the asset established out of an agreement to purchase a bulk-annuity policy from an insurer to fully cover the liabilities for members of the pension plan. The asset value is based on the fair value of the contract as determined by the insurance company using inputs that are not observable. (c) This category comprises a mutual fund that invests in instruments or derivatives having economic characteristics similar to fixed income securities. The fund invests in investment grade fixed income instruments, including U.S. and foreign corporate obligations, fixed income securities issued by sovereigns or agencies in both developed and emerging foreign markets, debt obligations issued by governments or other municipalities, and securities issued or guaranteed by the U.S. Government and its agencies. The fund will seek to maintain an effective average duration between three (d) This category comprises a mutual fund that invests in instruments or derivatives having economic characteristics similar to fixed income securities. The fund invests in investment grade fixed income instruments, including securities issued or guaranteed by the U.S. Government and its agencies and instrumentalities, corporate bonds, asset-backed securities, exchange traded funds, mortgage-backed securities and collateralized mortgage-backed securities. The fund invests primarily in long duration government and corporate fixed income securities, and uses derivative instruments, including interest rate swap agreements and Treasury futures contracts, for the purpose of managing the overall duration and yield curve exposure of the Fund’s portfolio of fixed income securities. (e) This category comprises a mutual fund that invests primarily in investment grade bonds and similar fixed income and floating rate securities.
Expected Benefit Payments	The following table provides information about the expected benefit payments under its U.S. and foreign plans for each of the five succeeding years and the aggregate of the five years thereafter: Pension Other Benefits 2025 $ 2,080 $ 1,022 2026 2,114 756 2027 2,014 602 2028 2,086 574 2029 2,174 563 Years 2030 — 2034 10,693 2,488

Business segments and other i_2

Business segments and other information (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Business segments and other information	The following tables present our segment results for the years ended December 31, 2024, 2023 and 2022: 2024 Americas EMEA Asia Segment Total Net revenues $ 2,066,292 $ 617,984 $ 363,048 $ 3,047,324 Cost of goods sold 834,987 289,645 132,030 1,256,662 Research and development expenses 94,912 38,939 18,584 152,435 Selling, general and administrative expenses 465,917 156,375 97,764 720,056 Segment operating profit (1) $ 670,476 $ 133,025 $ 114,670 $ 918,171 2023 Americas EMEA Asia Segment Total Net revenues $ 2,041,339 $ 586,245 $ 346,905 $ 2,974,489 Cost of goods sold 824,514 273,772 118,729 1,217,015 Research and development expenses 82,685 54,787 14,105 151,577 Selling, general and administrative expenses 420,158 146,551 93,119 659,828 Segment operating profit (1) $ 713,982 $ 111,135 $ 120,952 $ 946,069 2022 Americas EMEA Asia Segment Total Net revenues $ 1,926,348 $ 558,373 $ 306,320 $ 2,791,041 Cost of goods sold 780,538 255,210 101,037 1,136,785 Research and development expenses 67,795 69,822 13,379 150,996 Selling, general and administrative expenses 408,068 136,464 87,211 631,743 Segment operating profit (1) $ 669,947 $ 96,877 $ 104,693 $ 871,517 (1) Segment operating profit represents income from continuing operations before interest, loss on extinguishment of debt and taxes adjusted to exclude unallocated corporate expenses manufacturing variances other than fixed manufacturing cost absorption variances, restructuring and impairment charges. See reconciliation of segment operating profit measures for further details. Year Ended December 31, 2024 2023 2022 Reconciliation of segment operating profit measure Segment operating profit $ 918,171 $ 946,069 $ 871,517 Other unallocated expenses (1) 372,435 383,356 357,997 Goodwill impairment charge 240,000 — — Restructuring and impairment charges 21,991 15,604 20,299 Gain on sale of assets and business — (4,448) (6,504) Pension settlement charge 132,732 45,244 — Income from continuing operations before interest, loss on extinguishments of debt and taxes $ 151,013 $ 506,313 $ 499,725 (1) Other unallocated expenses include expenses within costs of goods sold, research and development and selling, general and administrative costs and primarily consist of manufacturing variances other than fixed manufacturing cost absorption variances and unallocated corporate function expenses. Year Ended December 31, Depreciation and amortization 2024 2023 2022 Americas $ 193,949 $ 168,787 $ 161,842 EMEA 49,596 42,057 38,266 Asia 12,344 10,548 9,311 Corporate (1) 18,712 20,726 21,171 Consolidated depreciation and amortization $ 274,601 $ 242,118 $ 230,590 (1) Reflects depreciation and amortization included within other allocated expenses per reconciliation of segment operating profit measure.
Total Net Revenues and Total Net Property, Plant and Equipment by Geographic Region	The following tables provide total net revenues and total net property, plant and equipment by geographic region for the years ended December 31, 2024, 2023 and 2022 and as of December 31, 2024 and 2023, respectively. Year Ended December 31, 2024 2023 2022 Net revenues (based on selling location): U.S. $ 1,889,312 $ 1,879,898 $ 1,786,467 Europe 705,094 665,185 622,343 Asia Pacific 326,371 307,513 270,749 All other 126,547 121,893 111,482 $ 3,047,324 $ 2,974,489 $ 2,791,041 As of December 31, Net property, plant and equipment: 2024 2023 U.S. $ 215,806 $ 200,969 Malaysia 73,430 71,947 Mexico 121,287 112,339 All other 92,329 94,658 $ 502,852 $ 479,913

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	12 Months Ended
	Dec. 31, 2024
Condensed Consolidated Guarantor Financial Information [Abstract]
Schedule of Cash and Cash Equivalents	Cash, cash equivalents, and restricted cash equivalents consisted of the following at December 31, 2024 and December 31, 2023: December 31, 2024 December 31, 2023 Cash and cash equivalents $ 290,188 $ 222,848 Restricted cash equivalents in other current assets (1) 14,700 — Restricted cash equivalents in other assets (1) 22,762 — Total cash, cash equivalents and restricted cash equivalents $ 327,650 $ 222,848 (1) Restricted cash equivalents represent surplus plan assets resulting from the termination of the Teleflex Incorporated Retirement Income Plan that were transferred to a suspense account within the Teleflex 401(k) Savings Plan as of December 31, 2024 as described in Note 16. Amounts expected to be transferred from the suspense account to employees within one year are classified as other current assets.

Summary of significant accoun_3

Summary of significant accounting policies (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Summary Of Significant Accounting Policies [Line Items]
Allowance for credit losses	$ 10	$ 9.5
Current portion of allowance for credit losses	6.1	5.5
Goodwill and intangible asset impairment	$ 240
Weighted average amortization period of intangible assets, in years	12 years
Reserve for returns and allowances	$ 41.7	22.2
Reserve for estimated rebates	$ 24.9	$ 26.7
Sales Revenue, Net | Hospitals And Healthcare Providers | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	87%
Sales Revenue, Net | Other Medical Device Manufacturers | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	11%
Sales Revenue, Net | Home Care Providers such as Pharmacies | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	2%
Minimum | Intellectual property
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	8 years
Minimum | Customer relationships
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	8 years
Minimum | Distribution rights
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	10 years
Minimum | Trade names
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	15 years
Maximum | Intellectual property
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	20 years
Maximum | Customer relationships
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	27 years
Maximum | Trade names
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	30 years
Building
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	30 years
Machinery and Equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	3 years
Machinery and Equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	15 years
Computer Equipment and Software | Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	3 years
Computer Equipment and Software | Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	10 years

Net revenues (Details)

Net revenues (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Net revenues	$ 3,047,324	$ 2,974,489	$ 2,791,041
Vascular access
Disaggregation of Revenue [Line Items]
Net revenues	732,675	708,044	683,612
Interventional
Disaggregation of Revenue [Line Items]
Net revenues	586,057	511,434	445,018
Anesthesia
Disaggregation of Revenue [Line Items]
Net revenues	395,285	389,957	388,890
Surgical
Disaggregation of Revenue [Line Items]
Net revenues	450,482	427,359	392,917
Interventional urology
Disaggregation of Revenue [Line Items]
Net revenues	331,092	319,785	322,832
OEM
Disaggregation of Revenue [Line Items]
Net revenues	344,511	326,008	272,624
Other
Disaggregation of Revenue [Line Items]
Net revenues	$ 207,222	$ 291,902	$ 285,148

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 29, 2024 USD ($)	Dec. 31, 2023 USD ($) payment	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Business Acquisition [Line Items]
Goodwill measurement adjustment			$ 1,953	$ (357,025)
Palette Life Sciences AB
Business Acquisition [Line Items]
Business combination, consideration transferred		$ 594,900
Number of milestone payments | payment		2
Aggregate contingent consideration amount		$ 50,000		50,000
Milestone payments on sales, period (in years)		2 years
Business combination, goodwilll		$ 355,100		355,100
Business combination, intellectual property		264,000		264,000
Business combination, trade name assets		40,500		40,500
Business combination, customer relationship assets		$ 29,000		$ 29,000
Deferred income taxes adjustment	$ 2,000
Goodwill measurement adjustment	$ 2,000
Foreign currency translation adjustment			$ 19,700

Acquisitions - Pro Forma Net In

Acquisitions - Pro Forma Net Income (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Acquisition of businesses	$ 0	$ 27,000	$ 43,168
Palette Life Sciences AB
Business Acquisition [Line Items]
Net income		$ 310,356	$ 282,425
Earnings per share, basic (in dollars per share)		$ 6.61	$ 6.02
Earnings per share, diluted (in dollars per share)		$ 6.56	$ 5.97

Restructuring and other impai_3

Restructuring and other impairment charges - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 14,157		$ 18,802
Impairment of leasehold	7,800
Asset impairments	7,834		1,497
2024 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	6,100
2024 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	11,203
2023 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,377	$ 1,451
Restructuring expenses	2,800
Cost incurred to date	2,700
Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	13,951		17,385
Asset impairments	0		$ 0
Termination benefits | 2024 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	6,086
Termination benefits | 2024 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	11,164
Termination benefits | 2023 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,344	$ 1,451
Selling, General And Administrative Expenses | 2024 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	200
Restructuring related charges | 2024 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	6,600
Restructuring related charges | 2023 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2,600
Minimum | 2024 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	37,000
Minimum | 2023 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	11,000
Minimum | Termination benefits | 2024 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	6,000
Minimum | Selling, General And Administrative Expenses | 2024 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	3,000
Minimum | Restructuring related charges | 2024 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	21,000
Minimum | Restructuring related charges | 2023 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	7,000
Maximum | 2024 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	46,000
Maximum | 2023 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	15,000
Maximum | Termination benefits | 2024 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	7,000
Maximum | Selling, General And Administrative Expenses | 2024 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	4,000
Maximum | Restructuring related charges | 2024 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	26,000
Maximum | Restructuring related charges | 2023 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 9,000

Restructuring and other impai_4

Restructuring and other impairment charges - Expected costs to be incurred (Details) $ in Millions	Dec. 31, 2024 USD ($)
2024 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 37
2024 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	46
2023 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	11
2023 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	15
Restructuring charges | 2024 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	16
Restructuring charges | 2024 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	20
Restructuring charges | 2023 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	4
Restructuring charges | 2023 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	6
Restructuring related charges | 2024 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	21
Restructuring related charges | 2024 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	26
Restructuring related charges | 2023 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	7
Restructuring related charges | 2023 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 9

Restructuring and other impai_5

Restructuring and other impairment charges - Reconciliation of changes in accrued liabilities associated with restructuring program (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
2024 Restructuring plan
Restructuring Reserve [Roll Forward]
Balance, beginning	$ 0	$ 0
Accruals	6,100	0
Cash payments	(777)	0
Foreign currency translation and other	427
Balance, ending	5,750	0
2024 Footprint realignment plan
Restructuring Reserve [Roll Forward]
Balance, beginning	0	0
Accruals	11,203	0
Cash payments	(1,442)	0
Foreign currency translation and other	961
Balance, ending	10,722	0
2023 Footprint realignment plan
Restructuring Reserve [Roll Forward]
Balance, beginning	1,343	0
Accruals	1,377	1,451
Cash payments	(32)	(108)
Foreign currency translation and other	0
Balance, ending	$ 2,688	$ 1,343

Restructuring and other impai_6

Restructuring and other impairment charges - Restructuring program (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	$ 14,157		$ 18,802
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]			Cost of goods sold
Asset impairment charges	7,834		$ 1,497
Total restructuring and other impairment charges	21,991	$ 15,604	20,299
2024 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	6,100
2024 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	11,203
2023 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	(1,442)	12,535
2023 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	1,377	1,451
2022 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	(1,432)	3,128	15,523
Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		(929)	578
2019 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges			(987)
2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges			2,076
Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	(1,649)	(581)	1,612
Termination benefits
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	13,951		17,385
Asset impairment charges	0		0
Total restructuring and other impairment charges	13,951	14,784	17,385
Termination benefits | 2024 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	6,086
Termination benefits | 2024 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	11,164
Termination benefits | 2023 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	(1,524)	12,535
Termination benefits | 2023 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	1,344	1,451
Termination benefits | 2022 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	(1,454)	2,759	15,465
Termination benefits | Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		(946)	504
Termination benefits | 2019 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges			(1,120)
Termination benefits | 2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges			1,230
Termination benefits | Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	(1,665)	(1,015)	1,306
Other costs
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	206		1,417
Asset impairment charges	7,834		1,497
Total restructuring and other impairment charges	8,040	820	2,914
Other costs | 2024 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	14
Other costs | 2024 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	39
Other costs | 2023 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	82	0
Other costs | 2023 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	33	0
Other costs | 2022 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	22	369	58
Other costs | Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		17	74
Other costs | 2019 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges			133
Other costs | 2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges			846
Other costs | Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	$ 16	$ 434	$ 306

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 155,201	$ 179,517
Work-in-process	115,814	111,132
Finished goods	329,118	335,567
Inventories	$ 600,133	$ 626,216

Property, plant, equipment (Det

Property, plant, equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Land, buildings and leasehold improvements	$ 291,696	$ 284,604
Machinery and equipment	474,879	459,268
Computer equipment and software	234,251	214,573
Construction in progress	112,708	94,633
Property, plant and equipment, gross	1,113,534	1,053,078
Less: Accumulated depreciation	(610,682)	(573,165)
Property, plant and equipment, net	$ 502,852	$ 479,913

Goodwill and other intangible_3

Goodwill and other intangible assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Asset impairments	$ 7,834		$ 1,497
Goodwill	2,632,314	$ 2,914,055
Intangible asset amortization expense	197,669	$ 173,974	$ 164,088
Trade names
Finite-Lived Intangible Assets [Line Items]
Indefinite lived intangible assets	227,700
North America | IU Reporting Unit
Finite-Lived Intangible Assets [Line Items]
Asset impairments	240,000
Goodwill	$ 403,900
Goodwill, quantitative assessment, discount rate	10.75%

Goodwill and other intangible_4

Goodwill and other intangible assets - Changes in carrying amount by reporting segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 2,914,055
Goodwill			$ 2,536,730
Goodwill impairment charge	(240,000)
Goodwill related to acquisitions	(1,953)	$ 357,025
Translation and other adjustments	(39,788)	20,300
Goodwill, ending balance	2,632,314	2,914,055
Americas | Operating Segments
Goodwill [Roll Forward]
Goodwill, beginning balance	2,180,082
Goodwill			1,843,103
Goodwill impairment charge	(240,000)
Goodwill related to acquisitions	(1,953)	333,462
Translation and other adjustments	(5,360)	3,517
Goodwill, ending balance	1,932,769	2,180,082
EMEA | Operating Segments
Goodwill [Roll Forward]
Goodwill, beginning balance	487,744
Goodwill			468,524
Goodwill impairment charge	0
Goodwill related to acquisitions	0	4,284
Translation and other adjustments	(22,255)	14,936
Goodwill, ending balance	465,489	487,744
Asia | Operating Segments
Goodwill [Roll Forward]
Goodwill, beginning balance	246,229
Goodwill			$ 225,103
Goodwill impairment charge	0
Goodwill related to acquisitions	0	19,279
Translation and other adjustments	(12,173)	1,847
Goodwill, ending balance	$ 234,056	$ 246,229

Goodwill and other intangible_5

Goodwill and other intangible assets - Components of intangible assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 3,896,260	$ 3,937,653
Accumulated Amortization	(1,627,546)	(1,435,693)
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Indefinite lived intangible assets	23,666	27,476
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,354,087	1,363,839
Accumulated Amortization	(620,619)	(561,753)
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,870,407	1,890,957
Accumulated Amortization	(863,066)	(745,094)
Distribution rights
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	23,004	23,301
Accumulated Amortization	(22,524)	(22,048)
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	603,202	610,146
Accumulated Amortization	(99,443)	(84,864)
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	21,894	21,934
Accumulated Amortization	$ (21,894)	$ (21,934)

Goodwill and other intangible_6

Goodwill and other intangible assets - Estimated annual amortization expense (Detail) $ in Thousands	Dec. 31, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 189,100
2026	186,300
2027	183,100
2028	179,100
2029	$ 169,900

Leases - Additional information

Leases - Additional information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Lease, cost	$ 29.3	$ 31.1	$ 30.8
Minimum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, option to terminate or extend	1 year

Leases - Maturities of lease li

Leases - Maturities of lease liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
2025	$ 21,965
2026	23,254
2027	21,860
2028	20,327
2029	16,745
2030 and thereafter	32,764
Total lease payments	136,915
Less: interest	(20,403)
Present value of lease liabilities	$ 116,512	$ 130,801

Leases - Supplemental balance s

Leases - Supplemental balance sheet information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Total lease liabilities	$ 116,512	$ 130,801
Cash paid for amounts included in the measurement of lease liabilities within operating cash flows	24,483	26,938
Right of use assets obtained in exchange for operating lease obligations	$ 4,349	$ 12,145
Weighted average remaining lease term	6 years 6 months	7 years
Weighted average discount rate	4.60%	4.40%

Borrowings - Components of Long

Borrowings - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2020	Dec. 31, 2017
Line of Credit Facility [Line Items]
Long-term debt, Gross	$ 1,663,000	$ 1,824,500
Less: Unamortized debt issuance costs	(7,129)	(9,428)
Net carrying amount	1,655,871	1,815,072
Current portion of borrowings	(100,000)	(87,500)
Long-term borrowings	1,555,871	1,727,572
Revolving Credit Facility
Line of Credit Facility [Line Items]
Long-term line of credit	$ 113,000	$ 262,000
Senior credit facility interest rate	5.71%	6.71%
Securitization Program
Line of Credit Facility [Line Items]
Long-term line of credit	$ 75,000	$ 75,000
Securitization program, at a rate of 5.18% at December 31, 2024 and 6.34% at December 31, 2023	$ 75,000	$ 75,000
Interest rate	5.18%	6.34%
Term loan facility, at a rate of 5.71% at December 31, 2024 and 6.71% at December 31 2023, due 2027 | Term Loan
Line of Credit Facility [Line Items]
Long-term line of credit	$ 475,000	$ 487,500
Senior credit facility interest rate	5.71%	6.71%
4.625% Senior Notes due 2027 | Senior Notes
Line of Credit Facility [Line Items]
Senior notes	$ 500,000	$ 500,000		$ 500,000
Interest rate	4.625%	4.625%		4.625%
4.25% Senior Notes due 2028 | Senior Notes
Line of Credit Facility [Line Items]
Senior notes	$ 500,000	$ 500,000	$ 500,000
Interest rate	4.25%	4.25%	4.25%

Borrowings - Additional Informa

Borrowings - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2017	Dec. 31, 2023
Securitization Program
Debt Instrument [Line Items]
Interest rate	5.18%				6.34%
Long-term line of credit	$ 75,000				$ 75,000
Revolving Credit Facility
Debt Instrument [Line Items]
Long-term line of credit	$ 113,000				$ 262,000
4.625% Senior Notes due 2027 | Minimum
Debt Instrument [Line Items]
Declining percent of redemption price to principal amount				0.771%
4.625% Senior Notes due 2027 | Maximum
Debt Instrument [Line Items]
Declining percent of redemption price to principal amount				100%
4.625% Senior Notes due 2027 | Senior Notes
Debt Instrument [Line Items]
Interest rate	4.625%			4.625%	4.625%
Senior notes	$ 500,000			$ 500,000	$ 500,000
Debt issuance, line of credit				$ 7,900
4.625% Senior Notes due 2027 | Senior Notes | Maximum
Debt Instrument [Line Items]
Percent of redemption price to principal amount				102.313%
4.25% Senior Notes due 2028 | Minimum
Debt Instrument [Line Items]
Declining percent of redemption price to principal amount			1.0625%
4.25% Senior Notes due 2028 | Maximum
Debt Instrument [Line Items]
Declining percent of redemption price to principal amount			100%
4.25% Senior Notes due 2028 | Senior Notes
Debt Instrument [Line Items]
Interest rate	4.25%		4.25%		4.25%
Senior notes	$ 500,000		$ 500,000		$ 500,000
Debt issuance, line of credit			$ 8,500
Percent of redemption price to principal amount			102.125%
Third Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Interest rate		2%
Leverage ratio, required	4.50
Interest coverage ratio, required	3.50
Third Amended and Restated Credit Agreement | Secured Overnight Financing Rate (SOFR) | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate		1.125%
Third Amended and Restated Credit Agreement | Secured Overnight Financing Rate (SOFR) | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate		2%
Third Amended and Restated Credit Agreement | Federal Funds | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate		0.50%
Third Amended and Restated Credit Agreement | Adjusted SOFR
Debt Instrument [Line Items]
Basis spread on variable rate		1%
Third Amended and Restated Credit Agreement | Adjusted SOFR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate		0.125%
Third Amended and Restated Credit Agreement | Adjusted SOFR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate		1%
Third Amended and Restated Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Debt, term	2 years	5 years
Maximum amount available for borrowing	$ 550,000	$ 1,000,000
Third Amended and Restated Credit Agreement | Term Loan
Debt Instrument [Line Items]
Maximum amount available for borrowing	$ 500,000	$ 500,000
Third Amended and Restated Credit Agreement | Term Loan | Adjusted SOFR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate		1.125%
Third Amended and Restated Credit Agreement | Term Loan | Adjusted SOFR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate		2%

Borrowings - Fair Value of Debt

Borrowings - Fair Value of Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Level 2
Fair Value Measurements [Line Items]
Fair value of debt	$ 1,632,020	$ 1,838,993

Borrowings - Aggregate Amounts

Borrowings - Aggregate Amounts of Long-Term Debt (Detail) $ in Thousands	Dec. 31, 2024 USD ($)
Debt Disclosure [Abstract]
2025	$ 100,000
2026	25,000
2027	1,038,000
2028	500,000
2029 and thereafter	$ 0

Borrowings - Supplemental Cash

Borrowings - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Cash interest paid	$ 98,376	$ 100,218	$ 70,918

Financial instruments - Additio

Financial instruments - Additional Information (Detail)			12 Months Ended
	Apr. 25, 2024 USD ($) counterparty agreement	Feb. 26, 2024 USD ($) agreement	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2024 EUR (€)	Apr. 25, 2024 EUR (€) counterparty agreement	Oct. 02, 2023 EUR (€) derivative_instrument	Oct. 01, 2023 USD ($)	Dec. 31, 2019 USD ($) counterparty	Dec. 31, 2019 EUR (€) counterparty
Derivatives Fair Value [Line Items]
Derivative, number of instruments held | derivative_instrument								6
Cash Flow Hedging
Derivatives Fair Value [Line Items]
Ineffectiveness on hedging derivatives			$ 0	$ 0	$ 0
Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Loss on sale of derivatives	$ 400,000
Foreign Currency Exchange Contracts | Not Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Gain on derivative			4,100,000
Loss on derivative				3,200,000
Total notional amount for all open foreign currency forward contracts			168,600,000	195,000,000
Foreign Currency Exchange Contracts | Designated as Hedging Instrument | BIOTRONIK
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts | €						€ 700,000,000
Foreign Currency Exchange Contracts | Designated as Hedging Instrument | Cash Flow Hedging
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts			$ 270,900,000	234,100,000
Cross Currency Interest Rate Contract | Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts				$ 500,000,000				€ 474,700,000	$ 500,000,000	$ 250,000,000	€ 219,200,000
Derivative, number of instruments held | counterparty										5	5
Derivative, fixed interest rate								3.05%	4.63%	4.88%	4.88%
Derivative, annual interest rate										2.46%	2.46%
Proceeds from derivative instrument, investing activities		$ 12,100,000
Number of new agreements | agreement	2	2					2
Cross Currency Interest Rate Contract, Expiring 2027 | Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Derivative, number of counterparties | counterparty	5						5
Cross Currency Interest Rate Contract, Expiring 2027 | Designated as Hedging Instrument | Short
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts	$ 250,000,000	$ 250,000,000
Derivative, fixed interest rate	4.25%						4.25%
Cross Currency Interest Rate Contract, Expiring 2027 | Designated as Hedging Instrument | Long
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts | €							€ 233,400,000
Derivative, fixed interest rate	2.44%						2.44%
Cross Currency Interest Rate Contract, Expiring 2029 | Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Derivative, number of counterparties | counterparty	4						4
Cross Currency Interest Rate Contract, Expiring 2029 | Designated as Hedging Instrument | Short
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts	$ 250,000,000
Derivative, fixed interest rate	4.25%						4.25%
Cross Currency Interest Rate Contract, Expiring 2029 | Designated as Hedging Instrument | Long
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts | €							€ 233,400,000
Derivative, fixed interest rate	2.45%						2.45%

Financial instruments - Schedul

Financial instruments - Schedule of foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange gains (losses)	$ (92,594)	$ 44,902	$ (62,904)
Interest benefit on swaps not designed as hedging instrument	17,410	18,814	$ 20,880
Cross Currency Interest Rate Contract | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Interest benefit on swaps not designed as hedging instrument	17,410	18,814
Cross Currency Interest Rate Contract | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange gains (losses)	$ 28,387	$ (24,210)

Financial instruments - Fair va

Financial instruments - Fair value of derivatives (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Derivatives Fair Value [Line Items]
Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other liabilities
Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Prepaid expenses and other current assets
Other assets
Derivatives Fair Value [Line Items]
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other assets
Other liabilities
Derivatives Fair Value [Line Items]
Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities
Foreign Currency Exchange Contracts | Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	$ 0	$ 32,097
Cash Flow Hedging
Derivatives Fair Value [Line Items]
Total asset derivatives	27,415	19,449
Total liability derivatives	13,584	35,303
Cash Flow Hedging | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	22,006	19,449
Cash Flow Hedging | Other assets
Derivatives Fair Value [Line Items]
Total asset derivatives	5,409	0
Cash Flow Hedging | Foreign Currency Exchange Contracts | Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	13,584	3,206
Cash Flow Hedging | Foreign Currency Exchange Contracts | Designated as Hedging Instrument | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	5,780	1,629
Cash Flow Hedging | Foreign Currency Exchange Contracts | Designated as Hedging Instrument | Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	3,078	1,866
Cash Flow Hedging | Foreign Currency Exchange Contracts | Not Designated as Hedging Instrument | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	254	937
Cash Flow Hedging | Foreign Currency Exchange Contracts | Not Designated as Hedging Instrument | Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	931	1,340
Cash Flow Hedging | Cross Currency Interest Rate Contract | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	15,972	16,883
Cash Flow Hedging | Cross Currency Interest Rate Contract | Other assets
Derivatives Fair Value [Line Items]
Total asset derivatives	5,409	0
Cash Flow Hedging | Cross Currency Interest Rate Contract | Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	$ 9,575	$ 32,097

Fair value measurement - Financ

Fair value measurement - Financial assets and liabilities carried at fair value measured on recurring basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	$ 39,559	$ 5,306
Derivative assets	27,415	19,449
Derivative liabilities	13,584	35,303
Contingent consideration liabilities	49,277	39,486
Standard Bariatrics | Maximum
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Contingent consideration liabilities	177,000
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	39,559	5,306
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	0	0
Significant Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	27,415	19,449
Derivative liabilities	13,584	35,303
Contingent consideration liabilities	0	0
Significant Unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	$ 49,277	$ 39,486

Fair value measurement - Valuat

Fair value measurement - Valuation Technique (Details)	Dec. 31, 2024
Revenue-based | Revenue volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, contingent consideration, liability, measurement input	0.175

Fair value measurement - Reconc

Fair value measurement - Reconciliation of changes in three financial liabilities measured at fair value on recurring (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Changes in Level 3 Financial Liabilities Related to Contingent Consideration [Roll Forward]
Beginning balance	$ 39,486	$ 44,022
Initial estimate upon acquisition	0	27,000
Payments	(236)	(4,293)
Revaluations and other adjustments	10,027	(27,243)
Ending balance	$ 49,277	$ 39,486
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general and administrative expenses	Selling, general and administrative expenses

Shareholders' equity - Addition

Shareholders' equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions			12 Months Ended
	Oct. 30, 2024	Aug. 02, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Feb. 28, 2025	Feb. 27, 2025	Jul. 30, 2024
Shareholders Equity [Line Items]
Common shares, authorized (in shares)			200,000,000
Common shares, par value (in dollars per share)			$ 1	$ 1
Preference shares, authorized (in shares)			500,000
Preference shares, outstanding (in shares)			0	0	0
Share repurchase program, authorized amount		$ 200						$ 500
Share repurchase program, authorized (in shares)	172,351	678,110
Percent purchased of authorized amount		80%
Cost per share (in USD per share)	$ 235.17	$ 235.95
Subsequent Event
Shareholders Equity [Line Items]
Share repurchase program, authorized amount						$ 300	$ 300
Stock Option
Shareholders Equity [Line Items]
Weighted average antidilutive which were not included in the calculation of earnings per share (in shares)			900,000	700,000	500,000

Shareholders' equity - Reconcil

Shareholders' equity - Reconciliation of basic to diluted weighted average common shares outstanding (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Basic (in shares)	46,837	46,981	46,898
Dilutive effect of share based awards (in shares)	257	323	411
Diluted (in shares)	47,094	47,304	47,309

Shareholders' equity - Change i

Shareholders' equity - Change in accumulated other comprehensive income (loss), net of tax (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	$ 4,440,988	$ 4,021,968	$ 3,754,748
Other comprehensive income (loss) before reclassifications	(80,152)	95,596
Amounts reclassified from accumulated other comprehensive income	77,888	(6,479)
Other comprehensive (loss) income	(2,264)	89,117	(56,563)
Ending Balance	4,278,140	4,440,988	4,021,968
Cash Flow Hedges
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	1,396	4,931
Other comprehensive income (loss) before reclassifications	1,977	8,314
Amounts reclassified from accumulated other comprehensive income	(1,534)	(11,849)
Other comprehensive (loss) income	443	(3,535)
Ending Balance	1,839	1,396	4,931
Pension and Other Postretirement Benefit Plans
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(88,049)	(135,799)
Other comprehensive income (loss) before reclassifications	10,465	42,380
Amounts reclassified from accumulated other comprehensive income	79,422	5,370
Other comprehensive (loss) income	89,887	47,750
Ending Balance	1,838	(88,049)	(135,799)
Foreign Currency Translation Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(227,752)	(272,654)
Other comprehensive income (loss) before reclassifications	(92,594)	44,902
Amounts reclassified from accumulated other comprehensive income	0	0
Other comprehensive (loss) income	(92,594)	44,902
Ending Balance	(320,346)	(227,752)	(272,654)
Accumulated Other Comprehensive (Loss) Income
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(314,405)	(403,522)	(346,959)
Other comprehensive (loss) income	(2,264)	89,117	(56,563)
Ending Balance	$ (316,669)	$ (314,405)	$ (403,522)

Shareholders' equity - Accumula

Shareholders' equity - Accumulated other comprehensive income (loss) into income expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	$ 1,344,645	$ 1,327,558	$ 1,259,954
Income from continuing operations before taxes	75,478	434,012	445,919
Taxes on income from continuing operations	(5,316)	(76,440)	(83,003)
Net of tax	70,162	357,572	362,916
Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Impact on income from continuing operations, net of tax	77,888	(6,479)	1,768
Reclassification out of Accumulated Other Comprehensive Income | Cash Flow Hedges | Foreign Exchange Forward
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	(1,626)	(12,234)	(3,532)
Income from continuing operations before taxes	(1,626)	(12,234)	(3,532)
Taxes on income from continuing operations	92	385	203
Net of tax	(1,534)	(11,849)	(3,329)
Reclassification out of Accumulated Other Comprehensive Income | Pension and Other Postretirement Benefit Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income from continuing operations before taxes	137,324	6,981	6,643
Taxes on income from continuing operations	(57,902)	(1,611)	(1,546)
Net of tax	79,422	5,370	5,097
Actuarial losses	1,152	7,989	7,660
Prior-service credits	(1,967)	(1,008)	(1,017)
Settlements	$ 138,139	$ 0	$ 0

Stock compensation plans - Addi

Stock compensation plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	May 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of common stock authorized to be issued under plan (in shares)				4,300,000
Number of options, granted (in shares)	193,826
Unrecognized compensation expense	$ 41.5
Shares available for future grants (in shares)	3,583,530
Stock option granted, weighted average grant date fair value (in dollars per share)	$ 70.28	$ 76.46	$ 88.92
Stock option granted, weighted average grant date fair value	$ 4.7	$ 13.5	$ 5
Stock option expenses including selling general and administrative expenses	$ 12.8
Non-vested restricted stock units issued (in shares)	108,777	98,201	85,780
Non vested restricted stock expense including selling general and administrative expense	$ 17.6
Performance Shares Units (PSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance period	3 years
Weighted average grant date fair value, granted (in dollars per share)	$ 220.45
Performance Shares Units (PSUs) | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant of stock awards (in shares)	45,052
Performance Shares Units (PSUs) | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant of stock awards (in shares)	111,696
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant of stock awards (in shares)	108,777
Weighted average grant date fair value, granted (in dollars per share)	$ 220.18	$ 235.14	$ 323.35
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of options, granted (in shares)	193,826
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant of stock awards (in shares)	108,777
Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense	$ 13.7
Period for recognition	1 year 6 months
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense	$ 20.3
Period for recognition	1 year 3 months 18 days

Stock compensation plans - Shar

Stock compensation plans - Share-based Compensation Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Noncash Expense [Abstract]
Share-based compensation expense	$ 31,348	$ 31,465	$ 27,224
Total income tax benefit recognized for share-based compensation arrangements	5,325	7,820	6,824
Net excess tax (deficiency) benefit	$ (1,542)	$ 1,351	$ 1,292

Stock compensation plans - Weig

Stock compensation plans - Weighted-average assumptions used to estimate fair value of options granted (Detail) - Stock Options	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Weighted Average Fair Values [Line Items]
Risk-free interest rate	4.28%	4.13%	1.56%
Expected life of option	5 years 1 month 9 days	5 years 25 days	5 years 10 days
Expected dividend yield	0.60%	0.57%	0.41%
Expected volatility	30%	31.42%	30.09%

Stock compensation plans- Summa

Stock compensation plans- Summary of stock option activity (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options, outstanding, beginning of year (in shares) | shares	1,293,775
Number of options, granted (in shares) | shares	193,826
Number of options, exercised (in shares) | shares	(50,465)
Number of options, forfeited or expired (in shares) | shares	(43,382)
Number of options, outstanding, ending of year (in shares) | shares	1,393,754
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted average exercise price, outstanding, beginning of year (in dollars per share) | $ / shares	$ 239.55
Weighted average exercise price, granted (in dollars per share) | $ / shares	223.94
Weighted average exercise price, exercised (in dollars per share) | $ / shares	135.91
Weighted average exercise price, forfeited or expired (in dollars per share) | $ / shares	294.22
Weighted average exercise price, outstanding, beginning of year (in dollars per share) | $ / shares	$ 239.43
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Number of options, exercisable, end of year (in shares) | shares	1,052,394
Weighted average exercise price, exercisable, end of year (in dollars per share) | $ / shares	$ 238.65
Weighted average remaining contractual life in years, outstanding, end of year	4 years 6 months
Weighted average remaining contractual life in years, exercisable, end of year	3 years 2 months 12 days
Aggregate intrinsic value, outstanding, end of year | $	$ 13,718
Aggregate intrinsic value, exercisable, end of year | $	$ 13,718

Stock compensation plans - Summ

Stock compensation plans - Summary of non vested restricted stock unit activity (Detail) - Restricted Stock Units - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of non-vested shares, outstanding, beginning of the year (in shares)	190,500
Number of non-vested shares, granted (in shares)	108,777
Number of non-vested shares, vested (in shares)	(42,896)
Number of non-vested shares, forfeited (in shares)	(28,057)
Number of non-vested shares, outstanding, end of the year (in shares)	228,324	190,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted average grant date fair value, outstanding, beginning of the year (in dollars per share)	$ 294.63
Weighted average grant date fair value, granted (in dollars per share)	220.18	$ 235.14	$ 323.35
Weighted average grant date fair value, vested (in dollars per share)	370.96
Weighted average grant date fair value, forfeited (in dollars per share)	262.41
Weighted average grant date fair value, outstanding, end of the year (in dollars per share)	$ 248.79	$ 294.63
Weighted average remaining contractual life In years, outstanding, end of the year	1 year 3 months 18 days
Aggregate intrinsic value, outstanding, end of the year	$ 40,637

Income taxes - Components of pr

Income taxes - Components of provision for income taxes from continuing operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Current:
Federal	$ 74,748	$ 51,717	$ 32,798
State	16,476	8,266	8,747
Non-U.S.	43,830	30,408	56,442
Deferred:
Federal	(103,387)	(24,396)	(27,528)
State	(10,265)	5,439	10,116
Non-U.S.	(16,086)	5,006	2,428
Provision for income taxes from continuing operations	$ 5,316	$ 76,440	$ 83,003

Income taxes - Additional Infor

Income taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Contingency [Line Items]
Cumulative unremitted earnings, non-permanently reinvested	$ 2,600,000,000
Cumulative unremitted earnings, permanently reinvested	$ 0
Effective income tax rate, total	7%	17.60%	18.60%
Realized net benefit as result of reducing our reserves with respect to uncertain tax positions	$ 900,000	$ 2,300,000	$ 2,000,000
Tax effect, carry forwards	114,200,000
Deferred tax assets, valuation allowance	88,412,000	95,747,000
Unrecognized tax benefits that would impact effective tax rate	700,000
Unrecognized tax benefits, interest expense (benefit)	100,000	100,000	200,000
Unrecognized tax benefits, penalties	300,000	600,000	$ 200,000
Unrecognized tax benefits, interest (benefit) expense accrued	300,000	400,000
Unrecognized tax benefits, penalties accrued	500,000	$ 1,000,000
Minimum
Income Tax Contingency [Line Items]
Unrecognized tax benefits change within next twelve months due to potential for resolution of foreign and U.S. examinations	0
Maximum
Income Tax Contingency [Line Items]
Unrecognized tax benefits change within next twelve months due to potential for resolution of foreign and U.S. examinations	700,000
No Expiration Date
Income Tax Contingency [Line Items]
Tax effect, carry forwards	21,000,000
After 2024 but before the end of 2029
Income Tax Contingency [Line Items]
Tax effect, carry forwards	12,500,000
After 2029
Income Tax Contingency [Line Items]
Tax effect, carry forwards	$ 80,700,000

Income taxes - Summary of U.S.

Income taxes - Summary of U.S. and non-U.S. components of income from continuing operations before taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
U.S.	$ (171,380)	$ 45,363	$ 164,151
Non-U.S.	246,858	388,649	281,768
Income from continuing operations before taxes	$ 75,478	$ 434,012	$ 445,919

Income taxes - Reconciliations

Income taxes - Reconciliations between statutory federal income tax rate and effective income tax rate (Detail)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal statutory rate	21%	21%	21%
Tax effect of international items	(57.60%)	(6.10%)	(4.60%)
Pension settlement charge	(38.50%)	(0.20%)	0%
Legal entity rationalization - deferred taxes	0%	5.70%	0%
Excess tax benefits related to share-based compensation	2%	(0.30%)	(0.30%)
State taxes, net of federal benefit	10.40%	0.60%	3.40%
Uncertain tax contingencies	(1.20%)	(0.60%)	(0.40%)
Contingent consideration	3.80%	(1.30%)	0.10%
Goodwill impairment charge	66.80%	0%	0%
Research and development tax credit	(5.90%)	(1.30%)	(1.00%)
Other, net	6.20%	0.10%	0.50%
Effective income tax rate, total	7%	17.60%	18.60%

Income taxes - Deferred tax ass

Income taxes - Deferred tax assets and liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets:
Tax loss and credit carryforwards	$ 114,244	$ 114,147
Lease Liabilities	26,897	30,397
Reserves and accruals	77,493	72,040
Other	11,079	33,472
Less: valuation allowances	(88,412)	(95,747)
Total deferred tax assets	141,301	154,309
Deferred tax liabilities:
Property, plant and equipment	16,598	34,852
Intangibles — stock acquisitions	419,172	462,559
Unremitted non-U.S. earnings	51,638	61,734
Lease Assets	26,897	30,397
Other	6,688	14,099
Total deferred tax liabilities	520,993	603,641
Net deferred tax liability	$ (379,692)	$ (449,332)

Income taxes - Uncertain tax po

Income taxes - Uncertain tax positions for liabilities associated with unrecognized tax benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Unrecognized Tax Benefits [Roll Forward]
Beginning balance	$ 2,020	$ 4,260	$ 6,105
Increase in unrecognized tax benefits related to prior years	0	0	215
Decrease in unrecognized tax benefits related to prior years	0	0	(761)
Reductions in unrecognized tax benefits due to lapse of applicable statute of limitations	(902)	(2,287)	(1,117)
(Decrease) increase in unrecognized tax benefits due to foreign currency translation		(47)
(Decrease) increase in unrecognized tax benefits due to foreign currency translation	(97)		(182)
Ending balance	$ 1,021	$ 2,020	$ 4,260

Income Taxes - Supplemental Cas

Income Taxes - Supplemental Cash Flow (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income taxes paid, net of refunds	$ 164,902	$ 114,211	$ 162,046

Pension and other postretirem_3

Pension and other postretirement benefits - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Accumulated benefit obligations for plans with accumulated benefit obligations and projected benefit obligations in excess of plan assets	$ 262,600	$ 14,600	$ 262,600
Projected benefit obligations for plans with accumulated benefit obligations and projected benefit obligations in excess of plan assets	263,200	15,100	263,200
Fair value of plan assets for plans with accumulated benefit obligations and projected benefit obligations in excess of plan assets	272,300	0	272,300
Defined contribution plans, costs		33,200	26,100	$ 24,300
Pension
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Funded status, end of year	$ 10,116	$ (14,575)	$ 10,116
Discount rate	4.70%	4.40%	4.70%
Accumulated benefit obligation	$ 274,900	$ 24,700	$ 274,900
Expected employer contribution next fiscal year		$ 1,100
Pension | UNITED STATES
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate		5.48%
Pension | Foreign Plan
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets with accumulated benefit obligation in excess of plan assets	1,000	$ 500	1,000
Other Benefits
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Funded status, end of year	$ (9,535)	$ (7,275)	$ (9,535)
Discount rate	5%	5.60%	5%
Expected employer contribution next fiscal year		$ 1,000
Other Benefits | UNITED STATES
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate		5.61%
Teleflex Incorporated Retirement Income Plan | Pension
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Payment for settlement	$ 45,200	$ 132,700
Funded status, end of year		$ 43,000

Pension and other postretirem_4

Pension and other postretirement benefits - Net benefit cost of pension and postretirement benefit plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Settlements, net	$ 132,732	$ 45,244	$ 0
Pension
Defined Benefit Plan Disclosure [Line Items]
Service cost	823	1,435	1,346
Interest cost	2,940	17,297	10,776
Expected return on plan assets	(2,591)	(25,277)	(25,776)
Net amortization and deferral	1,849	8,536	7,900
Settlements, net	132,732	45,244	0
Net benefit expense (income)	135,753	47,235	(5,754)
Other Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	0	0
Interest cost	384	824	477
Expected return on plan assets	0	0	0
Net amortization and deferral	(2,664)	(1,564)	(1,258)
Settlements, net	0	0	0
Net benefit expense (income)	$ (2,280)	$ (740)	$ (781)

Pension and other postretirem_5

Pension and other postretirement benefits - Weighted average assumptions used in determining net periodic benefit cost (Detail)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pension
Defined Benefit Plan Disclosure [Line Items]
Discount rate	4.70%	5.10%	2.80%
Rate of return	4.80%	7.30%	5.60%
Other Benefits
Defined Benefit Plan Disclosure [Line Items]
Discount rate	5%	5.10%	2.70%
Initial healthcare trend rate	6.90%	6.10%	6.40%
Ultimate healthcare trend rate	4.50%	4.50%	4.50%

Pension and other postretirem_6

Pension and other postretirement benefits - Summarized information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pension
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation, beginning of year	$ 275,397	$ 356,757
Service cost	823	1,435	$ 1,346
Interest cost	2,940	17,297	10,776
Actuarial loss (gain)	(7,798)	11,557
Currency translation	1,028	1,067
Benefits paid	(227,491)	(21,208)
Liability gain due to settlement	(16,969)	(15,272)
Medicare Part D reimbursement	0	0
Plan amendments	0	0
Settlements	0	(73,932)
Administrative costs	(767)	(2,304)
Projected benefit obligation, end of year	25,107	275,397	356,757
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets, beginning of year	285,513	357,270
Actual return on plan assets	(5,241)	23,740
Contributions	1,663	1,276
Benefits paid	(227,491)	(95,139)
Administrative costs	(767)	(2,304)
Assets Transferred to Qualified Replacement Plan	(42,966)	0
Currency translation	(179)	670
Fair value of plan assets, end of year	10,532	285,513	357,270
Funded status, end of year	(14,575)	10,116
Other Benefits
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation, beginning of year	9,535	18,620
Service cost	0	0	0
Interest cost	384	824	477
Actuarial loss (gain)	(2,150)	(508)
Currency translation	0	0
Benefits paid	(545)	(1,910)
Liability gain due to settlement	0	0
Medicare Part D reimbursement	51	(3)
Plan amendments	0	(7,488)
Settlements	0	0
Administrative costs	0	0
Projected benefit obligation, end of year	7,275	9,535	$ 18,620
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Administrative costs	0	0
Funded status, end of year	$ (7,275)	$ (9,535)

Pension and other postretirem_7

Pension and other postretirement benefits - Amounts recognized in consolidated balance sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Payroll and benefit-related liabilities	$ (151,263)	$ (146,535)
Pension and postretirement benefit liabilities	(20,185)	(23,989)
Pension
Defined Benefit Plan Disclosure [Line Items]
Other assets	477	27,370
Payroll and benefit-related liabilities	(1,117)	(1,439)
Pension and postretirement benefit liabilities	(13,935)	(15,815)
Accumulated other comprehensive loss (gain)	12,677	164,139
Amounts recognized in balance sheet	(1,898)	174,255
Other Benefits
Defined Benefit Plan Disclosure [Line Items]
Other assets	0	0
Payroll and benefit-related liabilities	(1,025)	(1,361)
Pension and postretirement benefit liabilities	(6,250)	(8,174)
Accumulated other comprehensive loss (gain)	(13,730)	(14,244)
Amounts recognized in balance sheet	$ (21,005)	$ (23,779)

Pension and other postretirem_8

Pension and other postretirement benefits - Amounts recognized in accumulated other comprehensive (income) loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan, Chance in Amounts Recognized in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance, accumulated other comprehensive (income) loss, net of tax	$ 314,405
Impact of currency translation, accumulated other comprehensive (income) loss, net of tax	92,594	$ (44,902)	$ 62,904
Ending balance, accumulated other comprehensive (income) loss, net of tax	316,669	314,405
Pension
Defined Benefit Plan, Chance in Amounts Recognized in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance, prior service cost (credit)	191	200
Net amortization and deferral, prior service cost	0	(9)
Actuarial changes in benefit obligation, prior service cost	0	0
Impact of currency translation, prior service cost (credit)	0	0
Ending balance, prior service cost (credit)	191	191	200
Beginning balance, net (gain) or loss	163,948	219,355
Net amortization and deferral, net (gain) or loss	(1,849)	(8,527)
Actuarial changes in benefit obligation, net gain (loss)	(149,294)	(47,453)
Impact of currency translation, net (gain) or loss	(319)	573
Ending balance, net (gain) or loss	12,486	163,948	219,355
Beginning balance, deferred taxes	(64,720)	(77,347)
Net amortization and deferral, deferred taxes	446	1,961
Actuarial changes in benefit obligation, deferred taxes	60,645	10,805
Impact of currency translation, deferred taxes	86	(139)
Ending balance, deferred taxes	(3,543)	(64,720)	(77,347)
Beginning balance, accumulated other comprehensive (income) loss, net of tax	99,419	142,208
Net amortization and deferral, accumulated other comprehensive (income) loss, net of tax	(1,403)	(6,575)
Actuarial changes in benefit obligation, accumulated other comprehensive income (loss), net of tax	(88,649)	(36,648)
Impact of currency translation, accumulated other comprehensive (income) loss, net of tax	(233)	434
Ending balance, accumulated other comprehensive (income) loss, net of tax	9,134	99,419	142,208
Other Benefits
Defined Benefit Plan, Chance in Amounts Recognized in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance, prior service cost (credit)	(1,618)	(2,635)
Net amortization and deferral, prior service cost	1,967	1,017
Actuarial changes in benefit obligation, prior service cost	0	0
Ending balance, prior service cost (credit)	349	(1,618)	(2,635)
Beginning balance, net (gain) or loss	(12,626)	(5,177)
Net amortization and deferral, net (gain) or loss	697	547
Actuarial changes in benefit obligation, net gain (loss)	(2,150)	(7,996)
Ending balance, net (gain) or loss	(14,079)	(12,626)	(5,177)
Beginning balance, deferred taxes	2,874	1,403
Net amortization and deferral, deferred taxes	(609)	(359)
Actuarial changes in benefit obligation, deferred taxes	493	1,830
Ending balance, deferred taxes	2,758	2,874	1,403
Beginning balance, accumulated other comprehensive (income) loss, net of tax	(11,370)	(6,409)
Net amortization and deferral, accumulated other comprehensive (income) loss, net of tax	2,055	1,205
Actuarial changes in benefit obligation, accumulated other comprehensive income (loss), net of tax	(1,657)	(6,166)
Ending balance, accumulated other comprehensive (income) loss, net of tax	$ (10,972)	$ (11,370)	$ (6,409)

Pension and other postretirem_9

Pension and other postretirement benefits - Weighted average assumptions used in determining benefit obligations (Detail)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Pension
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	4.40%	4.70%
Rate of compensation increase	2.90%	3%
Other Benefits
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	5.60%	5%
Initial healthcare trend rate	6.80%	6.60%
Ultimate healthcare trend rate	4.50%	4.50%

Pension and other postretire_10

Pension and other postretirement benefits - Fair values of pension plan assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Minimum
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Effective average duration to maintain	3 years
Maximum
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Effective average duration to maintain	10 years
Fair Value, Measurements, Recurring
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	$ 10,532	$ 285,513
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	10,532	285,513
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	129	200,364
Fair Value, Measurements, Recurring | Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	72,354
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	10,403	12,795
Fair Value, Measurements, Recurring | Cash | Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	110	909
Fair Value, Measurements, Recurring | Cash | Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	110	909
Fair Value, Measurements, Recurring | Cash | Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring | Cash | Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring | Money market funds | Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	19	4,424
Fair Value, Measurements, Recurring | Money market funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	19	4,424
Fair Value, Measurements, Recurring | Money market funds | Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring | Money market funds | Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring | Intermediate duration bond fund | Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		193,674
Fair Value, Measurements, Recurring | Intermediate duration bond fund | Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		193,674
Fair Value, Measurements, Recurring | Intermediate duration bond fund | Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		0
Fair Value, Measurements, Recurring | Intermediate duration bond fund | Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		0
Fair Value, Measurements, Recurring | Long duration bond fund | Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		1,357
Fair Value, Measurements, Recurring | Long duration bond fund | Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		1,357
Fair Value, Measurements, Recurring | Long duration bond fund | Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		0
Fair Value, Measurements, Recurring | Long duration bond fund | Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		0
Fair Value, Measurements, Recurring | Corporate, government and foreign bonds | Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		72,037
Fair Value, Measurements, Recurring | Corporate, government and foreign bonds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		0
Fair Value, Measurements, Recurring | Corporate, government and foreign bonds | Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		72,037
Fair Value, Measurements, Recurring | Corporate, government and foreign bonds | Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		0
Fair Value, Measurements, Recurring | Absolute return credit fund | Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		317
Fair Value, Measurements, Recurring | Absolute return credit fund | Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		0
Fair Value, Measurements, Recurring | Absolute return credit fund | Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		317
Fair Value, Measurements, Recurring | Absolute return credit fund | Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		0
Fair Value, Measurements, Recurring | Contract with insurance company | Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	10,403	12,795
Fair Value, Measurements, Recurring | Contract with insurance company | Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring | Contract with insurance company | Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring | Contract with insurance company | Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	$ 10,403	$ 12,795

Pension and other postretire_11

Pension and other postretirement benefits - Expected benefit payments (Detail) $ in Thousands	Dec. 31, 2024 USD ($)
Pension
Schedule Of Pension Expected Future Benefit Payments [Line Items]
2025	$ 2,080
2026	2,114
2027	2,014
2028	2,086
2029	2,174
Years 2030 — 2034	10,693
Other Benefits
Schedule Of Pension Expected Future Benefit Payments [Line Items]
2025	1,022
2026	756
2027	602
2028	574
2029	563
Years 2030 — 2034	$ 2,488

Commitments and contingent li_2

Commitments and contingent liabilities (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Palette Life Sciences AB
Loss Contingencies [Line Items]
Loss contingency accrual	$ 3.5
Italian parliament legislation
Loss Contingencies [Line Items]
Loss contingency, loss in period	22.1
Loss contingency accrual	35.7
Italian Parliament Legislation, Pertaining To Prior Years
Loss Contingencies [Line Items]
Loss contingency, loss in period	$ 13.8
Minimum
Loss Contingencies [Line Items]
Estimated time frame over which accrued amounts may be paid out	10 years
Maximum
Loss Contingencies [Line Items]
Estimated time frame over which accrued amounts may be paid out	15 years
Accrued Liabilities
Loss Contingencies [Line Items]
Waste disposed accrued liability	$ 0.5	$ 2.5
Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]	Other current liabilities	Other current liabilities
Contingency reserve for litigation	$ 0.8	$ 0.8
Other Liabilities
Loss Contingencies [Line Items]
Waste disposed accrued liability	$ 3.4	$ 3.8
Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities

Business segments and other i_3

Business segments and other information - Segment Result (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) segment	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Revenues From External Customers And Long Lived Assets [Line Items]
Number of reportable segments | segment	3
Number of operating segments | segment	3
Net revenues	$ 3,047,324	$ 2,974,489	$ 2,791,041
Cost of goods sold	1,344,645	1,327,558	1,259,954
Research and development expenses	161,672	154,351	153,819
Selling, general and administrative expenses	995,271	929,867	863,748
Asset impairments	7,834		1,497
Restructuring and other impairment charges	21,991	15,604	20,299
Gain on sale of assets and business	0	(4,448)	(6,504)
Pension settlement charge	132,732	45,244	0
Income from continuing operations before interest, loss on extinguishment of debt and taxes	151,013	506,313	499,725
Depreciation and amortization	274,601	242,118	230,590
Operating Segments
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	3,047,324	2,974,489	2,791,041
Cost of goods sold	1,256,662	1,217,015	1,136,785
Research and development expenses	152,435	151,577	150,996
Selling, general and administrative expenses	720,056	659,828	631,743
Operating profit	918,171	946,069	871,517
Income from continuing operations before interest, loss on extinguishment of debt and taxes	151,013	506,313	499,725
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
Revenues From External Customers And Long Lived Assets [Line Items]
Operating profit	372,435	383,356	357,997
Asset impairments	240,000	0	0
Americas
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	2,066,292	2,041,339	1,926,348
Cost of goods sold	834,987	824,514	780,538
Research and development expenses	94,912	82,685	67,795
Selling, general and administrative expenses	465,917	420,158	408,068
Depreciation and amortization	193,949	168,787	161,842
Americas | Operating Segments
Revenues From External Customers And Long Lived Assets [Line Items]
Operating profit	670,476	713,982	669,947
EMEA
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	617,984	586,245	558,373
Cost of goods sold	289,645	273,772	255,210
Research and development expenses	38,939	54,787	69,822
Selling, general and administrative expenses	156,375	146,551	136,464
Depreciation and amortization	49,596	42,057	38,266
EMEA | Operating Segments
Revenues From External Customers And Long Lived Assets [Line Items]
Operating profit	133,025	111,135	96,877
Asia
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	363,048	346,905	306,320
Cost of goods sold	132,030	118,729	101,037
Research and development expenses	18,584	14,105	13,379
Selling, general and administrative expenses	97,764	93,119	87,211
Depreciation and amortization	12,344	10,548	9,311
Asia | Operating Segments
Revenues From External Customers And Long Lived Assets [Line Items]
Operating profit	114,670	120,952	104,693
Corporate
Revenues From External Customers And Long Lived Assets [Line Items]
Depreciation and amortization	$ 18,712	$ 20,726	$ 21,171

Business segments and other i_4

Business segments and other information - Total net revenues and total net property, plant and equipment by geographic region (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Net revenues	$ 3,047,324	$ 2,974,489	$ 2,791,041
Property, plant and equipment, net	502,852	479,913
UNITED STATES
Segment Reporting Information [Line Items]
Net revenues	1,889,312	1,879,898	1,786,467
Property, plant and equipment, net	215,806	200,969
Europe
Segment Reporting Information [Line Items]
Net revenues	705,094	665,185	622,343
Asia Pacific
Segment Reporting Information [Line Items]
Net revenues	326,371	307,513	270,749
All other
Segment Reporting Information [Line Items]
Net revenues	126,547	121,893	$ 111,482
Property, plant and equipment, net	92,329	94,658
Malaysia
Segment Reporting Information [Line Items]
Property, plant and equipment, net	73,430	71,947
Mexico
Segment Reporting Information [Line Items]
Property, plant and equipment, net	$ 121,287	$ 112,339

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Condensed Consolidated Guarantor Financial Information [Abstract]
Cash and cash equivalents	$ 290,188	$ 222,848
Restricted Cash Equivalents, Current	14,700	0
Restricted Cash Equivalents, Noncurrent	22,762	0
Restricted Cash and Cash Equivalents	$ 327,650	$ 222,848

Subsequent events (Details)

Subsequent events (Details) $ in Millions		12 Months Ended
	Feb. 24, 2025 EUR (€)	Dec. 31, 2024 USD ($)	Dec. 31, 2022 USD ($)	Feb. 28, 2025 USD ($)	Feb. 27, 2025 USD ($)	Dec. 31, 2024 EUR (€)	Aug. 02, 2024 USD ($)	Jul. 30, 2024 USD ($)
Subsequent Event [Line Items]
Share repurchase program, authorized amount							$ 200	$ 500
Third Amended and Restated Credit Agreement | Adjusted SOFR
Subsequent Event [Line Items]
Basis spread on variable rate			1%
Third Amended and Restated Credit Agreement | Adjusted SOFR One Month Credit Spread
Subsequent Event [Line Items]
Basis spread on variable rate			0.10%
Third Amended and Restated Credit Agreement | Minimum | Federal Funds
Subsequent Event [Line Items]
Basis spread on variable rate			0.50%
Third Amended and Restated Credit Agreement | Minimum | Adjusted SOFR
Subsequent Event [Line Items]
Basis spread on variable rate			0.125%
Third Amended and Restated Credit Agreement | Minimum | Base Rate
Subsequent Event [Line Items]
Basis spread on variable rate			0.125%
Third Amended and Restated Credit Agreement | Maximum | Adjusted SOFR
Subsequent Event [Line Items]
Basis spread on variable rate			1%
Third Amended and Restated Credit Agreement | Maximum | Base Rate
Subsequent Event [Line Items]
Basis spread on variable rate			1%
Third Amended and Restated Credit Agreement | Term Loan
Subsequent Event [Line Items]
Maximum amount available for borrowing		$ 500	$ 500
Third Amended and Restated Credit Agreement | Term Loan | Minimum | Adjusted SOFR
Subsequent Event [Line Items]
Basis spread on variable rate			1.125%
Third Amended and Restated Credit Agreement | Term Loan | Maximum | Adjusted SOFR
Subsequent Event [Line Items]
Basis spread on variable rate			2%
Third Amended and Restated Credit Agreement | Revolving Credit Facility
Subsequent Event [Line Items]
Maximum amount available for borrowing		$ 550	$ 1,000
Debt, term		2 years	5 years
BIOTRONIK
Subsequent Event [Line Items]
Business acquisition, transaction costs		$ 11.5
BIOTRONIK | Foreign Currency Exchange Contracts | Designated as Hedging Instrument
Subsequent Event [Line Items]
Total notional amount for all open foreign currency forward contracts | €						€ 700,000,000
Subsequent Event
Subsequent Event [Line Items]
Share repurchase program, authorized amount				$ 300	$ 300
Subsequent Event | BIOTRONIK
Subsequent Event [Line Items]
Business combination, consideration transferred | €	€ 760,000,000

SCHEDULE II - VALUATION AND Q_2

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS - DEFERRED TAX ASSET VALUATION ALLOWANCE (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 95,747
Balance at End of Year	88,412	$ 95,747
Valuation Allowance of Deferred Tax Assets
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	95,747	91,531	$ 143,177
Additions Charged to Expense	5,413	4,799	8,489
Reductions Credited to Expense	(2,813)	(4,937)	(59,520)
Translation and Other	(9,935)	4,354	(615)
Balance at End of Year	$ 88,412	$ 95,747	$ 91,531